Cyclic urea
Cyclic urea compounds are developed to address the limitations of current RIP1 kinase inhibitors by providing stable, effective inhibition of necroptosis and ferroptosis, offering therapeutic benefits for diverse pathological conditions.
Patent Information
- Application Number
- JP2021528861
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-11-20
- Filing Date
- 2019-11-20
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-11-20
AI Technical Summary
Current treatments for necroptosis, mediated by receptor-interacting protein 1 (RIP1) kinase, are limited in efficacy and stability, particularly in inhibiting necroptosis and ferroptosis, which are involved in various pathological conditions such as ischemic brain injury, neurodegenerative diseases, and viral infections.
Development of cyclic urea compounds that act as inhibitors of RIP1 kinase, specifically designed as prodrugs with improved metabolic stability, converting into active inhibitors in the intestine or blood, and formulated as pharmaceutical compositions for therapeutic use.
The compounds exhibit excellent metabolic stability and effectively inhibit necroptosis and ferroptosis, offering potential therapeutic benefits for conditions like brain injury, neurodegenerative diseases, and viral infections, enhancing tumor immunity in cancers like pancreatic cancer and melanoma.
Smart Images

Figure 0007577655000001 
Figure 0007577655000002 
Figure 0007577655000003
Abstract
Description
[Background technology]
[0001] Introduction Activation of nuclear factor-κB (NF-κB) by tumor necrosis factor-α (TNF-α) plays a central role in the immune system and inflammatory responses. Receptor-interacting protein 1 (RIP1) is a multifunctional signal transduction pathway that mediates NF-κB activation, apoptosis, and necroptosis. The kinase activity of RIP1 plays a key role in mediating necroptosis, a caspase-independent pathway of necrotic cell death (Holler et al. Nat Immunol 2000; 1: 489-495; Degterev et al. Nat Chem Biol 2008; 4: 313-321).
[0002] Necroptosis is involved in various pathological forms of cell death, including ischemic brain injury, neurodegenerative diseases, and viral infections (Dunai, et al., Dec 2011, Pathol. Oncol. Res.: POR 17 (4): 791-800). Necrostatin-1 (Nec-1), a small molecule compound that inhibits RIP1 kinase activity, can inhibit necroptosis (Degterev et al. Nat Chem Biol 2005; 1: 112-119).
[0003] RIP1 is thought to be involved in resistance to D-1 immunotherapy (e.g., Manguso et al., 2017 Nature 547, 413-418) and to act as a checkpoint kinase that controls tumor immunity (e.g., Wang et al., Cancer Cell 34, 757-774, Nov 12, 2018).
[0004] Related patent publications include US9974762, US10092529, US6756394, US8278344, US2012122889, US2009099242, US2010317701, US2011144169, US20030083386, US20120309795, WO2009023272, WO2010075290, WO2010075561, and WO2012125544. Summary of the Invention [Means for solving the problem]
[0005] The present invention provides compounds that are inhibitors of necrosis, ferroptosis, human receptor-interacting protein 1 kinase (RIP1), or diseases related to these, and prodrugs thereof, i.e., drugs that are converted to the inhibitors by hydrolysis, usually in the intestine or blood. These inhibitors have been confirmed to exhibit unexpectedly excellent metabolic stability based on liver microsome and PK data.
[0006] In one aspect, the present invention provides a compound, or a sulfonamide or prodrug thereof, that is an inhibitor of necrosis, ferroptosis, human RIP1, or a disease related thereto, i.e., a compound having the following structure: [ka] (In the formula, R1 is C3-C 14 cyclic or heterocyclic group, in particular a substituted or unsubstituted C3-C9 cycloalkyl, cycloalkenyl, or cycloalkynyl having 0 to 3 heteroatoms, or a substituted or unsubstituted C5-C 14 is aryl; R2 is C3-C 14 Heterocyclic groups, in particular substituted or unsubstituted C3-C9 cycloalkyl, cycloalkenyl, or cycloalkynyl having 1 to 3 heteroatoms, or substituted or unsubstituted C5-C14 is aryl; R3 and R4 are each independently H, a substituted or unsubstituted hydrocarbyl having 0 to 3 heteroatoms, or a substituted heteroatom, and R3 and R4 may bond to form a 3 to 8 membered ring having 1 to 3 heteroatoms, i.e., N, or N and any of N, S, and O, provided that when R3 is H, R4 is neither H nor phenyl (i.e., excluding compound 17 of US2012122889)). or a sulfonamide corresponding to said amide compound, or a pharmaceutically acceptable salt, hydrate or stereoisomer of said amide compound or the corresponding sulfonamide.
[0007] In an embodiment, R1 is (a) Substituted or unsubstituted phenyl; (b) substituted or unsubstituted 2-pyridine, 3-pyridine, or 4-pyridine; (c) Substituted or unsubstituted naphthyl or 3-azanaphthyl; (d) substituted or unsubstituted cyclohexyl or cyclopentyl having 0 to 3 heteroatoms; or (e) Substituted or unsubstituted cyclopentene or cyclopentadiene having 0 to 3 heteroatoms and; R1 is a substituted or unsubstituted phenyl, cyclohexyl, furan, thiophene, or azole; R1 is substituted or unsubstituted phenyl or cyclohexyl; R1 is a substituted or unsubstituted phenyl; R1 is fluorine-substituted phenyl (e.g., 3,5-difluorophenyl) or unsubstituted phenyl; R2 is a substituted or unsubstituted C3-C6 saturated or unsaturated ring having 1 to 3 heteroatoms, i.e., N, or N and either N, S, or O; R2 is a substituted or unsubstituted C3-C6 saturated ring having 1 to 3 heteroatoms, i.e., N, or N and any of N, S, and O; when the heteroatom is N, it is, for example, aziridine, azetidine, pyrrolidine, piperidine, etc.; when the heteroatom is N and O, it is, for example, oxaziridine, isoxaziridine, oxazetidine, oxazolidine, oxazinane, etc.; when the heteroatom is N and S, it is, for example, thiaziridine, thiazetidine, thiazolidine, thiazinane, etc.; when the heteroatom is N and N, it is, for example, diaziridine, diazetidine, diazolidine (pyrazolidine), diazinane, etc.; R2 is a substituted or unsubstituted C3-C6 unsaturated ring having 1 to 3 heteroatoms, i.e., N, or N and any of N, S, and O, and when the heteroatom is N, it is, for example, pyrrole, dihydropyrrole, pyridine, dihydropyridine, tetrahydropyridine, etc., and when the heteroatom is N and any of N, S, and O, it is, for example, azole (e.g., pyrazole, dihydropyrazole, imidazole, triazole, tetrazole, pentazole, oxazole, isoxazole, thiazole, or isothiazole), pyrimidine, oxazine, thiazine, triazine, ozadiazine, thiadiazine, etc.; R2 is a substituted or unsubstituted C5 saturated or unsaturated ring (e.g., cycloalkyl, cycloalkenyl, or aryl) having 1 to 3 heteroatoms, i.e., N, or N and either N, S, or O; R2 is pyrrolidine, dihydropyrazole, or isoxazolidine; R3 and R4 are not linked, R3 is H or C1-C4 alkyl, and R4 is C3-C 14 cyclic or heterocyclic group, in particular a substituted or unsubstituted C3-C9 cycloalkyl, cycloalkenyl, or cycloalkynyl having 0 to 3 heteroatoms, or a substituted or unsubstituted C5-C 14 is aryl; R3 and R4 are not bonded, R3 is H or Me, and R4 is a substituted or unsubstituted C4-C9 ring having 0-3 heteroatoms; R3 and R4 are not linked, R3 is H or Me, and R4 is C4-C6 cycloalkyl or pyrrolidine; R3 and R4 are linked together to form a 4-8 membered ring having 1-3 heteroatoms, i.e., N, or N and any of N, S, and O; R3 and R4 combine to form a 4-6 membered N-containing heterocycloalkyl ring, which may also be fused to a second ring, e.g., phenyl, to form isoindoline, etc.; R3 and R4 are bonded to form a 4-6 membered N-containing heterocycloalkyl ring, and the N-containing heterocycloalkyl ring is connected to R5 (wherein R5 is a C3-C 14 cyclic or heterocyclic group, in particular a substituted or unsubstituted C3-C9 cycloalkyl, cycloalkenyl, or cycloalkynyl having 0 to 3 heteroatoms, or a substituted or unsubstituted C5-C 14 is bonded to a aryl; L is -CH2-, -O-, or -CH-; R5 is (a) Substituted or unsubstituted phenyl; (b) substituted or unsubstituted 2-pyridine, 3-pyridine, or 4-pyridine; (c) Substituted or unsubstituted naphthyl or 3-azanaphthyl; (d) substituted or unsubstituted cyclohexyl or cyclopentyl having 0 to 3 heteroatoms; or (e) Substituted or unsubstituted cyclopentene or cyclopentadiene having 0 to 3 heteroatoms and; R5 is a substituted or unsubstituted phenyl, cyclohexyl, furan, thiophene, or azole; R5 is substituted or unsubstituted phenyl or cyclohexyl; R5 is a substituted or unsubstituted phenyl; R5 is fluorine-substituted phenyl (e.g., 3,5-difluorophenyl) or unsubstituted phenyl; and / or The compounds have the structures set forth in Table 1.
[0008] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and one or more pharmaceutically acceptable excipients, wherein the compound is in a therapeutically effective amount in a unit dosage form.
[0009] In another aspect, the invention provides use of a compound or composition of the invention in the manufacture of a medicament for inhibiting necrosis, ferroptosis, and / or human receptor-interacting protein 1 kinase (RIP1) in a human in need thereof.
[0010] In another aspect, the invention provides a compound or composition of the invention for use in inhibiting necrosis, ferroptosis, and / or human receptor-interacting protein 1 kinase (RIP1) in a human in need thereof, or for use in the manufacture of a medicament for necrosis, ferroptosis, and / or human RIP1 in a human in need thereof.
[0011] In another aspect, the present invention provides a method of inhibiting necrosis, ferroptosis, and / or human receptor-interacting protein 1 kinase (RIP1), comprising administering a compound or composition of the present invention to a human in need thereof.
[0012] In embodiments, the relevant diseases are brain injury, neurodegenerative diseases, viral infections, immune tolerance, cancer, etc., for example, enhancing tumor immunity in pancreatic cancer and melanoma.
[0013] The present invention includes all combinations of the individual embodiments described herein, all of which are intended to be described herein. DETAILED DESCRIPTION OF THE INVENTION
[0014] The examples and embodiments described herein are merely illustrative of the present invention, and it will be apparent to those skilled in the art that various modifications or variations are possible based on these examples and embodiments, and such modifications or variations are intended to fall within the spirit and scope of this application and the scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
[0015] "Alkyl" refers to a hydrocarbon group selected from straight-chain or branched-chain saturated hydrocarbon groups having 1 to 18 carbon atoms, 1 to 12 carbon atoms, or 1 to 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or s-butyl ("s-Bu"), and 1,1-dimethylethyl or t-butyl ("t-Bu"). Other examples of alkyl groups include 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl groups.
[0016] The term "lower alkyl" refers to a group having 1 to 8 carbon atoms, preferably 1 to 6, and more preferably 1 to 4. The term "lower alkenyl" or "lower alkynyl" refers to a group having 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
[0017] "Alkenyl" refers to a hydrocarbon group containing at least one C=C double bond and selected from straight or branched chain hydrocarbon groups having 2 to 18 carbon atoms, 2 to 12 carbon atoms, or 2 to 6 carbon atoms. Examples of alkenyl groups may be selected from ethenyl or vinyl groups, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-diene, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hexa-1,3-dienyl groups.
[0018] "Alkynyl" refers to a hydrocarbon group containing at least one C≡C triple bond and selected from straight-chain or branched-chain hydrocarbon groups having 2 to 18, 2 to 12, or 2 to 6 carbon atoms. Examples of alkynyl groups include ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl groups.
[0019] "Cycloalkyl" refers to a hydrocarbon group selected from saturated and partially unsaturated cyclic hydrocarbon groups, including monocyclic and polycyclic (e.g., bicyclic and tricyclic) groups. For example, the cycloalkyl group may have 3 to 12, 3 to 8, or 3 to 6 carbon atoms. Furthermore, for example, the cycloalkyl group may be a monocyclic group having 3 to 12, 3 to 8, or 3 to 6 carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl. Examples of bicyclic cycloalkyl groups include groups having 7 to 12 ring atoms arranged as a bicyclic group selected from a [4,4], [4,5], [5,5], [5,6], and [6,6] ring system, and groups having 7 to 12 ring atoms arranged as a bridged bicyclic group selected from bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, and bicyclo[3.2.2]nonane. These rings may be saturated, may contain at least one double bond (i.e., may be partially unsaturated), but are not fully conjugated and are not aromatic as defined herein.
[0020] As used herein, "aryl" refers to a group selected from a 5- or 6-membered carbocyclic aromatic ring (such as phenyl); a bicyclic ring system (such as a 7- to 12-membered bicyclic ring system) in which at least one ring is carbocyclic aromatic (such as a bicyclic ring system selected from naphthalene, indane, and 1,2,3,4-tetrahydroquinoline); and a tricyclic ring system (such as a 10- to 15-membered tricyclic ring system) in which at least one ring is carbocyclic aromatic (such as fluorene).
[0021] For example, an aryl group may be selected from a 5- or 6-membered carbocyclic aromatic ring fused to a 5- to 7-membered cycloalkyl ring or heterocycle, optionally containing at least one heteroatom selected from N, O, and S. When the carbocyclic aromatic ring is fused to a heterocycle, the point of attachment is on the carbocyclic aromatic ring; when the carbocyclic aromatic ring is fused to a cycloalkyl group, the point of attachment may be on either the carbocyclic aromatic ring or the cycloalkyl group. Divalent groups formed from substituted benzene derivatives and having free valences on ring atoms are called substituted phenylene groups. In monovalent polycyclic hydrocarbon groups whose names end in "yl," divalent groups obtained by removing one hydrogen atom from the carbon atom having the free valence are named by adding "idene" to the name of the corresponding monovalent group; for example, a naphthyl group with two points of attachment is called naphthylidene.
[0022] "Halogen" or "halo" refers to F, Cl, Br, or I.
[0023] "Heteroalkyl" refers to an alkyl that contains at least one heteroatom.
[0024] "Heteroaryl" refers to a group selected from: a 5- to 7-membered aromatic monocyclic group containing 1, 2, 3, or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon; an 8- to 12-membered bicyclic group containing 1, 2, 3, or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon, wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring; and an 11- to 14-membered tricyclic group containing 1, 2, 3, or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon, wherein at least one ring is aromatic and at least one heteroatom is present in the aromatic ring.
[0025] For example, heteroaryl groups include 5- to 7-membered heteroaromatic rings fused to 5- to 7-membered cycloalkyl rings. In such fused bicyclic heteroaryl ring systems, where only one ring contains at least one heteroatom, the point of attachment can be on either the heteroaromatic ring or the cycloalkyl ring.
[0026] When the total number of S and O atoms in a heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is 2 or less. In some embodiments, the total number of S and O atoms in the aromatic heterocycle is 1 or less.
[0027] Examples of heteroaryl groups (numbered from the first attachment position) include pyridyl (e.g., 2-pyridyl, 3-pyridyl, or 4-pyridyl), cinnolinyl, pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 2,4-imidazolyl, imidazopyridinyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, tetrazolyl, thienyl, triazinyl, benzothienyl, furyl, benzofuryl, benzimidazolyl, indolyl, isoindolyl, indolinyl, phthalazinyl, pyrazinyl, pyridazinyl, pyrrolyl, triazolyl, quinolinyl, isoquinolinyl, pyrazolyl, pyrrolopyridinyl (e.g., 1H-pyrrolo[2,3-b]pyridin-5-yl), pyrazolopyridinyl (e.g., 1H-pyrazolo[3,4-b]pyridin-5-yl), and the like. benzo[d]thiazol-6-yl), pteridinyl, purinyl, 1-oxa-2,3-diazolyl, 1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl, 1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl, 1-thia-3,4-diazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, benzothiazolyl (e.g., benzo[d]thiazol-6-yl), indazolyl (e.g., 1H-indazol-5-yl), and 5,6,7,8-tetrahydroisoquinoline.
[0028] "Heterocyclic," "heterocycle," or "heterocyclyl" refers to a 4-12-membered monocyclic, bicyclic, or tricyclic saturated or partially unsaturated ring containing at least one carbon atom in addition to 1, 2, 3, or 4 heteroatoms selected from oxygen, sulfur, and nitrogen. "Heterocycle" also refers to a 5- to 7-membered heterocycle containing at least one heteroatom selected from N, O, and S fused to a 5-, 6-, and / or 7-membered cycloalkyl, carbocyclic, or heterocyclic aromatic ring; when the heterocycle is fused to a carbocyclic or heterocyclic aromatic ring, the point of attachment is on the heterocycle; when the heterocycle is fused to a cycloalkyl, the point of attachment can be on either the cycloalkyl or heterocycle.
[0029] Additionally, "heterocycle" also refers to an aliphatic spirocycle containing at least one heteroatom selected from N, O, and S, where the point of attachment is at the heterocycle. These rings may be saturated or have at least one double bond (i.e., may be partially unsaturated). The heterocycle may be substituted with oxo. The point of attachment may be at a carbon or a heteroatom of the heterocycle. A heterocycle is not a heteroaryl as defined herein.
[0030] Examples of heterocyclic rings (numbered starting from the bonding position) include 1-pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2,5-piperazinyl, pyranyl, 2-morpholinyl, 3-morpholinyl, oxiranyl, aziridinyl, thiiranyl, azetidinyl, and oxetanyl. , thietanyl, 1,2-dithietanyl, 1,3-dithietanyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl, oxepanyl, thiepanyl, 1,4-oxathianyl, 1,4-dioxepanyl, 1,4-oxathiepanyl, 1,4-oxazepanyl, 1,4-dithiepanyl, 1,4-thi Examples include, but are not limited to, azepanyl, 1,4-diazepane, 1,4-dithianyl, 1,4-azathiyl, oxazepinyl, diazepinyl, thiazepinyl, dihydrothienyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, 1,4-dioxanyl, 1,3-dioxolanyl, pyrazolinyl, pyrazolidinyl, dithianyl, dithiolanyl, pyrazolidinyl, imidazolinyl, pyrimidinonyl, 1,1-dioxo-thiomorpholinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, and azabicyclo[2.2.2]hexanyl. Substituted heterocycles also include ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl, and 1,1-dioxo-1-thiomorpholinyl.
[0031] As used herein, the term "fused ring" refers to a polycyclic ring system (e.g., a bicyclic or tricyclic ring system) in which two rings share only two ring atoms and one bond. Examples of fused rings include fused bicyclic cycloalkyl rings, such as groups having 7 to 12 ring atoms arranged as a bicyclic group selected from the aforementioned [4,4] ring system, [4,5] ring system, [5,5] ring system, [5,6] ring system, and [6,6] ring system; fused bicyclic aryl rings, such as the aforementioned 7- to 12-membered bicyclic aryl ring system; fused tricyclic aryl rings, such as the aforementioned 10- to 15-membered tricyclic aryl ring system; fused bicyclic heteroaryl rings, such as the aforementioned 8- to 12-membered bicyclic heteroaryl ring; fused tricyclic heteroaryl rings, such as the aforementioned 11- to 14-membered tricyclic heteroaryl ring; and the aforementioned fused bicyclic heterocyclyl rings and fused tricyclic heterocyclyl rings.
[0032] In embodiments, the substituents include optionally substituted heteroatoms and C-C groups which may be substituted, may contain heteroatoms, and may be cyclic. 18 In particular, C-C hydrocarbyls, which may be substituted, may contain heteroatoms, and may be cyclic. 18 The hydrocarbyl is alkyl, alkenyl or alkynyl, which may be substituted, may contain heteroatoms, and may be cyclic, or aryl, which may be substituted and may contain heteroatoms, and / or the optionally substituted heteroatoms are halogen, optionally substituted hydroxyl (alkoxy, aryloxy, etc.), optionally substituted acyl (formyl, alkanoyl, carbamoyl, carboxyl, amido, etc.), optionally substituted amino (amino, alkylamino, dialkylamino, amido, sulfamidyl, etc.), optionally substituted thiol (mercapto, alkylthiol, arylthiol, etc.), optionally substituted sulfinyl or sulfonyl (alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, etc.), nitro or cyano.
[0033] In embodiments, substituents are halogen, —R′, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —COR′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′—C(O)NR″R′″, —NR′—SONR′″, —NR″COR′, —NH—C(NH 2)=NH, -NR'C(NH2)=NH, -NH-C(NH2)=NR', -S(O)R', -S2R', -SON2NR'R'', -NR''S2R, -CN, -NO2, -N3, -CH(Ph)2, perfluoro(C1-C4)alkoxy, and perfluoro(C1-C4)alkyl, the number of substituents is 0 to 3, with groups having 0, 1, or 2 substituents being particularly preferred. R', R'' and R''' each independently represent hydrogen, unsubstituted (C1-C8)alkyl or heteroalkyl, (C1-C8)alkyl or heteroalkyl substituted with 1 to 3 halogen atoms, unsubstituted aryl, aryl substituted with 1 to 3 halogen atoms, unsubstituted alkyl group, unsubstituted alkoxy group, unsubstituted thioalkoxy group, or aryl-(C1-C4)alkyl group. When R' and R" are attached to the same nitrogen atom, R' and R" can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. Thus, -NR'R" includes 1-pyrrolidinyl and 4-morpholinyl, "alkyl" includes groups such as trihaloalkyl (e.g., -CF3 and -CH2CF3), and when the aryl group is 1,2,3,4-tetrahydronaphthalene, the aryl group can be optionally substituted with a substituted or unsubstituted (C3-C7) spirocycloalkyl group, which can be optionally substituted as "cycloalkyl" as defined herein.
[0034] Preferred substituents are selected from halogen, —R′, —OR′, ═O, —NR′R″, —SR′, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —COR′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR″COR′, —NR′-SONR″R′″, —S(O)R′, —SOR′, —SONR′R″, —NR″SOR, —CN, —NO, perfluoro(C1-C4)alkoxy, and perfluoro(C1-C4)alkyl, where R′ and R″ are as defined above.
[0035] Preferred substituents are disclosed herein, specific examples of which are given in the tables, structures, examples and claims, and may be applied to various compounds of the invention, i.e., the substituents of a given compound may be used in combination with another compound.
[0036] In certain embodiments, applicable substituents are each independently a substituted or unsubstituted heteroatom, a substituted or unsubstituted C1-C6 alkyl having 0-3 heteroatoms, a substituted or unsubstituted C2-C6 alkenyl having 0-3 heteroatoms, a substituted or unsubstituted C2-C6 alkynyl having 0-3 heteroatoms, or a substituted or unsubstituted C6-C6 alkyl having 0-3 heteroatoms. 14 aryl, and each heteroatom is independently oxygen, phosphorus, sulfur, or nitrogen.
[0037] In more specific embodiments, each applicable substituent is independently aldehyde, aldimine, alkanoyloxy, alkoxy, alkoxycarbonyl, alkyloxy, alkyl, amine, azo, halogen, carbamoyl, carbonyl, carboxamide, carboxyl, cyanyl, ester, halo, haloformyl, hydroperoxyl, hydroxyl, imine, isocyanide, isocyanate, N-tert-butoxycarbonyl, nitrate, nitrite, nitro, nitroso, phosphate, phosphono, sulfide, sulfonyl, sulfo, sulfhydryl, thiol, thiocyanyl, trifluoromethyl, or trifluoromethyl ether (OCF3).
[0038] The compounds of the present invention may have asymmetric centers and therefore may exist as enantiomers. When the compounds of the present invention have two or more asymmetric centers, they may further exist as diastereomers. Enantiomers and diastereomers are included in the broader definition of stereoisomers. All possible stereoisomers, including substantially pure resolved enantiomers, racemic mixtures thereof, and mixtures of diastereomers, are intended to be included in the present invention. Also, all possible stereoisomers of the compounds of the present invention and / or pharmaceutically acceptable salts thereof are intended to be included in the present invention. Unless otherwise specified herein, a reference to one isomer applies to all possible isomers. When the isomeric composition is not specified, all possible isomers are included.
[0039] By "substantially pure" is meant that the stereoisomer of interest contains no more than 35% by weight of other stereoisomers, such as no more than 30% by weight, further such as no more than 25% by weight, further such as no more than 20% by weight. In some embodiments, "substantially pure" means that the stereoisomer of interest contains no more than 10% by weight of other stereoisomers, such as no more than 5% by weight, such as no more than 1% by weight.
[0040] Unless specifically stated herein, when compounds of the invention contain olefinic double bonds, such double bonds are meant to include both E and Z geometric isomers.
[0041] Some compounds of the present invention may have different points of attachment of hydrogen; such compounds are called tautomers. For example, a compound having a carbonyl group (-CHC(O)-) (keto form) may undergo tautomerism to form a hydroxyl group (-CH=C(OH)-) (enol form). Where applicable, both the keto and enol forms, either the keto or enol forms, and mixtures of the keto and enol forms are intended to be included.
[0042] It may be advantageous to separate the various reaction products from one another and / or from the starting materials. The desired products from each step or series of steps are separated and / or purified (hereinafter "separated") to the desired homogeneity by techniques common in the art. Typically, such separations involve multiphase extraction, crystallization from a single solvent or a mixture of solvents, distillation, sublimation, or chromatography. Chromatography encompasses a variety of methods, including, for example, reverse-phase and normal-phase chromatography; size-exclusion chromatography; ion-exchange chromatography; high-, medium-, and low-pressure liquid chromatography methods and devices; small-volume analytical chromatography; simulated moving bed ("SMB") chromatography; preparative thin-layer chromatography; preparative thick-layer chromatography; small-volume thin-layer chromatography techniques; and flash chromatography techniques. Those skilled in the art will be able to apply the techniques most likely to achieve the desired separation.
[0043] Diastereomeric mixtures can be separated into their individual diastereomers based on their physical chemical differences using methods known to those skilled in the art, such as chromatography and / or fractional crystallization. Enantiomeric mixtures can be converted to a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), followed by separation of the diastereomers and conversion (e.g., by hydrolysis) of each resulting diastereomer into its corresponding pure enantiomer. Enantiomers can also be separated using a chiral HPLC column.
[0044] Single stereoisomers (e.g., substantially pure enantiomers) may be obtained by resolving a racemic mixture, such as by forming diastereomers using an optically active resolving agent. Racemic mixtures of chiral compounds of the present invention can be separated and isolated by appropriate methods, such as (1) forming ionic diastereomeric salts with a chiral compound and then separating them by methods such as fractional crystallization, (2) forming diastereomeric compounds with a chiral derivatizing agent, separating the diastereomers, and converting them to pure stereoisomers, and (3) directly isolating substantially pure or enriched stereoisomers under chiral conditions.
[0045] "Pharmaceutically acceptable salts" include, but are not limited to, inorganic acid salts selected from hydrochlorides, phosphates, diphosphates, hydrobromides, sulfates, sulfinates, nitrates, and the like, and organic acid salts selected from malate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, alkanoates (such as acetate), salts with HOOC-(CH)-COOH (n is selected from 0 to 4), and the like. Similarly, examples of pharmaceutically acceptable cations include, but are not limited to, sodium, potassium, calcium, aluminum, lithium, and ammonium.
[0046] Furthermore, if a compound is obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product obtained is a free base, an addition salt (such as a pharmaceutically acceptable addition salt) can be obtained by dissolving the free base in a suitable organic solvent and treating the resulting solution with an acid, according to conventional methods for preparing acid addition salts from basic compounds. Those skilled in the art will be able to prepare pharmaceutically acceptable, non-toxic addition salts by appropriately selecting from a variety of available synthetic methods without undue experimentation.
[0047] "Treating," "treat," or "treatment" refers to administering at least one compound, at least one stereoisomer thereof, and / or at least one pharmaceutically acceptable salt thereof to a subject identified in need thereof.
[0048] An "effective amount" refers to an amount of at least one compound, at least one stereoisomer thereof, and / or at least one pharmaceutically acceptable salt thereof that is effective in "treating" a disease or disorder in a subject, e.g., sufficient upon administration to induce to some significant extent a desired biological or medical response in a tissue, system, animal, or human, and to prevent the development of or alleviate to some extent one or more symptoms of the condition or disorder being treated. The therapeutically effective amount will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal being treated.
[0049] "At least one substituent" includes, for example, 1 to 4 substituents, for example, 1 to 3 substituents, and further, for example, 1 or 2 substituents. For example, as used herein, "at least one substituent R 16 " is R 16 The group may contain 1 to 4 substituents, such as 1 to 3 substituents, further such as 1 or 2 substituents selected from the list of:
[0050] The compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof may be used alone in therapy, or the compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof may be used in combination with at least one additional therapeutic agent in therapy. In some embodiments, the compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof may be used in combination with at least one additional therapeutic agent. The compounds disclosed herein and / or one pharmaceutically acceptable salt may be administered together with at least one additional therapeutic agent in a single unit dosage form, or in separate dosage forms. When administered in separate dosage forms, the at least one additional therapeutic agent may be administered before, simultaneously with, or after the administration of the compounds disclosed herein and / or one pharmaceutically acceptable salt.
[0051] Additionally, there is provided a composition comprising a compound of the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
[0052] Compositions containing the compounds of the present invention, their stereoisomers, or pharmaceutically acceptable salts thereof can be administered by a variety of known methods, including oral, topical, rectal, parenteral, inhalation spray, and implanted reservoirs. In each case, the most appropriate route will depend on the individual recipient and the nature and severity of the condition for which the active ingredient is being administered. As used herein, "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection or infusion. The compositions disclosed herein may be conveniently provided in unit dosage form and may be prepared by any method well known in the art.
[0053] The compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof can be administered orally in solid dosage forms such as capsules, tablets, lozenges, dragees, granules, and powders, or in liquid dosage forms such as elixirs, syrups, emulsions, dispersions, and suspensions. The compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof disclosed herein can also be administered parenterally in sterile liquid dosage forms such as dispersions, suspensions, and solutions. The compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof disclosed herein can also be administered using other dosage forms, such as ointments, creams, drops, transdermal patches, or powders for topical administration; ophthalmic solutions or suspensions (i.e., eye drops) for ophthalmic administration; aerosol spray or aerosol powder compositions for inhalation or intranasal administration; and creams, ointments, sprays, or suppositories for rectal or vaginal administration.
[0054] Gelatin capsules containing the compounds disclosed herein and / or at least one pharmaceutically acceptable salt thereof and a powdered carrier such as lactose, starch, cellulose derivatives, magnesium stearate, or stearic acid can also be used. Compressed tablets can also be prepared using similar diluents. Tablets and capsules can also be prepared as sustained-release formulations for continuous release of the drug over a period of time. Compressed tablets can be sugar-coated or film-coated to mask unpleasant tastes or protect the tablet from the atmosphere, or enteric-coated to selectively disintegrate in the gastrointestinal tract.
[0055] Liquid dosage forms for oral administration may further comprise at least one additive selected from coloring agents and flavoring agents to facilitate easier administration by the patient.
[0056] Suitable carriers for parenteral solutions typically include water, suitable oils, saline, aqueous dextrose (glucose), related sugar solutions, and glycols (e.g., propylene glycol and polyethylene glycol). Parenteral solutions may contain a water-soluble salt of at least one compound described herein, at least one suitable stabilizer, and, if necessary, at least one buffer substance. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid, which may be used alone or in combination. Suitable stabilizers include citric acid or its salts, or sodium EDTA. Furthermore, parenteral solutions may contain at least one preservative selected from, for example, benzalkonium chloride, methylparaben, propylparaben, and chlorobutanol.
[0057] Pharmaceutically acceptable carriers are selected from carriers that are compatible with the active ingredients in the composition (and in some embodiments, can stabilize the active ingredients) and are not harmful to the subject being treated. For example, solubilizing agents such as cyclodextrins (which can form specific, highly soluble complexes with at least one compound and / or at least one pharmaceutically acceptable salt disclosed herein) can be used as pharmaceutical additives for delivering the active ingredients. Other examples of carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments (such as D&C Yellow #10). Suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in the field.
[0058] For administration by inhalation, the compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof may be conveniently delivered in the form of an aerosol spray from a pressurized container or inhaler. Alternatively, the compounds of the present invention, their stereoisomers, and pharmaceutically acceptable salts thereof may be formulated and delivered in powder form as a powder, and such powder compositions may be inhaled using an insufflation powder inhaler. An example of a delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution containing the compounds of the present invention disclosed herein, their stereoisomers, or pharmaceutically acceptable salts thereof in at least one suitable propellant selected from, for example, fluorocarbons or hydrocarbons.
[0059] For ocular administration, the ophthalmic preparation may be formulated as a suspension or solution containing the compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof in an appropriate weight percentage in an appropriate ophthalmic solvent, thereby maintaining the compound of the present invention, its stereoisomer, or at least one pharmaceutically acceptable salt thereof in contact with the surface of the eye for a period of time sufficient to allow the compound of the present invention, its stereoisomer, or at least one pharmaceutically acceptable salt thereof to penetrate the cornea and the interior of the eye.
[0060] Pharmaceutical dosage forms useful for administering the compounds of the invention disclosed herein, their stereoisomers, and their pharmaceutically acceptable salts include, but are not limited to, hard gelatin capsules, soft gelatin capsules, tablets, parenteral injections, and oral suspensions.
[0061] The dosage is determined by factors such as the recipient's age, health condition, and weight, the severity of the disease, the type of concomitant therapy (if any), the frequency of treatment, and the desired characteristics of the effect. The daily dosage of the active ingredient is generally not universally determined, but may be, for example, 0.1 to 2,000 mg per day. For example, administering 10 to 500 mg once or multiple times daily may be effective in achieving the desired results.
[0062] In some embodiments, for example, a number of unit capsules can be prepared by filling a standard two-shell hard gelatin capsule with 100 mg of a powdered compound of the invention disclosed herein, its stereoisomer, or a pharmaceutically acceptable salt thereof, 150 mg of lactose, 50 mg of cellulose, and 6 mg of magnesium stearate.
[0063] In some embodiments, a soft gelatin capsule containing 100 mg of the active ingredient can be prepared by preparing a mixture of the compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof with a digestible oil such as soybean oil, cottonseed oil, or olive oil, and injecting the mixture into gelatin using a positive displacement pump. The resulting capsule is washed and then dried.
[0064] In some embodiments, tablets can be prepared in bulk by conventional methods, for example, where each dosage contains 100 mg of the compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg of lactose. Appropriate coatings may be applied to improve palatability or delay absorption.
[0065] In some embodiments, a parenteral composition suitable for administration by injection can be prepared by adding 1.5% by weight of a compound disclosed herein and / or at least one enantiomer, diastereomer, or pharmaceutically acceptable salt thereof to 10% by volume of propylene glycol and stirring. The resulting solution is made up to the desired volume with water for injection and sterilized.
[0066] In some embodiments, an aqueous suspension for oral administration can be prepared. For example, 5 ml of an aqueous suspension containing 100 mg of a micronized compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof, 100 mg of sodium carboxymethylcellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution (USP), and 0.025 ml of vanillin can be used.
[0067] When the compound of the present invention, its stereoisomer, or a pharmaceutically acceptable salt thereof is administered stepwise or together with at least one other therapeutic agent, the same dosage form can usually be used. When the drugs are administered in physical combination, the dosage form and administration route should be selected according to the compatibility of the combined drugs. Therefore, "co-administration" is understood to include simultaneous or sequential administration of at least two drugs, or administration of at least two active ingredients as a multi-drug combination.
[0068] The compounds disclosed herein, their stereoisomers, or pharmaceutically acceptable salts thereof can be administered as the sole active ingredient or can be administered in combination with at least one second active ingredient.
[0069] The compounds of the present invention are incorporated into pharmaceutical compositions or formulations. Pharmaceutical compositions contain pharmaceutically acceptable diluents and / or carriers, i.e., diluents or carriers that are physiologically compatible and substantially free of pathogenic impurities. Suitable additives or carriers and methods for preparing administrable compositions are known or apparent to those skilled in the art and are described in further detail in publications such as Remington's Pharmaceutical Science, Mack Publishing Co., NJ (1991). Pharmaceutical compositions may also be in the form of controlled-release or sustained-release compositions known in the art. In various applications, the compounds of the present invention are administered in the morning / midday with a rest period at night.
[0070] The compounds of the present invention may be used as they are, or may be used in the form of a pharmaceutically acceptable salt such as hydrochloride, hydrobromide, acetate, sulfate, citrate, carbonate, or trifluoroacetate. When the compounds of the present invention have a relatively acidic functional group, a salt can be obtained by adding a desired base without a solvent or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium salt, potassium salt, calcium salt, ammonium salt, organic amino salt, and magnesium salt. When the compounds of the present invention have a relatively basic functional group, a salt can be obtained by adding a desired acid without a solvent or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include salts derived from inorganic acids such as hydrochloride, hydrobromide, nitrate, carbonate, bicarbonate, phosphate, monohydrogenphosphate, dihydrogenphosphate, sulfate, hydrogensulfate, hydroiodide, and phosphite, as well as salts derived from relatively non-toxic organic acids such as acetate, propionate, isobutyrate, maleate, malonate, benzoate, succinate, suberate, fumarate, lactate, mandelate, phthalate, benzenesulfonate, p-tolylsulfonate, citrate, tartrate, and methanesulfonate. Also included are salts of amino acids such as arginate, and organic acid salts such as glucuronate or galacturonate (see, e.g., Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 66, 1-19).
[0071] The neutral compound may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent compound may differ from the various salt forms in physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to the parent compound for purposes of this invention.
[0072] In addition to salt forms, the present invention provides compounds in prodrug forms. Prodrugs of the compounds described herein are compounds that are easily chemically transformed into compounds of the present invention under physiological conditions. Furthermore, prodrugs can be converted to compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. In some situations, prodrugs are often useful because they are easier to administer than the parent drug. For example, prodrugs may have better oral bioavailability than the parent drug. Prodrugs may also have higher solubility in pharmacological compositions than the parent drug. Various prodrug derivatives are known in the art, including prodrugs that utilize hydrolysis or oxidative activation. Examples of prodrugs include, but are not limited to, compounds of the present invention that are administered as esters ("prodrugs") and metabolically hydrolyzed to the active carboxylic acid.
[0073] Certain compounds of the present invention may exist in unsolvated form or in solvated form, including hydrated form. Usually, solvated form is the same as unsolvated form and is intended to be included within the scope of the present invention. Certain compounds of the present invention may exist in various crystalline forms or amorphous forms. Usually, for the purposes envisioned by the present invention, all physical forms are equivalent and are intended to be included within the scope of the present invention.
[0074] Some of the compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers of the compounds of the present invention are all intended to be encompassed within the scope of the present invention.
[0075] The compounds of the present invention may contain isotopes such as deuterium at one or more of the constituent atoms in proportions not found in nature, e.g., -CD3, CD2H, or CDH2 in place of methyl. For example, the compounds of the present invention may contain isotopes such as tritium ( 3 H), iodine-125( 125 I), carbon-14 ( 14 The compounds of the present invention may be radiolabeled with a radioactive isotope, such as C. Compounds of the present invention that contain isotopes, whether radioactive or non-radioactive, are intended to be encompassed within the scope of the present invention.
[0076] The compounds of the invention are typically administered in a "therapeutically effective amount," i.e., an amount of the compound of the invention capable of inducing in a tissue, system, animal, or human the biological or medical response sought by a researcher, veterinarian, physician, or other clinician. A "therapeutically effective amount" encompasses a sufficient amount of compound of the invention when administered to prevent the development of, or alleviate to some extent, one or more symptoms of the condition or disorder being treated. The therapeutically effective amount will vary depending on the compound, the disease and its severity, and the age and weight of the mammal being treated.
[0077] The contacting is typically achieved by administering to the subject an effective amount of one or more compounds having general formula I (see above), including the various embodiments described above. Typically, the administration is adjusted to a therapeutic dose of about 0.1 to 50 mg / kg, preferably 0.5 to 10 mg / kg, and more preferably 1 to 10 mg / kg, although the optimal dose varies depending on the compound and is typically determined for each compound by conducting experiments.
[0078] A "unit dosage form" refers to a physically discrete unit suitable as a unitary dose for human subjects and other mammals, each unit containing a predetermined amount of active agent calculated to produce a desired therapeutic effect, together with appropriate pharmaceutical excipients. Typical unit dosage forms include ampoules or syringes filled with premeasured amounts of liquid compositions, and for solid compositions, pills, tablets, capsules, lozenges, and the like. In such compositions, the mimetic is typically present as a minor component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), with the remainder being processing aids and various solvents or carriers to facilitate the formation of the desired dosage form. Unit dosage formulations are preferably about 5 mg, about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 250 mg, about 500 mg, or about 1,000 mg per unit. In one particular embodiment, the unit dosage forms are packaged in a multi-pack package suitable for successive use, for example a blister pack containing sheets containing at least 6, 9 or 12 unit dosage forms.
[0079] The compositions of the present invention may be formulated and / or co-administered with other compounds for the treatment of programmed cell death.
[0080] [Table 1] TIFF0007577655000003.tif233169TIFF0007577655000004.tif229167TIFF0007577655000005.tif213167TIFF0007577655000006.tif228167TIFF0007577655000007.tif228167TIFF0007577655000008.tif217168TIFF0007577655000009.tif217167TIFF0007577655000010.tif232167TIFF0007577655000011.tif227167TIFF0007577655000012.tif235167TIFF0007577655000013.tif203167TIFF0007577655000014.tif189167TIFF0007577655000015.tif212167TIFF0007577655000016.tif225167TIFF0007577655000017.tif233167TIFF0007577655000018.tif228167TIFF0007577655000019.tif212167TIFF0007577655000020.tif224168TIFF0007577655000021.tif224167TIFF0007577655000022.tif212166TIFF0007577655000023.tif233169TIFF0007577655000024.tif220167TIFF0007577655000025.tif232167TIFF0007577655000026.tif59167
[0081]
Table 2
[0082]
Table 3
[0083] synthesis Compound 1: Azetidin-1-yl(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] To a cooled solution of 5-phenyl-4,5-dihydro-1H-pyrazole (200 mg, 1.37 mmol) in dry DCM was added pyridine (216.7 mg, 2.74 mmol), followed by the addition of triphosgene (162.6 mg, 0.548 mmol) in several portions. The mixture was stirred at 0 °C for 3 h. Azetidine (150 mg, 2.7 mmol) and triethanolamine (270 mg, 2.7 mmol) were dissolved in dry DCM (5 mL), and the above reaction mixture was added to this solution and stirred overnight. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.32 - 7.27 (m, 2H), 7.23 - 7.15 (m, 3H), 6.73 (t, J = 1.7 Hz, 1H), 5.29 (dd, J = 12.2, 6.5 Hz, 1H), 4.22 - 4.04 LC-MS (m / z) 230.30 (M+H) + ).
[0084] Compound 2: N-cyclobutyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 2 was prepared in 35% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (300 mg), cyclobutanamine (180 mg) and triphosgene (280 mg) following the method outlined for compound 1. LC-MS (m / z) 244.3 (M+H + )
[0085] Compound 3: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(2-azaspiro[3.3]heptan-2-yl)methanone [ka] The title compound 3 was prepared in 40% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (300 mg), 2-azaspiro[3.3]heptane (530 mg) and triphosgene (280 mg) following the method outlined for compound 1. LC-MS (m / z) 270.4 (M+H + )
[0086] Compound 4: (3-methylazetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 4 was prepared in 16% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (200 mg), 3-methylazetidine hydrochloride (290 mg) and triphosgene (162.5 mg) following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.32 - 7.26 (m, 2H), 7.23-7.19 (m, 3H), 6.73 (t, J = 1.7 Hz, 1H), 5.29 (dd, J = 12.2, 6.5 Hz, 1H), 4.23 (dt, J = 21.5, 8.6 Hz, 2H), 3.69 (ddd, J = 34.7, 8.8, 5.7 Hz, 2H), 3.30 (ddd, J = 18.4, 12.2, 1.7 Hz, 1H), 2.69 (ddd, J = 18.4, 6.5, 1.7 Hz, 1H), 2.66 - 2.58 (m, 1H), 1.20 (d, J = 6.9 Hz, 3H). LC-MS (m / z) 244.3 (M+H + )
[0087] Compound 5: N-cyclopentyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 5 was prepared in 36% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (200 mg), cyclopentanamine (230 mg) and triphosgene (162.5 mg) following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.32 - 7.27 (m, 2H), 7.26 - 7.17 (m, 3H), 6.74 (t, J = 1.7 Hz, 1H), 5.27 (dd, J = 12.2, 6.1 Hz, 2H), 4.12-4.02 (m,1H), 3.40 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.78 (ddd, J = 18.6, 6.2, 1.8 Hz, 1H), 1.99-1.88 (m, 2H), 1.71 - 1.50 (m, 4H), 1.45 - 1.34 (m, 2H).LC-MS (m / z) 258.34 (M+H + )
[0088] Compound 6: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(pyrrolidin-1-yl)methanone [ka] The title compound 6 was prepared in 35% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (200 mg), pyrrolidine (190 mg) and triphosgene (162.5 mg) following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.33 - 7.26 (m, 3H), 7.26 - 7.19 (m, 2H), 6.74 (t, J = 1.7 Hz, 1H), 5.34 (dd, J = 12.0, 9.1 Hz, 1H), 3.64 - 3.55 LC-MS (m / z) 244.31 (M+H + )
[0089] Compound 7: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(piperidin-1-yl)methanone [ka] The title compound 7 was prepared in 8.5% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (200 mg), piperidine (235 mg) and triphosgene (250 mg) following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.34 - 7.25 (m, 4H), 7.24-7.19 (m, 1H), 6.78 (brs, 1H), 5.33 (dd, J = 11.6, 10.4 Hz, 1H), 3.61 - 3.38 (m, 4H), 3.25 (ddd, J = 18.1, 11.7, 1.6 Hz, 1H), 2.68 (ddd, J = 18.2, 10.3, 1.5 Hz, 1H), 1.70 - 1.40 (m, 6H). LC-MS (m / z) 258.3 (M+H + )
[0090] Compound 8: (2-methylpiperidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 8 was prepared in 17% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (13 mg), 2-methylpiperidine (8.91 mg) and triphosgene (7.1 mg) following the method outlined for compound 1. 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.27 (m, 3H), 7.26 - 7.18 (m, 2H), 6.79 (brs, 1H), 5.32 (t, J = 11.1 Hz, 1H), 4.72-4.66 (m, 1H), 3.89 (dd, J = 13.6, 3.2 Hz, 1H), 3.24 (ddd, J = 18.0, 11.6, 1.2 Hz, 1H), 3.02 (td, J = 13.4, 2.8 Hz, 1H), 2.73 - 2.61 (m, 1H), 1.81 - 1.69 (m, 1H), 1.62-1.35 (m, 5H), 1.11 (d, J = 7.0 Hz, 3H). LC-MS (m / z) 272.4 (M+H + )
[0091] Compound 9: (3-methylpiperidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] To a cooled solution of triphosgene (320 mg, 1.08 mmol) in dry DCM (5 mL), a mixture of 5-phenyl-4,5-dihydro-1H-pyrazole (400 mg, 2.74 mmol) and TEA (550 mg, 5.44 mmol) was added dropwise. The mixture was stirred at 0 °C for 3 h. 3-Methylpiperidine (260 mg, 2.7 mmol) and TEA (270 mg, 2.7 mmol) were dissolved in dry DCM (5 mL). Half of the reaction mixture was added to this solution and stirred overnight. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography (EA / PE = 1 / 3) afforded compound 9 as a yellow oil (180 mg, 48.2%). 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.25 (m, 3H), 7.24-7.22 (m, 2H), 6.78 (d, J = 1.2 Hz, 1H), 5.39 - 5.24 (t, J= 10.81H), 4.22 (ddd, J = 11.1, 3.3, 1.7 Hz, 1H), 4.13 - 3.99 (m, 1H), 3.25 (ddd, J = 18.1, 11.7, 1.7 Hz, 1H), 2.97 - 2.83 (m, 1H), 2.68 (ddd, J = 12.1, 10.3, 1.4 Hz, 1H), 2.53 - 2.36 LC-MS (m / z) 272.40 (M+H + ).
[0092] Compound 10: N-cyclohexyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 10 was prepared in 8.5% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (300 mg), cyclohexanamine (240 mg) and triphosgene (280 mg) following the method outlined for compound 1. 1H NMR (400 MHz, CDCl3) δ 7.32-7.27 (m, 2H), 7.24 - 7.13 (m, 3H), 6.74 (t, J = 1.6 Hz, 1H), 5.79 (d, J = 7.8 Hz, 1H), 5.30 - 5.22 (m, 1H), 3.60 (ddd, J = 14.8, 10.6, 4.2 Hz, 1H), 3.39 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.79 (ddd, J = 18.6, 6.2, 1.7 Hz, 1H), 1.90 (dd, J = 18.0, 14.6 Hz, 2H), 1.73 - 1.61 (m, 2H), 1.39 - 1.05 (m, 6H). LC-MS (m / z) 272.4 (M+H + ).
[0093] Compound 11: N-(3-methylcyclohexyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 11 was prepared in 25.5% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (200 mg), 3-methylcyclohexan-1-amine (233 mg) and triphosgene (162.3 mg) following the method outlined for compound 9. 1 H NMR (400 MHz, CDCl3) δ 7.36 - 7.29 (m, 2H), 7.26 - 7.19 (m, 2H), 6.79 - 6.75 (m, 1H), 6.09 (s, 1H), 5.76 (d, J= 8.2 Hz, 1H), 5.29 (ddd, J = 12.3, 6.1, 3.3 Hz, 1H), 3.68 - 3.54 (m, 1H), 3.42 (dddd, J = 18.5, 12.2, 3.1, 1.7 Hz, 1H), 3.25 (dt, J = 14.3, 4.5 Hz, 2H), 2.86 - 2.77 (m, 1H), 2.05 - 1.91 (m, 3H), 1.73 - 1.61 (m, 2H), 0.92-0.87(m, 3H). LC-MS (m / z) 286.4 (M+H+ )
[0094] Compound 12: N-cyclohexyl-N-methyl-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 12 was prepared in 15% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (200 mg), 3-methylcyclohexan-1-amine (305 mg) and triphosgene (162 mg) following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.35-7.30 (m, 3H), 7.26 - 7.23 (m, 2H), 6.80 (s, 1H), 5.34 (t, J = 11.1 Hz, 1H), 4.02 (t, J = 11.6 Hz, 1H), 3.27 (dd, J = 17.2, 12.4 Hz, 1H), 2.90 (s, 3H), 2.70 (dd, J = 18.6, 11.3 Hz, 1H), 1.81-1.58 (m, 4H), , 1.51 - 1.24 (m, 5H), 1.13 - 1.01 (m, 1H).LC-MS (m / z) 286.20 (M+H + )
[0095] Compound 13: Isoindolin-2-yl(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 13 was prepared in 23% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (300 mg), isoindoline (320 mg) and triphosgene (162.5 mg) following the method outlined for compound 1. 1H NMR (400 MHz, CDCl3) δ 7.33-7.30 (m, 2H), 7.25-7.22(m, 2H)7.23 - 7.11 (m, 5H), 6.72 (t, J = 1.7 Hz, 1H), 5.28 (dd, J = 12.2, 6.1 Hz, 1H), 4.72 - 4.55 (m, 1H), 3.40 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 3.34 - 3.23 (m, 2H), 2.87 - 2.74 (m, 3H).LC-MS (m / z) 292.4 (M+H) + )
[0096] Compound 14: N-(2,3-dihydro-1H-inden-2-yl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 14 was prepared in 20% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (300 mg), 2,3-dihydro-1H-inden-2-amine (450 mg) and triphosgene (162.5 mg) following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.33-7.30(m, 2H), 7.25-7.22 (m, 2H), 7.21 - 7.11 (m, 5H), 6.72 (t, J = 1.7 Hz, 1H), 6.10 (d, J = 7.9 Hz, 1H), 5.28 (dd, J = 12.2, 6.1 Hz, 1H), 4.72 - 4.55 (m, 1H), 3.40 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 3.34 - 3.23 (m, 2H), 2.87 - 2.74 (m, 3H). LC-MS (m / z) 306.4 (M+H + LC-MS (m / z) 306.4 (M+H + )
[0097] Compound 15: (3,4-Dihydroisoquinolin-2(1H)-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 15 was prepared in 30.6% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (25 mg), 1,2,3,4-tetrahydroisoquinoline (50 mg) and triphosgene (12.7 mg) following the method outlined for compound 1. LC-MS (m / z) 306.4 (M+H + )
[0098] Compound 16: (3-benzylazetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 16 was prepared in 64.6% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (25 mg), 3-benzylazetidine and triphosgene following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.36-7.26 (m, 4H), 7.26-7.12 (m, 6H), 6.75 (t, 1H, J = 1.6 Hz), 5.31 (dd, 1H, J = 12.4, 6.4 Hz), 4.25 (t, 1H, J = 8.4 Hz), 4.18 (t, 1H, J = 8.4 Hz), 3.92 (dd, 1H, J = 8.8, 5.6 Hz), 3.83 (dd, 1H, J = 8.8, 5.6 Hz), 3.32 (ddd, 1H, J = 18.5, 12.0, 1.6 Hz), 2.95-2.90 (m, 2H), 2.89-2.84 (m, 1H), 2.72 (ddd, 1H, J = 18.4, 6.4, 1.6 Hz). LC-MS (m / z):320.35 [M+H] + .
[0099] Compound 17: (3-benzylpyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 17 was prepared in 64.6% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (25 mg), 3-benzylazetidine and triphosgene following the method outlined for compound 1. 1H NMR (400 MHz, CDCl3) δ 7.27-7.35 (m, 7H), 7.13-7.25 (m, 3H), 6.74-6.76 (m, 1H), 5.31-5.37(m, 1H), 3.78-3.88 (m, 1H), 3.55-3.63 (m,1H), 3.28-3.35 (m, 1H), 3.21-3.26 (m, 1H), 2.59-2.77 (m, 3H), 2.29-2.46 (m, 2H), 1.87-1.96 (m, 1H), 1.51-1.68 (m, 1H). LC-MS (m / z): 334.41 [M+H] + .
[0100] Compound 18: (4-benzylpiperidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 18 was prepared in 14% yield from 5-phenyl-4,5-dihydro-1H-pyrazole, 4-benzylpiperidine and triphosgene following the method outlined for compound 9. 1 H NMR (400 MHz, CDCl3) δ 7.36 - 7.28 (m, 5H), 7.27 - 7.23 (m, 2H), 7.21-7.17 (m, 1H), 7.15-7.13 (m, 2H), 6.80 (t, J = 1.7 Hz, 1H), 5.35 (dd, J = 11.7, 10.3 Hz, 1H), 4.33 - 4.25 (m, 1H), 4.19 (ddt, J = 13.4, 4.4, 2.3 Hz, 1H), 3.28 (ddd, J = 18.2, 11.8, 1.8 Hz, 1H), 2.86 - 2.77 (m, 1H), 2.77 - 2.65 (m, 2H), 2.54 (d, J = 7.1 Hz, 2H), 1.80 - 1.58 (m, 1H), 1.40 - 1.29 (m, 2H), 1.24 - 1.08 (m, 2H). LC-MS (m / z) 348.5 (M+H + )
[0101] Compound 19: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-(phenylamino)azetidin-1-yl)methanone [ka] tert-Butyl (1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)carbamate (50 mg) was prepared by the method described for compound 1 and dissolved in DCM (6 mL) and 1 mL of TFA was added. The mixture was stirred at room temperature for 2 hours and concentrated to give crude (3-aminoazetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (30 mg). LC-MS (m / z) 244.4 (M+H + ). A mixture of (3-aminoazetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (30 mg), phenylboronic acid (20 mg), Cu(OAc) (3 mg), and TEA (30 mg) in DCM (10 mL) was stirred at 65 °C for 16 h. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 19 (14 mg, 32%). 1 H NMR (400 MHz, CDCl3) δ 7.50 - 7.22 (m, 9H), 6.74 (s, 1H), 6.51 (s, 1H), 4.84 - 4.10 (m, 5H), 3.33 (dd, J = 18.6, 12.4 Hz, 1H), 2.97 (s, 3H), 2.72 (dd, J = 18.8, 5.8 Hz, 1H) LC-MS (m / z) 321.40 (M+H + )
[0102] Compound 20: (3-(methyl(phenyl)amino)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 20 was prepared in 15% yield from 5-phenyl-4,5-dihydro-1H-pyrazole, N-methyl-N-phenylazetidin-3-amine and triphosgene following the method outlined for compound 9. 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.26 (m, 3H), 7.24 - 6.98 (m, 7H), 6.77 (s, 1H), 5.30 (dd, J = 11.9, 5.8 Hz, 1H), 4.34-4.28 (m, 5H), 3.33 (dd, J = 18.6, 12.4 Hz, 1H), 2.97 (s, 3H), 2.72 (dd, J = 18.8, 5.8 Hz, 1H). LC-MS (m / z) 335.5 (M+H + )
[0103] Compound 21: 5-phenyl-N-(3-phenylcyclopentyl)-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 21 was prepared in 14% yield from 5-phenyl-4,5-dihydro-1H-pyrazole (100 mg), 3-phenylcyclopentan-1-amine (100 mg) and triphosgene (81 mg) following the method outlined for compound 1. 1 H NMR (400 MHz, CDCl3) δ 7.40 - 7.14 (m, 10H), 6.79 (d, J = 5.1 Hz, 1H), 5.99 (d, J = 7.2 Hz, 1H), 5.31 (dd, J = 12.2, 6.0 Hz, 1H), 4.39-4.23 (m, 1H), 3.44 (dd, J = 18.4, 12.4 Hz, 1H), 3.29 - 2.99 (m, 2H), 2.83 (d, J = 18.7 Hz, 1H), 2.64 - 2.50 (m, 1H), 2.38 - 1.96 (m, 3H), 1.85 - 1.45 (m, 3H). LC-MS (m / z) 334.4 (M+H + )
[0104] Compound 22: 5-phenyl-N-(1-(pyrimidin-2-yl)pyrrolidin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] To a solution of 2-bromopyrimidine (150 mg) in DMF (5 mL) were added tert-butyl pyrrolidin-3-ylcarbamate (200 mg) and K2CO3 (400 mg). The mixture was stirred overnight at 95 °C under N2. The mixture was diluted with H2O (10 mL) and extracted with EA (15 mL x 3). The combined organic layer was washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography (EA / PE = 1 / 1) afforded tert-butyl (1-(pyrimidin-2-yl)pyrrolidin-3-yl)carbamate as a pale yellow solid (170 mg, 68.5%). LC-MS (m / z) 265.4 (M+H + ) To a solution of tert-butyl (1-(pyrimidin-2-yl)pyrrolidin-3-yl)carbamate (170 mg) in DCM (5 mL) at 0 °C, 1 ml of TFA was added. The mixture was stirred at room temperature for 3 h. The mixture was concentrated to dryness, dissolved in DCM (5 mL), and TEA (270 mg) was added. A solution of 5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl chloride (1.35 mmol, prepared by the method outlined for compound 1) in 2.5 ml of DCM was added to the above mixture at 0 °C and stirred at room temperature overnight. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography (EA / PE = 1 / 1) afforded compound 22 as a yellow oil (74 mg, 16.2%). 1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 4.8 Hz, 1H), 7.37 - 7.26 (m, 2H), 7.26 - 7.13 (m, 3H), 6.78 (t, J = 1.6 Hz, 1H), 6.54 (t, J = 4.8 Hz, 1H), 6.06 (d, J = 6.8 Hz, 1H), 5.29 (ddd, J = 12.1, 6.0, 3.3 Hz, 1H), 4.53 (dd, J = 11.9, 5.8 Hz, 1H), 3.87 (ddd, J = 11.6, 6.2, 2.2 Hz, 1H), 3.72 (ddd, J = 13.8, 7.6, 4.9 Hz, 2H), 3.59 - 3.37 (m, 2H), 2.82 (ddt, J = 18.7, 6.0, 1.6 Hz, 1H), 2.28 (dd, J = 13.6, 6.7 Hz, 1H), 2.04 (dd, J = 14.8, 6.7 Hz, 1H). LC-MS (m / z) 337.40 (M+H + )
[0105] Compound 23: N-(1-(5-fluoropyridin-2-yl)pyrrolidin-3-yl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 23 was prepared in 34% yield from 5-phenyl-4,5-dihydro-1H-pyrazole, 1-(5-fluoropyridin-2-yl)pyrrolidin-3-amine and triphosgene following the method outlined for compound 9. 1H NMR (400 MHz, CDCl3) δ 8.02 (d, 1H, J = 2.8 Hz), 7.34-7.31 (m, 2H), 7.25-7.19 (m, 3H), 6.78 (t, 1H, J = 1.6 Hz), 6.29 (dd, 1H, J = 9.2, 3.2 Hz), 6.06 (d, 1H, J = 7.2 Hz), 5.29 (dd, 1H, J = 12.4, 6.0 Hz), 4.55-4.48 (m, 1H), 3.70 (dd, 1H, J = 10.4, 6.4 Hz), 3.63-3.56 (m, 1H), 3.54-3.48 (m, 1H), 3.43 (ddd, 1H, J = 18.8, 12.4, 1.6 Hz), 3.34 (dd, 1H, J = 10.4, 4.4 Hz), 2.82 (ddd, 1H, J = 18.4, 6.0, 1.6 Hz), 2.32-2.24 (m, 1H), 2.08-1.92 (m, 1H). LC-MS (m / z): 354.39 [M+H] + .
[0106] Compound 24: 5-phenyl-N-(1-phenylpyrrolidin-3-yl)-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 24 was prepared from 5-phenyl-4,5-dihydro-1H-pyrazole, 1-phenylpyrrolidin-3-amine and triphosgene following the method outlined for compound 9 in 8.1% yield. 1H NMR (400 MHz, CDCl3) δ 7.36-7.30 (m, 3H), 7.29-7.26 (m, 1H), 7.25-7.20 (m, 4H), 6.78 (t, 1H, J = 1.6 Hz), 6.71-6.67 (m, 1H), 6.58-6.55 (m, 1H), 6.09 (d, 1H, J = 7.6 Hz), 5.28 (dd, 1H, J = 12.4, 6.0 Hz), 4.56-4.48(m, 1H), 3.59 (dd, 1H, J = 10.0, 6.4 Hz), 3.50-3.45 (m, 1H), 3.45-3.38 (m, 1H), 3.37-3.29 (m, 1H), 3.23 (dd, 1H, J = 8.4, 4.0 Hz), 2.82 (ddd, 1H, J = 18.8, 6.0, 1.6 Hz), 2.33-2.24 (m, 1H), 2.02-1.94 (m, 1H). LC-MS (m / z): 335.40 [M+H] +
[0107] Compound 25: N-((1S,3S)-3-phenoxycyclopentyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide [ka] The title compound 25 was prepared in 23% yield from 5-phenyl-4,5-dihydro-1H-pyrazole, (1S,3S)-3-phenoxycyclopentan-1-amine and triphosgene following the method outlined for compound 9. LC-MS (m / z) 350.4 (M+H + )
[0108] Compound 26: ((R)-3-phenoxypyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] Step 1 Preparation of (R)-tert-butyl 3-phenoxypyrrolidine-1-carboxylate A mixture of (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate (500 mg, 2.67 mmol), phenylboronic acid (490 mg, 4 mmol), Cu(OAc) (1.07 g, 5.34 mmol), pyridine (422 mg, 5.34 mmol), and DIEA (0.9 mL) in DCM (10 mL) was stirred at room temperature for 16 h. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded 200 mg of the desired product. LC-MS (m / z) 264.4 (M+H + ) Step 2 Preparation of (R)-3-phenoxypyrrolidine trifluoroacetate (R)-tert-Butyl 3-phenoxypyrrolidine-1-carboxylate (200 mg) was dissolved in DCM (3 ml) and TFA (865 mg) was added. The mixture was stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure, extracted with DCM, washed with saturated aqueous NaHCO3, dried (Na2SO4), and concentrated to give the crude product (200 mg). This was used in the next step without further purification. LC-MS (m / z) 164.2 (M+H + ) Step 3 Preparation of ((R)-3-phenoxypyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (26) To a cooled solution of 5-phenyl-4,5-dihydro-1H-pyrazole (121 mg, 0.83 mmol) in dry DCM (2 mL), TEA (168 mg, 1.66 mmol) was added, followed by triphosgene (99 mg, 0.33 mmol) in three portions. The mixture was stirred at 0 °C for 30 minutes and then at room temperature for 2 hours. (R)-3-phenoxypyrrolidine trifluoroacetate (200 mg) and TEA (231 mg, 2.28 mmol) were dissolved in dry DCM (5 mL), and the above reaction mixture was added to this solution and stirred overnight. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure to give a racemic mixture. Purification by silica gel chromatography gave compounds 26A and 26B. Compound 26A: 11H NMR (400 MHz, CDCl3) δ 7.32 - 7.25 (m, 5H), 7.24 - 7.20 (m, 2H), 6.94 (ddd, J = 8.4, 2.1, 1.1 Hz, 1H), 6.87 - 6.85 (m, 1H), 6.84 (dd, J = 2.0, 1.0 Hz, 1H), 6.75 (t, J = 1.7 Hz, 1H), 5.35 (dd, J = 12.0, 9.2 Hz, 1H), 4.88 (t, J = 4.3 Hz, 1H), 3.94 (dd, J = 12.8, 4.4 Hz, 1H), 3.84 (td, J = 11.1, 6.6 Hz, 1H), 3.72 (d, J = 12.8 Hz, 1H), 3.68 - 3.61 (m, 1H), 3.29 (ddd, J = 18.4, 12.1, 1.8 Hz, 1H), 2.70 (ddd, J = 18.4, 9.2, 1.6 Hz, 1H), 2.19 (ddd, J = 13.4, 6.6, 1.7 Hz, 1H), 2.07 - 1.95 (m, 1H). LC-MS (m / z) 336.4 (M+H + ). Compound 26B: 1 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.20 (m, 7H), 6.94 (tt, J = 7.5, 1.0 Hz, 1H), 6.89 - 6.83 (m, 2H), 6.75 (t, J = 1.7 Hz, 1H), 5.35 (dd, J = 13.6, 5.9 Hz, 1H), 4.89 - 4.85 (m, 1H), 3.96 - 3.80 (m, 3H), 3.67 - 3.60 (m, 1H), 3.28 (ddd, J = 18.3, 11.9, 1.7 Hz, 1H), 2.69 (ddd, J = 18.3, 7.7, 1.7 Hz, 1H), 2.12 (ddd, J = 7.3, 6.3, 3.5 Hz, 2H). LC-MS (m / z) 336.4 (M+H + ).
[0109] Compound 27: ((S)-3-phenoxypyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] Compounds 27A and 27B were prepared from (S)-3-hydroxypyrrolidine-1-carboxylate (200 mg), TFA, triphosgene, and 5-phenyl-4,5-dihydro-1H-pyrazole according to the method outlined for compound 26 and purified by silica gel chromatography. Compound 27A: 1 H NMR (400 MHz, CDCl3) δ 7.34 - 7.20 (m, 7H), 6.94 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 7.8 Hz, 2H), 6.76(brs, 1H), 5.37-5.32 (m, 1H), 4.88 (brs, 1H), 3.98 - 3.78 (m, 3H), 3.74-3.63 (m, 1H), 3.38 - 3.24 (m, 1H), 2.70 (dd, J = 19.8, 9.2 Hz, 1H), 2.25-2.18 (m, 1H), 2.07 - 1.99 (m, 1H).LC-MS (m / z) 336.4 (M+H + ). Compound 27B: 1 H NMR (400 MHz, CDCl3) δ 7.35 - 7.18 (m, 7H), 6.93 (t, J = 7.3 Hz, 1H), 6.85 (d, J = 7.9 Hz, 2H), 6.76(brs, 1H), 5.37 - 5.31 (m, 1H), 4.95 - 4.84 (m, 1H), 4.02 - 3.75 (m, 2H), 3.63 (dd, J = 24.1, 13.1 Hz, 1H), 3.40 - 3.19 (m, 1H), 2.77 - 2.59 (m, 1H), 2.26 - 2.20 (m, 1H), 2.18 - 2.06 (m, 1H), 2.01-1.95 (m, 1H). LC-MS (m / z) 336.4 (M+H + ).
[0110] Compound 28: ((2R,6S)-4-(5-fluoropyrimidin-2-yl)-2,6-dimethylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] Step 1 To a solution of 5-phenyl-4,5-dihydro-1H-pyrazole (73.5 mg, 0.5 mmol) in DCM, BTC (148 mg, 0.25 mmol) and TEA (0.28 mL, 1.0 mmol) were added at 0°C. After 3 h, a mixture of tert-butyl (3R,5S)-3,5-dimethylpiperazine-1-carboxylate (107 mg, 0.5 mmol) and TEA (0.28 mL, 1.0 mmol) in DCM was added to the reaction mixture at 0°C. The mixture was then stirred at 40°C for 2 h. The completion of the reaction was monitored by UPLC-MS. The reaction mixture was poured into water and extracted with EA. The organic layer was separated, and the aqueous layer was repeatedly extracted with EA (2 × 5 mL). The combined extracts were dried over Na2SO4 and concentrated. The resulting residue was purified by silica gel chromatography (PE:EA=2:1) to give 24 mg of 28-1 as a yellow solid. Yield: 13% (2 steps). LC-MS (ESI) m / z: 331.41 [M+H] + . Step 2 28-1 (24 mg, 0.06 mmol) was dissolved in DCM and cooled to 0 °C. TFA (0.09 ml, 1.2 mmol) was added dropwise, and the mixture was stirred for 2 h. The reaction completion was monitored by UPLC-MS. The reaction was quenched with saturated NaHCO3 and extracted with EA. The organic layer was separated, and the aqueous layer was repeatedly extracted with EA (2 × 5 mL). The combined extracts were dried over Na2SO4 and concentrated to give compound 28-2, which was used in the next reaction step without further purification. 28-2: LC-MS (ESI) m / z: 287.35, [M+H] + . Step 3 To a solution of 28-2 (26 mg, 0.09 mmol) in DMF (5 mL), 2-chloro-5-fluoropyrimidine (24 mg, 0.18 mmol) and K2CO3 (25 mg, 0.18 mmol) were added at room temperature, and the mixture was stirred at 100 °C for 16 h. Completion of the reaction was monitored by UPLC-MS. The reaction mixture was poured into water and extracted with EA. The organic layer was separated, and the aqueous layer was repeatedly extracted with EA (2 × 5 mL). The combined extracts were dried over Na2SO4 and concentrated. The resulting residue was purified by silica gel chromatography (PE:EA = 2:1) to give 6 mg of 28 as a yellow solid. Yield: 24%. 1 H-NMR (400 MHz, CDCl3): δ 8.20 (s, 2H), 7.39-7.20 (m, 5H), 6.83 (s, 1H), 5.37 (dd, J = 11.6, 9.6 Hz, 1H), 4.80 (m, 1H), 4.48-4.25 (m,3H), 3.53-3.03 (m, 3H), 2.80-2.61 (m, 1H), 1.35 (d, J = 6.8 Hz, 3H), 1.25 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 383.35, [M+H] + .
[0111] Compound 29: (5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((2R,6S)-4-(5-fluoropyrimidin-2-yl)-2,6-dimethylpiperazin-1-yl)methanone [ka] Compound 29 was synthesized using ((2R,6S)-2,6-dimethylpiperazin-1-yl)(5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone and 2-chloro-5-fluoropyrimidine according to the method for compound 28. (5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((2R,6S)-4-(5-fluoropyrimidin-2-yl)-2,6-dimethylpiperazin-1-yl)methanone was obtained as a white powder (31% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.19 (t, J = 0.6 Hz, 2H), 7.29 (m, 1H),7.09 (dt, J = 7.8, 1.2 Hz, 1H), 7.00 (ddd, J = 9.8, 2.6, 1.6 Hz, 1H), 6.93 (tdd, J = 8.4, 2.8, 1.0 Hz, 1H), 6.83 (t, J = 1.8 Hz, 1H), 5.41-5.32 (m, 1H), 4.85-4.74 (m, 1H), 4.47-4.29 (m, 3H), 3.42 - 3.22 (m,2H), 3.17 (dd, J = LC-MS (m / z) 401.45 [M+H] + .
[0112] Compound 30: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((2R,6S)-4-(5-fluoropyrimidin-2-yl)-2,6-dimethylpiperazin-1-yl)methanone [ka] Compound 30 was synthesized using (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((2R,6S)-2,6-dimethylpiperazin-1-yl)methanone and 2-chloro-5-fluoropyrimidine according to the method for compound 28. (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((2R,6S)-4-(5-fluoropyrimidin-2-yl)-2,6-dimethylpiperazin-1-yl)methanone was obtained as a white powder (23% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.26 (s, 2H), 6.89-6.77 (m, 3H), 6.74-6.65 (m, 1H), 5.34 (t, J = 10.9 Hz, 1H), 4.83 (s, 1H), 4.50 (d, J = 13.1 Hz, 1H), 4.43 (d, J = 12.0 Hz, 2H), 3.43 (dd, J = 13.2, 4.5 Hz, 1H), 3.35-3.19 (m, 2H), 2.66 (dd, J = 18.2, 10.2 Hz, 1H), 1.37 (d, J = 6.8 Hz, 3H), 1.29 (d, J = 6.8 Hz, 3H). LC-MS (m / z) 418.49 [M+H] + .
[0113] Compound 31: ((R)-3-(2-fluorophenoxy)pyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] (R)-3-(2-fluorophenoxy)pyrrolidine (304 mg), (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (403 mg), and TEA (506 mg) were dissolved in THF (10 mL) and stirred at room temperature for 16 h. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave 31 (186 mg, 31.4%). 1 H NMR (400 MHz, CDCl3)δ 7.35 - 7.27 (m, 3H), 7.26 - 7.19 (m, 2H), 7.11 - 7.00 (m, 2H), 6.98 - 6.89 (m, 2H), 6.77 (t, J = 1.6 Hz, 1H), 5.40 - 5.32 (m, 1H), 4.94-4.87 (m, 1H), 4.05 - 3.66 (m, 4H), 3.38-3.26 (m, 1H), 2.78 - 2.66 (m, 1H), 2.26 - 2.05 (m, 2H). LC-MS (m / z) 354.4 (M+H + )
[0114] Compound 32: ((R)-3-(3-fluorophenoxy)pyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] (R)-3-(3-fluorophenoxy)pyrrolidine (130 mg), prepared by the method outlined for compound 26, (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (172 mg), and TEA (513 mg) were dissolved in THF (5 mL) and stirred at room temperature for 16 hours. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave 32 (95.8 mg, 38%). 1 H NMR (400 MHz, CDCl3) δ 7.51 - 7.25 (m, 4H), 7.24 - 7.11 (m, 3H), 6.77-6.75 (m, 1H), 6.70-6.50 m, 2H), 5.38 - 5.29 (m, 1H), 4.84 (m, 1H), 3.99 - 3.78 (m, 2H), 3.75 - 3.50 (m, 2H), 3.36 - 3.21 (m, 1H), 2.70 (dd, J = 18.4, 7.8 Hz, 1H), 2.21 - 2.08 (m, 1H), 2.08 - 1.96 (m, 1H).LC-MS (m / z) 354.4 (M+H + )
[0115] Compound 33: ((R)-3-(4-fluorophenoxy)pyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 33 was prepared in 12% yield from (R)-3-(4-fluorophenoxy)pyrrolidine and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 32. 1H NMR (400 MHz, CDCl3) δ 7.33 - 7.25 (m, 3H), 7.24 - 7.19 (m, 2H), 6.98-6.91(m, 2H), 6.82-6.77 (m, 2H), 6.75 (t, J = 1.6 Hz, 1H), 5.33 (ddd, J = 12.0, 8.4, 4.0 Hz, 1H), 4.84 - 4.75 (m, 1H), 3.98 - 3.75 (m, 3H), 3.74 - 3.56 (m, 2H), 3.35-3.23 (m, 1H), 2.75-2.65 (m, 1H), 2.21 - 2.12 (m, 1H). LC-MS (m / z) 354.4 (M+H + )
[0116] Compound 34: ((R)-3-((5-fluoropyrimidin-2-yl)oxy)pyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] Step 1 To a cold solution of NaH (128 mg) in 5 mL of DMF (5 mL) was added a solution of (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate (300 mg) in DMF (2 mL). The mixture was stirred at room temperature for 1 hour, then cooled to 0°C, and 2-chloro-5-fluoropyrimidine (212 mg) was added. The mixture was stirred at room temperature for 16 hours. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated under reduced pressure to give 34-1 (100 mg). LC-MS (m / z) 284.4 (M+H + ) Step 2 Compound 34-1 (100 mg) was dissolved in DCM (2 ml) and TFA (401 mg) was added. The mixture was stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure, extracted with DCM, washed with saturated aqueous NaHCO3, dried (Na2SO4), and concentrated to give residue 34-2 (65 mg). This was used in the next step without further purification. Step 3 (R)-5-Fluoro-2-(pyrrolidin-3-yloxy)pyrimidine (64 mg), (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (84 mg), and TEA (106 mg) were dissolved in THF (10 mL) and stirred at room temperature for 16 h. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave 34 (118 mg, 94.4%). 1 H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 2.9 Hz, 2H), 7.31 - 7.26 (m, 3H), 7.23 - 7.19 (m, 2H), 6.75-6.73 (m, 1H), 5.37 - 5.29 (m, 1H), 3.93-3.88 (m, 3H), 3.74-3.66 (m, 2H), 3.33-3.28 (m, 1H), 2.74 - 2.65 (m, 1H). 2.21 - 2.12 (m, 1H). LC-MS (m / z) 356.4 (M+H + )
[0117] Compound 35: ((R)-3-(3-chlorophenoxy)pyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 35 was prepared in 19% yield from (R)-3-(3-chlorophenoxy)pyrrolidine and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 32. 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.24 (m, 7H), 7.23 - 7.14 (m, 1H), 6.95 - 6.82 (m, 1H), 6.77-6.71 (m, 1H), 5.38-5.30 (m, 1H), 4.88- 4.82 (m, 1H),3.96-3.78 (m, 2H), 3.75 - 3.54 (m, 2H), 3.35-3.23(m, 1H), 2.70 (dd, J = 18.8, 8.4 Hz, 1H), 2.18-2.09 (m, 1H), 2.07-1.94 (m, 1H).LC-MS (m / z) 370.8 (M+H + ).
[0118] Compound 36: (3-benzylideneazetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 36 was prepared in 23% yield from 5-phenyl-4,5-dihydro-1H-pyrazole, 3-benzylideneazetidine and triphosgene following the method outlined for compound 9. 1 H NMR (400 MHz, CDCl3) δ 7.34 - 7.28 (m, 4H), 7.26 - 7.17 (m, 7H), 7.11 (d, J = 7.2 Hz, 2H), 6.81 (t, J = 1.7 Hz, 1H), 6.25 - 6.21 (m, 1H), 5.34 (dd, J = 12.1, 6.3 Hz, 1H), 5.04 (dd, J = 34.9, 14.4 Hz, 2H), 4.82 (dd, J = 31.0, 14.9 Hz, 2H), 3.35 (ddd, J = 18.5, 12.2, 1.7 Hz, 1H), 2.75 (ddd, J = 18.5, 6.3, 1.7 Hz, 1H). LC-MS (m / z) 318.4 (M+H + )
[0119] Compound 37: (3-(2-methylbenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] Step 1 :Preparation of (2-methylbenzyl)triphenylphosphonium bromide A mixture of 1-(bromomethyl)-2-methylbenzene (1.5 g, 8.15 mmol), PPh3 (2.14 g, 8.15 mmol), and Tol (20 mL) was stirred at 110 °C for 18 h. The mixture was filtered, and the solid was washed three times with Et2O and dried to give the desired product as a white solid (1.8 g, 49.6%). LC-MS (m / z) 368.5 (M+H + ) Step 2 : Preparation of tert-butyl 3-(2-methylbenzylidene)azetidine-1-carboxylate To a suspension of (2-methylbenzyl)triphenylphosphonium bromide (236 mg, 0.528 mmol) in DMF (4 mL), NaH (13 mg) was added at 0° C., and the mixture was stirred at room temperature for 15 minutes. Next, tert-butyl 3-oxoazetidine-1-carboxylate (86 mg, 0.503 mmol) was added, and the mixture was stirred at room temperature for 2 days. Water was added to precipitate a large amount of white solid, which was collected by filtration and dried to give the crude product (470 mg). This was used in the next step without further purification. LC-MS (m / z) 260.4 (M+H + ). The following intermediates used in the preparation of the title example compounds were synthesized using methods similar to those described above to give various substituted tert-butyl 3-benzylideneazetidine-1-carboxylates, followed by removal of the Boc group using TFA in DCM to give the desired intermediates. [ka] Step 3 : Preparation of tert-butyl 3-(2-methylbenzyl)azetidine-1-carboxylate To a solution of tert-butyl 3-(2-methylbenzylidene)azetidine-1-carboxylate (270 mg) in MeOH (5 mL) was added Pt / C (30 mg), and the mixture was stirred at room temperature under an H atmosphere for 18 hours. The mixture was filtered, and the filtrate was concentrated to give the desired product as a white solid (270 mg, 99.6%). LC-MS (m / z) 262.4 (M+H + ) Step 4 : Preparation of 3-(2-methylbenzyl)azetidine hydrochloride A mixture of tert-butyl 3-(2-methylbenzyl)azetidine-1-carboxylate (270 mg) and HCl / EA (4 mL) was stirred at room temperature for 4 hours. The mixture was concentrated to give the desired product, which was used in the next step without further purification. The following intermediates used in the preparation of the title example compounds were synthesized using methods similar to 3-(2-methylbenzyl)azetidine hydrochloride described above. TFA / DCM may be used in place of HCl / EA, or the free base may be obtained by basification with saturated NaHCO. [ka] Step 5 Preparation of (3-(2-methylbenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone To a cooled solution of triphosgene (60 mg) in dry DCM (5 mL) was added a mixture of 5-phenyl-4,5-dihydro-1H-pyrazole (148 mg) and TEA (0.14 mL). The mixture was stirred at 0 °C for 3 h. 3-(2-methylbenzyl)azetidine hydrochloride (100 mg) and TEA (0.14 mL) were dissolved in dry DCM (2 mL). The reaction mixture was added to this solution and stirred overnight. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography (EA / PE = 1 / 3) afforded compound 37 as a yellow solid (80 mg, 47.3%). 1H NMR (400 MHz, CDCl3) δ 7.35-7.29 (m, 2H), 7.25-7.21 (m, 3H), 7.17-7.10 (m, 3H), 7.07-7.02 (m, 1H), 6.74 (t, 1H, J = 1.6 Hz), 5.31 (dd, 1H, J = 12.0,1.6 Hz), 4.34 -4.17 (m, 2H), 3.93 (dd, 1H, J = 9.6, 4.4 Hz), 3.83 (dd, 1H, J = 9.2, 4.4 Hz), 3.32 (ddd, 1H, J = 18.4, 12.4, 2.0Hz), 2.92-2.89 (m, 3H), 2.72 (ddd, 1H, J = 18.4, 6.4, 1.6 Hz), 2.30 (s, 3H). LC-MS (m / z): 334.55 [M+H] + .
[0120] Compound 38: (3-(2-methylbenzylidene)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 38 was prepared in 51.6% yield from 3-benzylideneazetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.36-7.30 (m, 2H), 7.25-7.21 (m, 3H), 7.19-7.12 (m, 3H), 7.08-7.06 (m, 1H), 6.81 (t, 1H, J = 1.6 Hz), 6.45-6.42 (m, 1H), 5.36 (dd, 1H, J = 12.0, 6.4 Hz), 5.07-4.93 (m, 2H), 4.90-4.77 (m, 2H), 3.37 (ddd, 1H, J = 18.4, 12.0, 1.6 Hz), 2.76 (ddd, 1H, J = 18.4, 6.4, 2.0 Hz), 2.32 (s, 3H). LC-MS (m / z): 332.36 [M+H] + .
[0121] Compound 39: (3-(3-methoxybenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 39 was prepared in 36.6% yield from 3-(4-methoxybenzyl)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H-NMR (400 MHz,CDCl3) δ 7.35 - 7.29 (m, 2H), 7.26 - 7.17 (m, 4H), 6.79 - 6.72 (m, 3H), 6.69 (t, J = 2.4Hz, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 4.22 (dt, J = 28.4, 8.4 Hz, 2H), 3.87 (ddd, J = 32.8,8.0, 4.8 Hz, 2H), 3.79 (s, 3H), 3.32 (ddd, J = 18.4, 12.4, 1.6 Hz, 1H), 2.93 - 2.80 (m, 3H), 2.72 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS(m / z): 350.34[M+H] + .
[0122] Compound 40: (3-(2-fluorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 40 was prepared in 22.4% yield from 3-(2-fluorobenzyl)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H-NMR (400 MHz,CDCl3) δ 7.37 - 7.29 (m, 2H), 7.25 - 7.12 (m, 5H), 7.09 - 6.98 (m, 2H), 6.77 (t, J = 1.5 Hz, 1H), 5.32 (dd, J = 12.0, 6.0 Hz, 1H), 4.26 (t, J = 8.0 Hz, 1H), 4.20 (t, J = 8.8 Hz, 1H), 3.93 (dd, J = 8.4,4.4 Hz, 1H), 3.86 (dd, J = 9.2,5.2 Hz, 1H), 3.33(ddd, J = 18.4, 12.0, 1.6Hz, 1H), 2.96-2.84(m, 3H),2.73 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS(m / z) :338.36[M+H] + .
[0123] Compound 41: (3-(3-fluorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 41 was prepared in 32.6% yield from 3-(3-fluorobenzyl)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H-NMR (400 MHz,CDCl3) δ 7.35 - 7.29 (m, 2H), 7.26 - 7.19 (m, 4H), 6.95 - 6.80 (m, 3H), 6.75 (t, J = 1.6 Hz, 1H), 5.31 (dd, J = 12.0, 6.0 Hz, 1H), 4.22 (dt, J = 28.2, 8.4 Hz, 2H), 3.86 (ddd, J = 32.4, 8.8, 5.2 Hz, 2H), 3.32 (ddd, J = 18.4, 12.4, 1.6 Hz, 1H), 2.92 (d, J = 7.6Hz, 2H), 2.90-2.80(m, 1H), 2.72 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS(m / z) :338.34[M+H] +.
[0124] Compound 42: (3-(4-fluorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 42 was prepared in 22.4% yield from 3-(4-fluorobenzyl)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H-NMR (400 MHz,CDCl3) δ 7.32 (t, J = 7.6 Hz, 2H), 7.26-7.18 (m, 3H), 7.10 (dd, J = 8.4, 5.6 Hz, 2H), 6.97 (t, J = 8.4Hz, 2H), 6.76-6.73 (m, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 4.21 (dt, J = 28.2, 8.4 Hz, 2H), 3.85 (ddd, J = 32.4, 9.0, 5.2 Hz, 2H), 3.32 (dd, J = 18.4, 12.0 Hz, 1H), 2.89 (d, J = 7.6 Hz, 2H), 2.85-2.77 (m, 1H), 2.72 (dd, J = 18.4, 6.4 Hz, 1H). LC-MS(m / z) :338.17[M+H] +
[0125] Compound 43: (3-(3-methoxybenzylidene)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 42 was prepared from 3-(3-methoxybenzylidene)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37 to prepare 43 in 36.6% yield. 1H-NMR (400 MHz,CDCl3) δ 7.36 - 7.30 (m, 2H), 7.27 - 7.22 (m, 4H), 6.82 (t, J = 1.6 Hz, 1H), 6.77 (dd, J = 8.0, 2.4 Hz, 1H), 6.73 (d, J = 7.6 Hz, 1H), 6.67 - 6.64 (m,1H), 6.22 (t, J = 2.4 Hz, 1H), 5.36 (dd, J = 12.4, 6.4 Hz, 1H), 5.05 (dd, J = 37.6, 14.4 Hz, 2H), 4.83 (dd, J = 32.4, 15.0 Hz, 2H), 3.80 (s, 3H), 3.37 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.77 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS(m / z): 348.32[M+H]+.
[0126] Compound 44: (3-(3-hydroxybenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] 3-((1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)methyl)phenyl acetate (10 mg), prepared by the method outlined for compound 37, was dissolved in MeOH (1 mL) and 1 N LiOH (0.041 mmol) was added. The mixture was stirred at room temperature for 2 h. The mixture was adjusted to pH 2-3 with concentrated HCl, extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography (EA / PE=1 / 1) gave compound 37 (7 mg, 77.8%). 1H-NMR (400 MHz,CDCl3) δ 7.35 - 7.27 (m, 2H), 7.26 - 7.19 (m, 3H), 7.10 (t, J = 7.8 Hz, 1H), 6.77-6.74 (m, 1H), 6.72 - 6.55 (m, 3H), 5.31 (dd, J = 12.4, 6.4 Hz, 1H), 4.28-4.15 (m, 2H), 3.95-3.78 (m, 2H), 3.32 (ddd, J = 18.8, 12.4, 1.6 Hz, 1H), 2.82 (s, 3H), 2.71 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS(m / z): 336.39[M+H] + .
[0127] Compound 45: (3-(3-fluorobenzylidene)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 45 was prepared in 36.3% yield from 3-(3-fluorobenzylidene)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H-NMR (400 MHz,CDCl3) δ 7.36 - 7.31 (m, 2H), 7.28 (m, 2H), 7.26 - 7.23 (m, 2H), 6.95 - 6.87 (m, 2H), 6.86 - 6.76 (m, 2H), 6.22 (t, J = 7.8 Hz, 1H), 5.36 (dd, J = 12.0, 6.4 Hz, 1H), 5.14-4.96 (m, 2H), 4.90 - 4.74(m, 2H), 3.38 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.77 (ddd, J = 18.4, 6.4, 16 Hz, 1H). LC-MS(m / z): 336.38[M+H] + .
[0128] Compound 46: (3-(4-fluorobenzylidene)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 46 was prepared in 36.6% yield from 3-(4-fluorobenzylidene)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H-NMR (400 MHz,CDCl3) δ 7.36 - 7.30 (m, 2H), 7.27-7.22 (m, 3H), 7.11-7.06 (m, 2H), 7.05-6.99 (m, 2H), 6.82 (t, J = 1.6 Hz, 1H), 6.21 (t, J = 2.4 Hz, 1H), 5.36 (dd, J = 12.0, 6.4 Hz, 1H), 5.02 (dd, J = 35.4, 14.6 Hz, 2H), 4.82 (dd, J = 32.2, 14.4 Hz, 2H), 3.37 (ddd, J = 18.4, 12.0, 1.6Hz, 1H), 2.77 (ddd, J = 18.4 6.4, 1.6 Hz, 1H). LC-MS(m / z) :336.29[M+H] + .
[0129] Compound 47: (3-(2-chlorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 47 was prepared in 22.4% yield from 3-(2-chlorobenzyl)azetidine, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H NMR (400 MHz, CDCl3) δ 7.36-7.27 (m, 3H), 7.26 - 7.18 (m, 3H), 7.18 - 6.94 (m, 3H), 6.74-6.71 (m, 1H), 5.29 (dd, J = 12.2, 6.5 Hz, 1H), 4.20 (dt, J = 25.9, 8.5 Hz, 2H), 3.87 (ddd, J = 32.7, 8.9, 5.3 Hz, 2H), 3.31 (dd, J = 18.5, 12.2 Hz, 1H), 3.14 - 2.82 (m, 3H), 2.70 (dd, J = 18.5, 6.4 Hz, 1H). LC-MS (m / z) 354.9 (M+H + ).
[0130] Compound 48: (3-(3-chlorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 48 was prepared in 28.2% yield from 3-(3-chlorobenzyl)azetidine and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 34. LC-MS (m / z) 354.9 (M+H + ). 1 H NMR (400 MHz, CDCl3) δ 7.34-7.28 (m, 1H), 7.24 - 7.11 (m, 7H), 7.04 - 6.96 (m, 1H), 6.74 (s, 1H), 5.29 (dd, J = 12.0, 6.4 Hz, 1H), 4.20 (dt, J = 29.6, 8.0 Hz, 2H), 3.80 (ddd, J = 31.8, 26.4 ,5.2Hz, 2H), 3.37 - 3.26 (m, 1H), 3.00-2.76 (m, 3H), 2.75 - 2.66 (m, 1H). LC-MS (m / z) 354.9 (M+H + ).
[0131] Compound 49: (3-(4-chlorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 49 was prepared in 11% yield from 3-(4-chlorobenzyl)azetidine and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 34. LC-MS (m / z) 354.9 (M+H + ). 1 H NMR (400 MHz, CDCl3) δ 7.34-7.28 (m, 1H), 7.24 - 7.11 (m, 7H), 7.04 - 6.96 (m, 1H), 6.74 (s, 1H), 5.29 (dd, J = 12.0, 6.4 Hz, 1H), 4.20 (dt, J = 29.6, 8.0 Hz, 2H), 3.80 (ddd, J = 31.8, 26.4 ,5.2Hz, 2H), 3.37 - 3.26 (m, 1H), 3.00-2.76 (m, 3H), 2.75 - 2.66 (m, 1H). LC-MS (m / z) 338.4 (M+H + ).
[0132] Compound 50: (3-(2,4-difluorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 50 was prepared in 24.7% yield from 1-(bromomethyl)-2,4-difluorobenzene, PPh3, NaH, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H-NMR (400 MHz,CDCl3) δ 7.35 - 7.29 (m, 2H), 7.25-7.19 (m, 3H ), 7.14 - 7.06 (m, 1H), 6.84 - 6.77 (m, 2H), 6.76 (t, J = 1.7 Hz, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 4.24(t J = 8.4 Hz, 1H), 4.18(t J = 8.4 Hz, 1H), 389 (dd, J = 9.2, 5.2 Hz, 1H), 381 (dd, J = 9.2, 5.2 Hz, 1H),3.33 (ddd, J = 18.4, LC-MS(m / z) :356.56[M+H] + .
[0133] Compound 51: (3-(4-chloro-2-fluorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 51 was prepared in 24.2% yield from 3-(4-chloro-2-fluorobenzyl)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.30 (m, 2H), 7.24 - 7.21 (m, 3H), 7.11 - 7.02 (m, 3H), 6.75 (t, J = 2.0 Hz, 1H), 5.30 (dd, J = 12.0, 6.4 Hz, 1H), 4.24 (t, J = 8.4 Hz, 1H), 4.17 (t, J = 8.4 Hz, 1H), 3.89 (dd, J = 9.2, 5.2 Hz, 1H), 3.80(dd, J = 9.2, 5.2 Hz, 1H), 3.32 (ddd, J = 18.4, 12.0, 1.6Hz, 1H), 2.92 - 2.89 (m, 2H), 2.88 - 2.80 (m, 1H), 2.72 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS (m / z):372.29 [M+H] + .
[0134] Compound 52: (3-(2-chloro-4-fluorobenzyl)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 52 was prepared in 24.2% yield from 3-(2-chloro-4-fluorobenzyl)azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H NMR (400 MHz, CDCl3) δ 7.34-7.31 (m, 2H), 7.26 - 7.22 (m, 3H), 7.15 - 7.10 (m, 2H), 6.91 (td, J = 8.0, 2.8 Hz, 1H), 6.77-6.74 (m, 1H), 5.31(dd, J = 12.8, 6.4 Hz, 1H), 4.25 (t, J = 8.8 Hz, 1H), 4.18 (t, J = 8.8 Hz, 1H), 3.91 (dd, J = 9.2, 5.2 Hz, 1H), 3.81 (dd, J = 9.2, 5.2 Hz, 1H), 3.33 (ddd, J = LC-MS (m / z):372.49 [M+H] + .
[0135] Compound 53: (3-(2,4-difluorobenzyl)azetidin-1-yl)(5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 53 was prepared in 23.5% yield from 3-(2,4-difluorobenzyl)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.25 (m, 1H), 7.14-7.07 (m, 1H), 7.01 (dt, J = 7.6, 1.2 Hz, 1H), 6.96 - 6.89 (m, 2H), 6.83 - 6.73 (m, 3H), 5.29 (dd, J = 12.0, 6.4 Hz, 1H), 4.21 (dt, J = 23.6, 8.2 Hz, 2H), 3.86 (ddd, J = 29.6, 8.7, 4.9 Hz, 2H),3.32 (ddd, J = 18.4, 12.0, 1.6Hz, 1H).,292-2.88.(m, 2H), 2.88-2.80(m, 1H), 2.68 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS (m / z):374.36 [M+H] + .
[0136] Compound 54: (3-(2,4-difluorobenzyl)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 54 was prepared in 22.3% yield from 3-(2,4-difluorobenzyl)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.14-7.08(m, 1H), 6.83 - 6.66 (m, 6H), 5.28 (dd, J = 12.0, 6.4 Hz, 1H), 4.28-4.20 (m, 2H), 3.95 - 3.83 (m, LC-MS (m / z):392.20 [M+H] + .
[0137] Compound 55: (3-(2,4-difluorobenzylidene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 55 was prepared in 27.9% yield from 3-(2,4-difluorobenzylidene)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.11-7.03 (m, 1H), 6.89 - 6.73 (m, 5H), 6.69 (tt, J = 8.0, 2.4 Hz, 1H), 6.39 (t J = 2.0 Hz, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 4.99 (q, J = 14.4 Hz,, 2H), 4.85 (q, J = 14.4 Hz, 2H), 3.42-3.32 (m, 1H), 2.71 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS (m / z):390.26 [M+H] + .
[0138] Compound 56: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-(2-fluorobenzylidene)azetidin-1-yl)methanone [ka] The title compound 56 was prepared in 18.7% yield from 3-(2-fluorobenzylidene)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H NMR (400 MHz, CDCl3) δ 7.23 - 7.17 (m, 1H), 7.13 - 7.00 (m, 3H), 6.83 - 6.74 (m, 3H), 6.69 (tt, J = 8.8, 2.4 Hz, 1H), 6.47 (t J = 2.4 Hz, 1H), 5.32 (dd, J = 12.0, 6.4 Hz, 1H), 5.10-4.96(m, 2H), 4.94 - 4.76 (m, 2H), 3.37 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.71 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS (m / z): 372.30 [M+H] + .
[0139] Compound 57: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-(4-fluorobenzylidene)azetidin-1-yl)methanone [ka] The title compound 57 was prepared in 25.5% yield from 3-(4-fluorobenzylidene)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.09 - 7.04 (m, 2H), 7.04 - 6.94 (m, 2H), 6.81 - 6.71 (m, 3H), 6.67 (tt, J = 8.8, 2.4 Hz, 1H), 6.24 - 6.17 (m, 1H), 5.30 (dd, J = 12.0, 6.4 Hz, 1H), 5.02 (q, J = 13.6 Hz, 2H), 4.82 (q, J = 13.6 Hz, 2H), 3.35 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.69 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H).LC-MS (m / z):372.29 [M+H] + .
[0140] Compound 58: (Z)-(3-benzylidenepyrrolidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 58 was prepared in 25% yield from (Z)-3-benzylidenepyrrolidine, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, Chloroform-d) δ 7.48-7.12 (m, 10H), 6.80 (s, 1H), 6.42 (d, J = 8.4 Hz, 1H), 5.37 (q, J = 9.2 Hz, 1H), 4.65 (dd, J = 26.4, 16.4 Hz, 1H), 4.29 (t, J = 18.4 Hz, 1H), 3.84 (dq, J = 35.2, 8.8 Hz, 1H), 3.67 (dq, J = 25.6, 10.2, 8.4 Hz, 1H), 3.32 (ddd, J = 18.2, 12.0, 4.6 Hz, 1H), 2.77 (td, J = 22.2, 18.0, 7.8 Hz, 3H). LC-MS (m / z) 332.6 [M+H]+.
[0141] Compound 59: (3-phenoxyazetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 59 was prepared in 18.7% yield from 3-(phenoxy)-azetidine hydrochloride, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 26. 1H NMR (400 MHz, CDCl3) δ 7.36-7.26 (m, 4H), 7.25-7.20 (m, 3H), 6.98 (t, 1H, J = 7.6 Hz), 6.80-6.70 (m, 3H), 5.32 (dd, 1H, J = 12.0, 6.4 Hz), 4.94-4.88 (m, 1H), 4.55 (dd, 1H, J = 10.0, 6.4 Hz), 4.48 (dd, 1H, J = 10.0, 6.4 Hz), 4.24 (dd, 1H, J = 10.0, 4.0 Hz), 4.17 (dd, 1H, J = 10.0, 4.0 Hz), 3.34 (ddd, 1H, J = 18.4, 12.4, 1.6 Hz), 2.74 (ddd, 1H, J = 18.4, 6.4, 1.6 Hz). LC-MS (m / z): 322.21 [M+H] + .
[0142] Compound 60: (3-(2-fluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] Step 1 : Preparation of tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate tert-Butyl 3-hydroxyazetidine-1-carboxylate (1 g, 5.35 mmol) was dissolved in 10 ml of dry DCM, and TEA (1.08 g, 10.7 mmol) was added. To this solution, MsCl (0.738 g, 6.42 mmol) was added slowly at 0 °C. The mixture was stirred overnight. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated to dryness to give the desired product. LC-MS (m / z) 252.3 (M+H + ). Step 2 Preparation of tert-butyl 3-(2-fluorophenoxy)azetidine-1-carboxylate tert-Butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (200 mg, 0.796 mmol), CsCO (518 mg, 1.6 mmol), and KI (3 mg) were added to DMF (2 mL). The mixture was stirred at 110 °C overnight, water was added, extracted with EA, washed with brine, dried (NaSO), and concentrated to dryness to give the desired product. LC-MS (m / z) 268.3 (M+H + ). Step 3 : Preparation of 3-(2-fluorophenoxy)azetidine trifluoroacetate tert-Butyl 3-(2-fluorophenoxy)azetidine-1-carboxylate was dissolved and stirred at room temperature for 4 hours. The mixture was concentrated to give the desired product, which was used in the next step without further purification. LC-MS (m / z) 168.3 (M+H + ).
[0143] The following intermediates used in the preparation of the title example compounds were synthesized in a manner similar to that of 3-(2-fluorophenoxy)azetidine trifluoroacetate described above and were used in the next step as either the TFA salt or the free base without further purification. [ka] Step 4 Preparation of (3-(2-fluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone 3-(2-Fluorophenoxy)azetidine (100 mg), (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (50 mg), and TEA (0.8 mL) were dissolved in THF (10 mL) and stirred at 65° C. for 16 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 60 (53 mg, 74.4%). 1H NMR (400 MHz, CDCl3) δ 7.31-7.35 (m, 2H), 7.21-7.27 (m, 3H), 7.01-7.12 (m, 2H), 6.90-6.96 (m, 1H), 6.78 (t, 1H, J = 1.6 Hz), 6.70 (td, 1H, J = 8.4, 1.6 Hz), 5.33 (dd, 1H, J = 12.0, 6.4 Hz), 4.91-4.94 (m, 1H), 4.55 (dd, 1H, J = 10.0, 6.8 Hz), 4.49 (dd, 1H, J = 10.0, 6.8 Hz), 4.30 (dd, 1H, J = LC-MS (m / z): 340.40 [M+H] + .
[0144] Compound 61: (3-(3-fluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 61 was prepared in 75.5% yield from 3-(3-fluorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.29-7.35 (m, 2H), 7.15-7.26 (m, 4H), 6.75-6.79 (m, 1H), 6.62-6.72 (m, 1H), 6.40-6.55 (m, 2H), 5.32 (dd, LC-MS (m / z): 340.32 [M+H]+ .
[0145] Compound 62: (3-(4-fluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 62 was prepared in 70.2% yield from 3-(4-fluorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.29-7.35 (m, 2H), 7.21-7.27 (m, 3H), 6.92-7.00 (m, 2H), 6.77 (t, 1H, J = 1.6 Hz), 6.66-6.72 (m, 2H), 5.32 (dd, 1H, J = 12.0, 6.4 Hz), 4.82-4.89 (m, 1H), 4.53 (dd, 1H, J = 9.6, 6.4 Hz), 4.46 (dd, 1H, J = 9.6, 6.4 Hz), 4.22 (dd, 1H, J = 10.0, 4.0 Hz), 4.14 (dd, 1H, J = LC-MS (m / z): 340.40 [M+H] + .
[0146] Compound 63: (3-(2,4-difluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 63 was prepared in 70.7% yield from 3-(2,4-difluorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.30-7.34 (m, 2H), 7.20-7.25 (m, 3H), 6.84-6.90 (m, 1H), 6.78-6.79 (m, 1H), 6.74-6.77 (m,1H), 6.67 (td, 1H, J = 8.8, 6.4 Hz), 5.31 (dd, 1H, J = 12.4, 6.4 Hz), 4.85-4.90 (m, 1H), 4.51 (dd, 1H, J = 10.0, 6.4 Hz), 4.46 (dd, 1H, J = 10.0, 6.4 Hz), 4.27 (dd, 1H, J = 10.0, LC-MS (m / z): 358.45 [M+H] + .
[0147] Compound 64: (3-(2-chlorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 64 was prepared in 52% yield from 3-(2-chlorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.27 (m, 3H), 7.26 - 7.14 (m, 4H), 6.93 (td, J = 7.7, 1.4 Hz, 1H), 6.78 (t, J = 1.7 Hz, 1H), 6.60 (dd, J = 8.2, 1.3 Hz, 1H), 5.32 (dd, J = 12.3, 6.5 Hz, 1H), 4.94 (ddd, J = 10.7, 5.4, 3.2 Hz, 1H), 4.61 - 4.44 (m, 2H), 4.28 (ddd, J = 31.8, 10.2, 4.0Hz, 2H), 3.35 (ddd, J = 18.5, 12.2, 1.7 Hz, 1H), 2.75 (ddd, J = 18.5, 6.3, 1.7 Hz, 1H). LC-MS (m / z) 356.8 (M+H + )
[0148] Compound 65: (3-(4-chlorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 65 was prepared in 40% yield from 3-(4-chlorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.36 - 7.26 (m, 3H), 7.25 - 7.18 (m, 4H), 6.78 (t, J = 1.7 Hz, 1H), 6.71 - 6.65 (m, 2H), 5.35 - 5.28 (m, 1H), 4.86 (ddd, J = 10.6, 5.3, 3.2 Hz, 1H), 4.59 - 4.43 (m, 2H), 4.18 (ddd, J = 31.7, 10.1, 3.6 Hz, 2H), 3.35 (ddd, J = 18.5, 12.2, 1.7 Hz, 1H), 2.75 (ddd, J = 18.6, 6.4, 1.7 Hz, 1H). LC-MS (m / z) 356.8 (M+H+ )
[0149] Compound 66: (3-(3,4-difluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 66 was prepared in 74.7% yield from 3-(3,4-difluorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.30-7.35 (m, 2H), 7.21-7.27 (m, 3H), 7.06 (dd, 1H, J = 18.8, 8.8 Hz), 6.78 (t, 1H, J = 1.6 Hz), 6.58 (ddd, 1H, J = 9.6, 6.8, 3.2 Hz), 6.41-6.45 (m, 1H), 5.31 (dd, 1H, J = 12.0, 6.0 Hz), 4.80-4.85 (m,1H), 4.53 (dd, 1H, J = 10.0, 6.4 Hz), 4.46 (dd, 1H, J = 10.0, 6.4 Hz), 4.21 (dd, 1H, J = 10.0, 4.0 Hz), 4.13 (dd, 1H, J = 10.0, 4.0 Hz), 3.34 (ddd, 1H, J = 18.8, 12.0, 1.6 Hz), 2.74 (ddd, 1H, J = 18.4, 6.4, 1.6 Hz). LC-MS (m / z): 358.42 [M+H] + .
[0150] Compound 67: (3-(2-chloro-4-fluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 67 was prepared in 35% yield from 3-(2-chloro-4-fluorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.36-7.30 (m, 2H), 7.26 - 7.20 (m, 3H), 7.15 (dd, J = 8.0, 3.2 Hz, 1H), 6.90 (ddd, J = 9.2, 7.6, 3.2 Hz, 1H), 6.79 (t, J = 1.6 Hz, 1H), 6.56 (dd, J = 9.0, 4.7 Hz, 1H), 5.32(dd, J = 12.0, 6.0 Hz,1H), 4.92-4.86 (m, 1H), 4.58-4.52 (dd, J = 9.6, 6.4 Hz,1H), 4.51-4.45 (dd, J = 9.6, 6.4 Hz,1H), 4.30 (dd, J = 10.4, 3.8 Hz, 1H), 4.22 (dd, J = 10.0, 4.0 Hz, 1H), 3.35 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.75 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS (m / z) 374.8 (M+H + )
[0151] Compound 68: 4-((1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)benzonitrile [ka] The title compound 67 was prepared in 70.7% yield from 4-(azetidin-3-yloxy)benzonitrile trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.57-7.61 (m, 2H), 7.30-7.35 (m, 2H), 7.25-7.27 (m, 1H), 7.21-7.23 (m, 2H), 6.81-6.82 (m, 1H), 6.79-6.80 (m, 2H), 5.31 ((dd, 1H, J = 12.0, 6.0 Hz), 4.92-4.97 (m, 1H), 4.57 (dd, 1H, J = 9.6, 6.0 Hz), 4.51 (dd, 1H, J = 10.0, 6.4 Hz), 4.24 (dd, 1H, J = 10.0, 4.0 Hz), 4.16 (dd, 1H, J = 10.0, 4.0 Hz), 3.35 (ddd, 1H, J = 18.8, 12.0, 2.0 Hz), 2.76 (ddd, 1H, J = 18.4, 6.4, 2.0 Hz). LC-MS (m / z): 347.40 [M+H] + .
[0152] Compound 69: (3-(4-chloro-2-fluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 69 was prepared in 10.6% yield from 3-(2-chloro-4-fluorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.34-7.28(m, 2H), 7.23 - 7.17 (m, 3H), 7.10 (dd, J = 10.8, 2.5 Hz, 1H), 7.03 - 6.97 (m, 1H), 6.76 (t, J = 1.6 Hz, 1H), 6.61 (t, J = 8.7 Hz, 1H), 5.30 (dd, J = 12.4, 6.4 Hz, 1H), 4.94 - 4.83 (m, 1H), 4.48 (ddd, J = 24.5, 9.6, 6.4 Hz, 2H), 4.23 (ddd, J = 29.0, 10.0, 4.0 Hz, 2H), 3.33 (ddd, J = 18.4, 12.4, 1.6 Hz, 1H), 2.73 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS (m / z) 374.8 (M+H + )
[0153] Compound 70: (3-(4-hydroxyphenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] (3-(4-(methoxymethoxy)phenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone was prepared in 16% yield from 3-(4-(methoxymethoxy)phenoxy)azetidine salt and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. This was reacted with concentrated HCl (1 mL) in MeOH (3 mL) for 1 hour. The mixture was concentrated and purified by preparative TLC to give the title compound 70 (18 mg, 41%). LC-MS (m / z) 338.4 (M+H + ) 1H NMR (400 MHz, CDCl3) δ 7.38-7.28 (m, 2H), 7.23-7.13 (m, 3H), 6.77 (brs, 1H), 6.66 (d, J = 8.6 Hz, 2H), 6.55 (d, J = 8.7 Hz, 2H), 5.30 (dd, J = 12.0, 6.2 Hz, 1H), 4.78 (brs, 1H), 4.55 - 4.35 (m, 2H), 4.16 (dd, J = 29.5, 6.6 Hz, 2H), 3.32 (dd, J = 18.5, 12.2 Hz, 1H), 2.72 (dd, J = 18.5, 6.2 Hz, 1H).
[0154] Compound 71: 3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)benzonitrile [ka] The title compound 71 was prepared in 22.3% yield from 3-(azetidin-3-yloxy)benzonitrile trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.39 (t, J = 8.0 Hz, 1H), 7.33 - 7.26 (m, 1H), 7.05 - 6.94 (m, 2H), 6.82 - 6.62 (m, 4H), 5.28 (dd, J = 12.2, 6.4 Hz, 1H), 4.93 (ddd, J = 10.4, 5.2, 3.2 Hz, 1H), 4.67-4.48 (m, 2H), 4.29 - 4.03 (m, 2H), 3.35 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.70 (ddd, J = 18.6, 6.5, 1.7 Hz, 1H).LC-MS (m / z) 383.4 (M+H + )
[0155] Compound 72: (3-((5-fluoropyridin-2-yl)oxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 72 was prepared in 32% yield from 2-(azetidin-3-yloxy)-5-fluoropyridine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 3.0 Hz, 1H), 7.37 - 7.27 (m, 4H), 7.24-7.21 (m, 1H), 7.20-7.18 (m, 1H), 6.76 - 6.69 (m, 2H), 5.33 - 5.24 (m, 2H), 4.57 - 4.44 (m, 2H), 4.13 (ddd, J = 24.4, 10.5, 4.3 Hz, 2H), 3.32 (ddd, J = 18.5, 12.2, 1.7 Hz, 1H), 2.71 (ddd, J = 18.5, 6.4, 1.7 Hz, 1H). LC-MS (m / z) 341.4 (M+H + )
[0156] Compound 73: (3-((6-fluoropyridin-3-yl)oxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 73 was prepared in 9.3% yield from 5-(azetidin-3-yloxy)-2-fluoropyridine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.66 - 7.62 (m, 1H), 7.33-7.28 (m, 2H), 7.24 - 7.16 (m, 4H), 6.85 (dd, J = 8.9, 3.5 Hz, 1H), 6.77 (t, J = 1.6 Hz, 1H), 5.34 - 5.26 (m, 1H), 4.89 (ddd, J = 10.4, 6.3, 4.0 Hz, 1H), 4.58 - 4.41 (m, 2H), 4.22 (dd, J = 10.2, 3.9 Hz, 1H), 4.14 (dd, J = 10.2, 3.9Hz, 1H), 3.34 (ddd, J = 18.6, 12.1, 1.6 Hz, 1H), 2.74 (ddd, J = 18.6, 6.3, 1.7 Hz, 1H). LC-MS (m / z) 341.4 (M+H + )
[0157] Compound 74: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-(pyridin-3-yloxy)azetidin-1-yl)methanone [ka] The title compound 74 was prepared in 3.1% yield from 3-(azetidin-3-yloxy)pyridine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.35-7.31 (m, 2H), 7.27 - 7.20 (m, 7H), 6.79 (s, 1H), 5.31 (dd, J = 12.0, 8.0 Hz, 1H), 4.99 (s, 1H), 4.61 - 4.51 (m, 2H), 4.22 (dd, J = 32.0, 8.0 Hz, 2H), 3.39-3.32 (m, 1H), 2.79-2.73 (m, 1H). LC-MS (m / z) 323.43 [M+H] + .
[0158] Compound 75: (3-(2,4-difluorophenoxy)azetidin-1-yl)(5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 75 was prepared in 16.8% yield from 3-(2,4-difluorophenoxy)azetidine trifluoroacetate, 5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.34 - 7.28 (m, 1H), 7.24-7.19 (m, 2H), 7.04 - 6.81 (m, 3H), 6.78 - 6.71 (m, 1H), 6.66 (td, J = 9.0, 5.2 Hz, 1H), 5.29 (dd, J = 12.2, 6.3 Hz, 1H), 4.92-4.85 (m, 1H), 4.54-4.42 (m, 2H), 4.34-4.16 (m, 2H), 3.33 (dd, J = 18.5, 12.1 Hz, 1H), 2.77 - 2.58 (m, 1H).LC-MS (m / z) 376.4 (M+H + )
[0159] Compound 76: (3-(2,4-difluorophenoxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 76 was prepared in 22.6% yield from 3-(2,4-difluorophenoxy)azetidine trifluoroacetate, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H NMR (400 MHz, CDCl3) δ 6.89 (ddd, J = 11.3, 8.3, 2.9 Hz, 1H), 6.80 - 6.74 (m, 3H), 6.73 - 6.65 (m, 2H), 5.28 (dd, J = 12.2, 6.5 Hz, 1H), 4.91 (ddd, J = 10.5, 6.3, 4.0 Hz, 1H), 4.57 - 4.43 (m, 2H), 4.27 (ddd, J = 14.4, 10.1, 3.3 Hz, 2H), 3.35 (ddd, J = 18.5, 12.2, 1.5 Hz, 1H), 2.69 (ddd, J = 18.6, 6.5, 1.5 Hz, 1H). LC-MS (m / z) 394.4 (M+H + )
[0160] Compound 77: (S)-(3-(2-fluorophenoxy)azetidin-1-yl)(3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 77 was prepared in 13% yield from 3-(2-fluorophenoxy)azetidine trifluoroacetate, (S)-3-phenylisoxazolidine and triphosgene following the method outlined for compound 26. 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.30 (m, 3H), 7.26-7.21 (m, 2H), 7.14 - 7.01 (m, 2H), 6.98 - 6.91 (m, 1H), 6.69 (t, J = 8.2 Hz, 1H), 5.55 (dd, J = 8.6, 5.3 Hz, 1H), 4.97 (ddd, J = 10.6, 6.5, 4.2 Hz, 1H), 4.54 (dt, J = 14.6, 7.4 Hz, 2H), 4.35 (dd, J = 10.6, 3.9 Hz, 1H), 4.22 (dd, J = 10.1, 3.4 Hz, LC-MS (m / z) 343.4 (M+H + )
[0161] Compound 78: (S)-(3-(4-fluorophenoxy)azetidin-1-yl)(3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 78 was prepared in 16% yield from 3-(4-fluorophenoxy)azetidine trifluoroacetate, (S)-3-phenylisoxazolidine and triphosgene following the method outlined for compound 26. 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.30 (m, 3H), 7.26-7.22(m, 1H), 7.02 - 6.94 (m, 2H), 6.72 - 6.66 (m, 2H), 5.54 (dd, J = 8.8, 5.4 Hz, 1H), 4.94 - 4.84 (m, 1H), 4.58 - 4.48 (m, 2H), 4.25 (dd, J = 10.4, 4.0 Hz, 1H), 4.12 (ddd, J = 11.4, 7.6, 3.7 Hz, 2H), 3.82 (dd, J = 16.1, 8.1 Hz, 1H), 2.82 - 2.68 (m, 1H), 2.42 - 2.28 (m, 1H). LC-MS (m / z) 343.4 (M+H + )
[0162] Compound 79: (S)-(3-(4-fluorobenzyl)azetidin-1-yl)(3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 78 was prepared in 16% yield from 3-(4-fluorobenzyl)azetidine trifluoroacetate, (S)-3-phenylisoxazolidine and triphosgene following the method outlined for compound 26. 1 H NMR (400 MHz, CDCl3) δ 7.41 - 7.29 (m, 4H), 7.26 - 7.22 (m, 1H), 7.10 (dd, J = 8.1, 5.6 Hz, 2H), 6.98 (t, J = 8.3 Hz, 2H), 5.54 (dd, J = 8.7, 5.2 Hz, 1H), 4.26 (t, J = 8.2 Hz, 1H), 4.17 (brs, 1H), 4.09 (td, J = 8.0, 3.4 Hz, 1H), 3.89-3.80 (m, 3H), 3.78 (dd, J = 16.2, 8.3 Hz, 1H), 2.93 - 2.80 (m, 3H), 2.78 - 2.69 (m, 1H), 2.29 (ddd, J = 15.2, 7.8, 3.9 Hz, 1H).LC-MS (m / z) 341.4 (M+H + )
[0163] Compound 80: (S)-(3-(2,4-difluorophenoxy)azetidin-1-yl)(3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 80 was prepared in 12% yield from 3-(2,4-difluorophenoxy)azetidine trifluoroacetate, (S)-3-phenylisoxazolidine and triphosgene following the method outlined for compound 26. 1 H NMR (400 MHz, CDCl3) δ 7.40 - 7.30 (m, 3H), 7.26-7.22 (m, 2H), 6.93 - 6.86 (m, 1H), 6.81 - 6.74 (m, 1H), 6.67 (td, J = 9.0, 5.5 Hz, 1H), 5.54 (dd, J = 8.7, 5.3 Hz, 1H), 4.96 - 4.88 (m, 1H), 4.57 - 4.46 (m, 2H), 4.32 (dd, J = 10.5, 3.8 Hz, 1H), 4.20 (d, J = 9.0 Hz, 1H), 4.12 (td, J = 8.0, 3.3 Hz, 1H), 3.82 (dd, J = 16.1, 8.2 Hz, 1H), 2.81 - 2.70 (m, 1H), 2.36 - 2.26 (m, 1H). LC-MS (m / z) 361.4 (M+H + )
[0164] Compound 81: (S)-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)(3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 81 was prepared in 61.8% yield from 5-fluoro-2-(piperazin-1-yl)pyrimidine, (S)-3-phenylisoxazolidine and triphosgene following the method outlined for compound 26. 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 2H), 7.42 - 7.30 (m, 4H), 7.26 - 7.23 (m, 1H), 5.46 (dd, J = 8.5, 4.9 Hz, 1H), 4.13 (td, J = 8.0, 4.1 Hz, 1H), 3.93 (q, J = 7.9 Hz, 1H), 3.86 - 3.57 (m, 8H), 2.85 - 2.76 (m, 1H), 2.36 - 2.26 (m, 1H).LC-MS (m / z) 358.4 (M+H + )
[0165] Compound 82: (S)-(3-(2,4-difluorobenzyl)azetidin-1-yl)(3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 82 was prepared in 11.6% yield from 3-(2,4-difluorobenzyl)azetidine, (S)-3-phenylisoxazolidine and triphosgene following the method outlined for compound 26. 1 H NMR (400 MHz, CDCl3) δ 7.40 - 7.35 (m, 2H), 7.35 - 7.29 (m, 2H), 7.26 - 7.20 (m, 1H), 7.13-7.06 (m, 1H), 6.84 - 6.75 (m, 2H), 5.53 (dd, J = 8.8, 5.2 Hz, 1H), 4.30 - 4.14 (m, 2H), 4.14 - 4.05 (m, 1H), 3.92-3.82 (m, 2H), 3.81 - 3.74 (m, 1H), 2.95 - 2.83 (m, 3H), 2.78 - 2.67 (m, 1H), 2.33-2.23 (m, 1H). LC-MS (m / z):359.51 [M+H] + .
[0166] Compound 83: (4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 81 was prepared in 61.8% yield from 5-fluoro-2-(piperazin-1-yl)pyrimidine, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 26. 1 H NMR (400Hz, CDCl3): δ 8.21 (s, 2H), 7.36-7.23 (m, 5H), 6.85 (s, 1H), 5.37 (dd, J = 11.6, 9.6 Hz, 1H), 3.95-3.56 (m, 8H), 3.36-3.28 (m, 1H), 2.79-2.71 (m, 1H). LC-MS (m / z) 355.4 (M+H + )
[0167] Compound 84: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone [ka] Step 1 To a solution of (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (50 mg, 0.19 mmol) and K2CO3 (67 mg, 0.48 mmol) in DMF (5 mL) was added (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-(pyrimidin-2-yl)piperazin-1-yl)methanone (31 mg, 0.19 mmol). The mixture was heated at 80 °C for 2.5 h. Then, 30 mL of H2O was added and extracted with EA (20 mL × 3). The solvent was evaporated under reduced pressure to give crude product 84. Further purification by silica gel column chromatography (PE / EA = 1 / 1) gave 35 mg of 84 as a pale yellow solid. 84: 1H NMR (400 MHz, CDCl3) δ 8.31 (d, J = 4.0 Hz, 2H), 7.35-7.22 (m, 5H), 6.84 (t, J = 4.0 Hz, 1H), 6.50 (t, J = 4.0 Hz, 1H), 5.37-5.31 (m, LC-MS (m / z) 337.31 [M+H] + .
[0168] Compound 85: (4-(5-fluoropyridin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 84 was prepared in 62.3% yield from 1-(5-fluoropyridin-2-yl)piperazine, 5-phenyl-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 26. 1 H NMR (400 MHz, CDCl3) δ 8.07 (d, 1H, J = 3.0 Hz), 7.35-7.28 (m, 5H), 7.25-7.21 (m, 1H), 6.84 (t, 1H, J = 1.6 Hz), 6.64 (dd, 1H, J = 9.6, 3.6 Hz), 5.36 (dd, 1H, J = 9.6, 11.6 Hz), 3.86-3.76 (m,2 H), 3.73-3.63 (m, 2H), 3.62-3.54 (m, 2H), 3.50-3.42 (m, 2H), 3.32 (ddd, 1H, J = 18.4, 12.0, 1.6 Hz), 2.75 (ddd, 1H, J = 18.4, 9.6, 1.6 Hz). LC-MS (m / z): 354.40 [M+H] + .
[0169] Compound 86: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-(pyrazin-2-yl)piperazin-1-yl)methanone [ka] The title compound 86 was prepared following the method for compound 28 as a yellow solid in 22% yield (15 mg). 1 H NMR (400Hz, CDCl3): δ 8.20-8.03 (m, 2H), 7.87 (s, 1H), 7.38-7.22 (m, 5H), 6.86 (s, 1H), 5.37 (dd, J = 11.6, 9.6 Hz, 1H), 3.90-3.50 (m, 8H), 3.40-3.21 (m, 1H), 2.79-2.72 (m, 1H). LC-MS (ESI) m / z: 337.41, [M+H] + .
[0170] Compound 87: (4-(5-methylpyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 87 was prepared following the method for compound 28 as a yellow solid in 36% yield (25 mg). 1 H NMR (400Hz, CDCl3): δ 8.16 (s, 2H), 7.40-7.20 (m, 5H), 6.84 (s, 1H), 5.37 (dd, J = 11.6, 9.6 Hz, 1H), 4.06-3.46 (m, 8H), 3.31 (m, 1H), 2.77-2.63 (m, 1H), 2.12 (s, 3H). LC-MS (ESI) m / z: 351.40, [M+H] + .
[0171] Compound 88: (4-(5-chloropyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 88 was prepared following the method for compound 28 as a yellow solid in 24% yield (18 mg). 1H NMR (400Hz, CDCl3): δ 8.23 (s, 2H), 7.36-7.23 (m, 5H), 6.85 (s, 1H), 5.37 (dd, J = 11.6, 9.6 Hz, 1H), 3.95-3.56 (m, 8H), 3.36-3.28 (m, 1H), 2.79-2.71 (m, 1H). LC-MS (ESI) m / z: 371.37, [M+H] + .
[0172] Compound 89: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-(pyridazin-3-yl)piperazin-1-yl)methanone [ka] The title compound 89 was prepared following the method for compound 28 as a yellow solid in 13% yield (9 mg). 1 H NMR (400Hz, CDCl3): δ 8.86 (s, 1H), 7.44-7.25(m, 7H), 6.90 (s, 1H), 5.36 (dd, J = 11.6, 9.6 Hz, 1H), 3.88-3.69 (m, 8H), 3.35 (m, 1H), 2.79 (m, 1H). LC-MS (ESI) m / z: 337.37, [M+H] + .
[0173] Compound 90: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-(pyrimidin-4-yl)piperazin-1-yl)methanone [ka] The title compound 90 was prepared following the method for compound 28 as a white solid in 44% yield (29 mg). 1 H NMR (400Hz, CDCl3): δ 8.62 (s, 1H), 8.28 (d, J = 6.8 Hz, 1H), 7.36-7.24 (m, 5H), 6.87 (s, 1H), 6.56 (d, J = 6.8 Hz, 1H), 5.35 (dd, J = 11.6, 9.6 Hz, 1H), 3.86-3.59 (m, 8H), 3.34 (m, 1H), 2.77 (m, 1H). LC-MS (ESI) m / z: 337.41, [M+H]+ .
[0174] Compound 91: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-phenylpiperazin-1-yl)methanone [ka] The title compound 91 was prepared following the method for compound 28 as a white solid in 23% yield (15 mg). 1 H NMR (400Hz, CDCl3): δ 7.38-7.25 (m, 7H), 7.18 (d, J = 8.4 Hz, 2H), 7.11 (t, J = 7.2 Hz, 1H), 6.87 (s, 1H), 5.37 (dd, J = 11.6, 9.6 Hz, 1H), 3.97-3.81 (m, 4H), 3.41-3.24 (m, 5H), 2.76 (m, 1H). LC-MS (ESI) m / z: 335.39, [M+H] + .
[0175] Compound 92: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-(thiazol-2-yl)piperazin-1-yl)methanone [ka] The title compound 92 was prepared following the method of 84 as a pale yellow solid in 19.7% yield (13.0 mg). 1 H NMR (400 MHz, CDCl3) δ 7.39-7.25 (m, 6H), 6.89 (s, 1H), 6.63 (d, J = 4.0 Hz, 1H), 5.34 (dd, J = 12.0, 12.0 Hz, 1H), 3.88- 3.82 (m, 2H), 3.78-3.70 (m, 4H), 3.66-3.61 (m, 2H), 3.38-3.30 (m, 1H), 2.81-2.74 (m, 1H). LC-MS (m / z) 342.41 [M+H] + .
[0176] Compound 93: (4-(cyclopropanecarbonyl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 93 was prepared following the method for compound 28 as a white solid in 76% yield (49 mg). 1 H NMR (400Hz, CDCl3): δ 7.36-7.26 (m, 5H), 6.85 (s, 1H), 5.35 (dd, J = 11.6, 9.6 Hz, 1H), 3.77-3.52 (m, 8H), 3.31(m, 1H), 2.75 (m, 1H), 1.14 (m, 1H), 1.02-0.98 (m, 2H), 0.80-0.75 (m, 2H) LC-MS (ESI) m / z: 327.35, [M+H] + .
[0177] Compound 94: (4-(furan-2-carbonyl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 94 was prepared following the method for compound 28 as a white solid in 77% yield (54 mg). 1 H NMR (400Hz, CDCl3): δ 7.48 (m, 1H), 7.36-7.25 (m, 5H), 7.02 (m, 1H), 6.85 (s, 1H), 6.49 (m, 1H), 5.36 (dd, J = 11.6, 9.6 Hz, 1H), 3.91-3.55 (m, 8H), 3.31 (m, 1H), 2.75 (m, 1H). LC-MS (ESI) m / z: 353.35, [M+H] + .
[0178] Compound 95: (4-benzoylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 95 was prepared following the method for compound 28 as a yellow solid in 71% yield (51 mg). 1H NMR (400Hz, CDCl3): δ 7.43- 7.25(m, 10H), 6.83 (s, 1H), 5.34 (dd, J = 11.6, 9.6 Hz, 1H), 3.91-3.17 (m, 9H), 2.72 (m, 1H). LC-MS (ESI) m / z: 363.42, [M+H] + .
[0179] Compound 96: (4-(5-fluoropyrimidin-2-yl)-1,4-diazepan-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 96 was prepared following the method of 84 as a pale yellow solid in 13.1% yield (13.0 mg). 1 H NMR (400 MHz, CDCl3) δ 8.14 (s, 2H), 7.28-7.18 (m, 5H), 6.77 (t, J = 4.0 Hz, 1H), 5.36-5.30 (m, 1H), 4.02-3.89 (m, 2H), 3.81-3.73 (m, 2H), 3.70-3.62 (m, 2H), 3.47-3.33 (m, 2H), 3.28-3.20 (m, 1H), 2.71-2.64 (m, 1H), 2.11-2.01 (m, 1H), 1.90-1.81 (m, 1H). LC-MS (m / z) 369.42 [M+H] + .
[0180] Compound 97: (4-benzylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] To a solution of (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (50 mg, 0.19 mmol) and K2CO3 (66.7 mg, 0.48 mmol) in DMF (5 mL) was added (bromomethyl)benzene (33 mg, 0.19 mmol). The mixture was stirred at room temperature for 2 hours, then 30 mL of H2O was added, and the mixture was extracted with EA (20 mL x 3). The solvent was evaporated under reduced pressure to give crude product 97. Further purification by silica gel column chromatography (PE / EA = 1 / 1) gave 20 mg of 97 as a pale yellow solid. 97: 1 H NMR (400 MHz, CDCl3) δ 7.35-7.23 (m, 10H), 6.80 (t, J = 4.0 Hz, 1H), 5.37-5.31 (m, 1H), 3.73-3.67 (m, 2H), 3.56-3.50 (m, 4H), 3.32-3.24 (m, 1H), 2.74-2.66 (m, 1H), 2.52-2.47 (m, 2H), 2.44-2.39 (m, 2H). LC-MS (m / z) 349.43 [M+H] + .
[0181] Compound 98: 4-((4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)methyl)benzonitrile [ka] The title compound 98 was prepared following the method for 97 as a pale yellow solid in 47% yield (34.0 mg). 1 H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.34-7.23 (m, 5H), 6.81 (t, J = 4.0 Hz, 1H), 5.34-5.29 (m, LC-MS (m / z) 374.51 [M+H] + .
[0182] Compound 99: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-(pyrimidin-5-yl)piperazin-1-yl)methanone [ka] The title compound 99 was prepared following the method for compound 28 as a yellow solid in 15% yield (19 mg). 1 H NMR (400Hz, CDCl3): δ 8.71 (s, 1H), 8.38 (s, 2H), 7.36-7.24 (m, 5H), 6.86 (s, 1H), 5.37 (dd, J = 11.6, 9.6 Hz, 1H), 3.89-3.69 (m, 4H), 3.37-3.19 (m, 5H), 2.76 (m, 1H). LC-MS (ESI) m / z: 337.32, [M+H] + .
[0183] Compound 100: (5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone [ka] Step 1 Compound 100-1 was synthesized using tert-butyl piperazine-1-carboxylate (1.0 g, 5.37 mmol) and 2-chloro-5-fluoropyrimidine (782 mg, 5.91 mmol) according to the procedure for compound 28. tert-Butyl 4-(5-fluoropyrimidin-2-yl)piperazine-1-carboxylate was obtained as a pale yellow powder (980 mg, 65% yield). LC-MS (m / z) 283.34 [M+H] + Step 2 Trifluoroacetic acid was added dropwise to a solution of tert-butyl 4-(5-fluoropyrimidin-2-yl)piperazine-1-carboxylate (980 mg, 3.47 mmol) in dichloromethane (10 mL) at 0° C. The mixture was then refluxed for 2 hours. The volatiles were removed under reduced pressure, and the residue was suspended in dichloromethane (saturated). The organic layer was washed successively with water, saturated aqueous NaHCO3, and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. 5-Fluoro-2-(piperazin-1-yl)pyrimidine was obtained as a pale pink solid (610 mg, 96% yield). The crude product was used directly in the next step without further purification. LC-MS (m / z) 183.44 [M+H] + . Step 3 To a solution of 5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazole (50 mg, 0.3 mmol) and triethylamine (93 mg, 0.94 mmol) in ultra-dry dichloromethane (8 mL) was added triphosgene (36 mg, 0.12 mmol) under argon protection at 0 °C. After stirring the mixture for 30 min, a solution of 5-fluoro-2-(piperazin-1-yl)pyrimidine (73 mg, 0.4 mmol) and triethylamine (61 mg, 0.61 mmol) in ultra-dry dichloromethane (2 mL) was added dropwise. The mixture was stirred for an additional 30 min. The reaction was quenched with saturated aqueous NaHCO3, the volatiles were removed under reduced pressure, and the residue was suspended in dichloromethane (saturated). The organic layer was washed successively with water and brine. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 1 / 1) and lyophilized to give (5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone 100 as a white powder (40.5 mg, 36% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.22-8.19 (s, 2H), 7.33-7.27 (m, 1H), 7.08 (dt, J = 7.6, 1.4 Hz, 1H), 7.03-6.91 (m, 2H), 6.84 (q, J = 1.8 Hz, 1H), 5.36 (dd, J = 11.8, 9.8 Hz, 1H), 3.90-3.79 (m, 2H), 3.79-3.70 (m, 4H), 3.67-3.54 (m, 2H), 3.32 (ddt, J = 18.2, 11.8, 1.8 Hz, 1H), 2.71 (ddt, J = 18.4, 9.8, 1.6 Hz, 1H).LC-MS (m / z) 373.42 [M+H] + .
[0184] Compound 101: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone [ka] Compound 101 was synthesized using 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole according to the method for Compound 100. (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)methanone was obtained as a white powder (39% yield). 1 H NMR (400 MHz, Chloroform-d) δ 8.21 (d, J = 0.6 Hz, 2H), 6.87-6.78 (m, 3H), 6.69 (tt, J = 8.8, 2.4 Hz, 1H), 5.33 (dd, J = 11.6, 9.8 Hz, 1H), 3.92-3.81 (m, 2H), 3.81-3.70 (m, 4H), 3.69-3.57 (m, 2H), 3.32 (ddd, J = 18.2, 11.8, 1.8 Hz, 1H), 2.68 (ddd, J = 18.2, 9.8, 1.6 Hz, 1H).LC-MS (m / z) 391.76 [M+H] + .
[0185] Compound 102: (4-(4-aminopyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] To a solution of (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (50.0 mg, 0.19 mmol) and 2-chloropyrimidin-4-amine (30.1 mg, 0.23 mmol) in ultra-dehydrated DMF (3.0 mL), K2CO3 (80.3 mg, 0.58 mmol) was added under argon protection. The mixture was stirred at 140 °C for 8 h. The solvent was removed under reduced pressure, and the residue was purified by column chromatography (silica gel, ethyl acetate / methanol = 1:0 to 10:1) to give (4-(4-aminopyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (Compound 102) as a pale yellow powder (26 mg, 38% yield). 1 H NMR (400 MHz, Chloroform-d) δ 7.88 (d, J = 5.8 Hz, 1H), 7.40-7.19 (m, 5H), 6.83 (t, J = 2.8 Hz, 1H), 5.82 (d, J = 5.8 Hz, 1H), 5.35 (t, J = LC-MS (m / z) 352.63 [M+H] + .
[0186] Compound 103: (4-(4-hydroxypyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] Compound 103 was synthesized using 2-chloropyrimidin-4-ol according to the method for compound 102. (4-(4-hydroxypyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone was obtained as a white powder (46% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.07 (s, 1H), 7.42-7.15 (m, 5H), 6.85 (d, J = 2.8 Hz, 1H), 5.33 (d, J = 9.8 Hz, 1H), 3.74-3.45 (m, 6H), 3.46-3.24 (m, 4H), 2.75 (d, J = 8.6 Hz, 2H). LC-MS (m / z) 353.36 [M+H] + .
[0187] Compound 104: (4-(5-chlorothiazol-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 104 was prepared following the method of 84 as a pale yellow solid in 2.8% yield (2.0 mg). 1 H NMR (400 MHz, CDCl3) δ 7.35-7.24 (m, 5H), 6.99 (s, 1H), 6.85 (s, 1H), 5.38-5.33 (m, 1H), 3.81-3.75 (m, 2H), 3.69-3.63 (m, 2H), 3.53-3.48 (m, 2H), 3.41-3.35 (m, 2H), 3.34-3.29 (m, 1H), 2.79-2.72 (m, 1H). LC-MS (m / z) 376.94 [M+H] + .
[0188] Compound 105: (4-(4-methylthiazol-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] (5-Phenyl-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (50 mg, 0.19 mmol), 2-bromo-4-methylthiazole (35 mg, 0.19 mmol), Pd(dba) (30 mg, 0.033 mmol), BINAP (36 mg, 0.058 mmol), and t-BuONa (22.3 mg, 0.23 mmol) were dissolved in toluene (5 mL). The mixture was heated at 105 °C overnight. The solvent was evaporated under reduced pressure to give crude product 105. Further purification by silica gel column chromatography (PE / EA = 1 / 1) afforded 5 mg of 105 as a pale yellow solid. 105:1H NMR (400 MHz, CDCl3) δ 7.36-7.32 (m, 2H), 7.28-7.26 (m, 3H), 6.90 (s, 1H), 6.20 (s, 1H), 5.35-5.30 (m, 1H), 3.88-3.82 (m, LC-MS (m / z) 356.51 [M+H] + .
[0189] Compound 106: (4-(5-methylthiazol-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 106 was prepared following the method for 105 as a pale yellow solid in 10.2% yield (7.0 mg). 1 H NMR (400 MHz, CDCl3) δ 7.36-7.32 (m, 2H), 7.28-7.25 (m, 3H), 7.06 (s, 1H), 6.90 (s, 1H), 5.35-5.30 (m, 1H), 3.88-3.82 (m, 2H), 3.78-3.70 (m, 4H), 3.67-3.61 (m, 2H), 3.39-3.31 (m, 1H), 2.82-2.75 (m, 1H), 2.32 (s, 3H). LC-MS (m / z) 356.51 [M+H] + .
[0190] Compound 107: 2-(4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)thiazole-4-carbonitrile [ka] Compound 107 was synthesized using 2-bromothiazole-4-carbonitrile according to the method for Compound 102. 2-(4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)thiazole-4-carbonitrile was obtained as a white powder (42% yield). 1 H NMR (400 MHz, Chloroform-d) δ 7.38-7.22 (m, 6H), 6.86 (t, J = 1.8 Hz, 1H), 5.35 (dd, J = 11.8, 9.6 Hz, 1H), 3.79 (m, 2H), 3.67 (m, 2H), 3.59 (m, 2H), 3.47 (m, 2H), 3.33 (m, 1H), 2.76 (m, 1H). LC-MS (m / z) 367.45 [M+H] + .
[0191] Compound 108: 2-(4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)thiazole-5-carbonitrile [ka] Compound 108 was synthesized using 2-chlorothiazole-5-carbonitrile according to the method for Compound 102. 2-(4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)thiazole-5-carbonitrile was obtained as a white powder (45% yield). 1 H NMR (400 MHz, Chloroform-d) δ 7.69 (s, 1H), 7.37-7.23 (m, 5H), 6.86 (t, J = 1.8 Hz, 1H), 5.35 (dd, J = 11.8, 9.4 Hz, 1H), 3.86-3.75 (m, 2H), 3.73-3.62 (m, 4H), 3.60-3.48 (m, 2H), 3.34 (m, 1H), 2.77 (m, 1H). LC-MS (m / z) 367.63 [M+H] +.
[0192] Compound 109: ((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)((S)-3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 109 was prepared following the method for compound 28 as a white solid in 65% yield (24 mg). 1H NMR (400 Hz, CDCl3): δ 8.19 (s, 2H), 7.42-7.24 (m, 5H), 5.48 (dd, J = 8.4, 4.4 Hz, 1H), 4.54-4.40 (m, 3H), 4.20-4.10 (m, 2H), 3.91 (m, 1H), 3.25-3.02 (m, 3H), 2.80 (m, 1H), 2.31 (m, 1H), 1.26 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 372.39, [M+H] +.
[0193] Compound 110: ((2R,6S)-4-(5-fluoropyrimidin-2-yl)-2,6-dimethylpiperazin-1-yl)((S)-3-phenylisoxazolidin-2-yl)methanone [ka] The title compound 110 was prepared following the method for compound 28 as a white solid in 37% yield (14 mg). 1H NMR (400Hz, CDCl3):δ 8.19 (s, 2H), 7.42-7.25 (m, 5H), 5.46 (dd, J = 8.4, 4.8 Hz, 1H), 4.67 (m, 1H), 4.43-4.34 (m, 3H), 4.13(m, LC-MS (ESI) m / z: 386.39, [M+H] +.
[0194] Compound 111A: (S)-(4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 111A was prepared following the method of 84 as a pale yellow solid in 16% yield (23.0 mg). 1 H NMR (400 MHz, CDCl3) δ 8.18 (s, 2H), 7.35-7.22 (m, 5H), 6.82 (t, J = 4.0 Hz, 1H), 5.41-5.35 (m, 1H), 4.50- 4.47 (m, 2H), 4.44- 4.40 LC-MS (m / z) 369.42 [M+H] + .
[0195] 111B: (S)-(4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 111B was prepared following the method of 84 as a pale yellow solid in 22.3% yield (32.0 mg). 1 H NMR (400 MHz, CDCl3) δ 8.18 (s, 2H), 7.36-7.22 (m, 5H), 6.85 (t, J = 4.0 Hz, 1H), 5.38-5.33 (m, 1H), 4.79-4.73 (m, 1H), 4.55-4.51 (m, 1H), 4.40-4.36 (m, 1H), 3.96-3.93 (m, 1H), 3.39-3.27 (m, 3H), 3.01-2.94 (m, 1H), 2.77-2.70 (m, 1H), 1.15 (d, J = 8.0 Hz, 3H). LC-MS (m / z) 369.41 [M+H] + .
[0196] Compound 112A: (S)-(2-methyl-4-(pyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 112A was prepared following the method of 84 as a pale yellow solid in 49.7% yield (32.0 mg). 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 4.0 Hz, 2H), 7.35-7.22 (m, 5H), 6.83-6.82 (m, 1H), 6.49-4.47 (m, 1H), 5.41-5.35 (m, 1H), 4.60-4.47 (m, 3H), 4.29-4.25 (m, 1H), 3.33-3.11 (m, 4H), 2.75-2.67 (m, 1H), 1.26 (d, J = 4.0 Hz, 3H). LC-MS (m / z) 351.41 [M+H] + .
[0197] Compound 112B: (S)-(2-methyl-4-(pyrimidin-2-yl)piperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 112B was prepared following the method of 84 as a pale yellow solid in 45.1% yield (29.0 mg). 1 H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 4.0Hz, 2H), 7.35-7.22 (m, 5H), 6.86-6.85 (m, 1H), 6.49-6.47 (m, 1H), 5.39-5.33 (m, 1H), 4.80-4.73 (m, 1H), 4.65-4.61 (m, 1H), 4.49- 4.45 (m, 1H), 3.98-3.93 (m, 1H), 3.40-3.26 (m, 3H), 3.00-2.95 (m, 1H), 2.77-2.70 (m, 1H), 1.15 (d, J = 8.0 Hz, 3H). LC-MS (m / z) 351.42 [M+H] + .
[0198] Compound 113A: ((S)-4-(5-chloropyrimidin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 113A was prepared following the method for compound 28 as a yellow solid in 41% yield (32 mg). 1H NMR (400 Hz, CDCl3): δ 8.21 (s, 2H), 7.35-7.22 (m, 5H), 6.82 (s, 1H), 5.38 (dd, J = 11.6, 10.0 Hz, 1H), 4.56-4.41 (m, 3H), 4.25 (m, 1H), 3.34-3.07 (m, 4H), 2.71 (m, 1H), 1.24 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 385.34, [M+H] + .
[0199] Compound 113B: ((S)-4-(5-chloropyrimidin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 113B was prepared according to the method for compound 28 as a yellow solid in 91% yield (70 mg). 1H NMR (400 Hz, CDCl3): δ 8.21 (s, 2H), 7.36-7.21 (m, 5H), 6.85 (s, 1H), 5.35 (dd, J = 11.6, 10.0 Hz, 1H), 4.79-4.39 (m, 3H), 3.95 (m, 1H), 3.38-3.25 (m, 3H), 3.03-2.94 (m, 1H), 2.72 (m, 1H), 1.13 (d, J = 7.2 Hz, 3H). LC-MS (ESI) m / z: 385.34, [M+H] + .
[0200] Compound 114A: ((R)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 114A was prepared following the method for compound 28 as a yellow solid in 15% yield (11.2 mg). 1H NMR (400 Hz, CDCl3): δ 8.18 (s, 2H), 7.35-7.23 (m, 5H), 6.83 (s, 1H), 5.38 (dd, J = 12.0, 10.0 Hz, 1H), 4.52-4.23 (m, 4H), 3.35-3.07 (m, 4H), 2.72 (m, 1H), 1.26 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 369.36, [M+H] +.
[0201] Compound 114B: ((R)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 114B was prepared following the method for compound 28 as a yellow solid in 38% yield (28 mg). 1 H NMR (400Hz, CDCl3): δ 8.18 (s, 2H), 7.35-7.23 (m, 5H), 6.86 (s, 1H), 5.36 (dd, J= 12.0, 10.0 Hz, 1H), 4.78-4.36 (m, 3H), 3.95 (m, 1H), 3.40-3.24 (m, 3H), 2.97 (m, 1H), 2.72 (m, 1H), 1.15 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 369.37, [M+H] + .
[0202] Compound 115A: ((S)-4-(5-fluoropyridin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 115A was prepared following the method for compound 28 as a yellow solid in 14% yield (10 mg). 1H NMR (400Hz, CDCl3): δ 8.07 (d, J= 2.8 Hz, 1H), 7.35-7.21 (m, 6H), 6.83 (s, 1H), 6.65(d, J= 9.2, 2.8 Hz, 1H), 5.37 (dd, J= 11.6, 9.6 Hz, 1H), 4.53 (m, 1H), 4.30 (m, 1H), 4.04-3.92 (m, 2H), 3.37-3.09(m, 4H), 2.72 (m, 1H), 1.34 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 368.34, [M+H] + .
[0203] Compound 115B: ((S)-4-(5-fluoropyridin-2-yl)-2-methylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 115B was prepared following the method for compound 28 as a yellow solid in 12% yield (9 mg). 1 H NMR (400Hz, CDCl3): δ 8.05 (d, J= 3.2 Hz, 1H), 7.34-7.23 (m, 6H), 6.85 (s, 1H), 6.63(d, J= 9.2, 3.2 Hz, 1H), 5.35 (dd, J= 11.6, 9.6 Hz, 1H), 4.80 (m, 1H), 4.09-3.89 (m, 3H), 3.48-3.07 (m, 4H), 2.72 (m, 1H), 1.23 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 368.35, [M+H] + .
[0204] Compound 116A: 2-((3S)-3-methyl-4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-5-carbonitrile [ka] The title compound 116A was prepared following the method for compound 28 as a white solid in 32% yield (12 mg). 1H NMR (400Hz, CDCl3): δ 8.48 (s, 2H), 7.36-7.24 (m, 5H), 6.84 (s, 1H), 5.37 (dd, J= 11.6, 9.6 Hz, 1H), 4.69-4.51 (m, 3H), 4.29 (m, 1H), 3.36-3.18(m, 4H), 2.74 (m, 1H), 1.22 (d, J = 6.8 Hz, 3H). LC-MS (ESI) m / z: 376.44, [M+H] + .
[0205] Compound 116B: 2-((3S)-3-methyl-4-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidine-5-carbonitrile
change
[0206] Compound 117A: ((S)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)methanone
change
[0207] Compound 117B: ((R)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)methanone [ka] Compound 117B was synthesized using (5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-2-methylpiperazin-1-yl)methanone and 2-chloro-5-fluoropyrimidine according to the method for Compound 102. ((S)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)methanone was obtained as a white powder (22% yield). 1H NMR (400 MHz, Chloroform-d) δ 8.20 (s, 2H), 7.08 (s, 1H), 7.02-6.91 (m, 3H), 6.83 (s, 1H), 5.32 (s, 1H), 4.36-4.52 (m, 3H), 4.26 (m, 1H), 3.05-3.36 (m, 4H), 2.71 (m, 1H), 1.24 (s, 3H). LC-MS (m / z) 387.69 [M+H] + .
[0208] Compound 118A: ((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)methanone [ka] Compound 118A was synthesized using (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-2-methylpiperazin-1-yl)methanone and 2-chloro-5-fluoropyrimidine according to the method for Compound 102. ((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)methanone was obtained as a white powder (14% yield). 1 H NMR (400 MHz, Chloroform-d) δ 8.22 (s, 2H), 6.86-6.76 (m, 3H), 6.74-6.64 (m, 1H), 5.34 (t, J = 10.8 Hz, 1H), 4.60-4.40 (m, 3H), 4.28 (d, LC-MS (m / z) 405.82 [M+H] + .
[0209] Compound 118B: ((R)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)methanone [ka] Compound 118B was synthesized using (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-2-methylpiperazin-1-yl)methanone and 2-chloro-5-fluoropyrimidine according to the method for Compound 102. ((R)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((S)-4-(5-fluoropyrimidin-2-yl)-2-methylpiperazin-1-yl)methanone was obtained as a white powder (16% yield). 1 H NMR (400 MHz, Chloroform-d) δ 8.22 (s, 2H), 6.84- 6.73 (m, 3H), 6.74-6.65 (m, 1H), 5.30 (t, J = 10.9 Hz, 1H), 4.60-4.41 (m, 3H), 4.28 LC-MS (m / z) 405.76 [M+H] + .
[0210] Compound 119: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-(pyrazin-2-yloxy)azetidin-1-yl)methanone [ka] The title compound 119 was prepared in 40% yield from 2-(azetidin-3-yloxy)pyrazine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 8.26 (s, 1H), 8.14 (d, J = 2.7 Hz, 1H), 8.06 - 8.00 (m, 1H), 7.34 - 7.27 (m, 2H), 7.24-7.18 (m, 3H), 6.81 - 6.72 (m, 1H), 5.36-5.26 (m, 2H), 4.62 - 4.44 (m, 2H), 4.17 (dd, J = 26.0, 6.5 Hz, 2H), 3.33 (dd, J = 18.5, 12.1 Hz, 1H), 2.73 (dd, J = 18.6, 6.3 Hz, 1H).LC-MS (m / z) 324.4 (M+H + )
[0211] Compound 120: 2-((1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-5-carbonitrile [ka] The title compound 120 was prepared in 30% yield from 2-(azetidin-3-yloxy)thiazole-5-carbonitrile trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.35 - 7.25 (m, 2H), 7.23-7.13 (m, 3H), 6.77 (t, J = 1.7 Hz, 1H), 5.47 - 5.39 (m, 1H), 5.29 (dd, J = 12.1, 6.3 Hz, 1H), 4.61 - 4.43 (m, 2H), 4.22 (dd, J = 31.0, 9.3 Hz, 2H), 3.40 - 3.27 (m, 1H), 2.74 (ddd, J = 18.6, 6.3, 1.7 Hz, 1H). LC-MS (m / z) 354.4 (M+H + )
[0212] Compound 121: 2-((1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carbonitrile [ka] The title compound 121 was prepared in 28% yield from 2-(azetidin-3-yloxy)thiazole-4-carbonitrile trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. LC-MS (m / z) 354.4 (M+H + )
[0213] Compound 122: ((2R,6R)-4-(5-fluoropyrimidin-2-yl)-2,6-dimethylpiperazin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 122 was prepared following the method of 84 as a pale yellow solid in 40.5% yield (6.0 mg). 1 H NMR (400 MHz, CDCl3) δ 8.23 (s, 2H), 7.35-7.29 (m, 4H), 7.27-7.23 (m, 1H), 6.89 (s, 1H), 5.37 (dd, J = 12.0, 8.0 Hz, 1H), 4.53-4.46 LC-MS (m / z) 383.43 [M+H] + .
[0214] Compound 123: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-(1-phenylethylidene)azetidin-1-yl)methanone [ka] Step 1 To a solution of triphenylphosphine (6.13 g, 23.37 mmol) in anhydrous dichloromethane (15 mL), carbon tetrabromide (3.87 g, 11.68 mmol) was added under argon protection at 0°C. After stirring the solution at the same temperature for 5 minutes, a solution of tert-butyl 3-oxoazetidine-1-carboxylate (1 g, 5.84 mmol) in anhydrous dichloromethane (5 mL) was added dropwise. The reaction mixture was stirred for 20 minutes and then at room temperature for 24 hours. Hexane was added, and the resulting precipitate was removed by filtration. The filtrate was concentrated to give an off-white solid. This solid was stirred in hexane with sonication, and the remaining solid was removed by suction filtration. The filtrate was concentrated to give tert-butyl 3-(dibromomethylene)azetidine-1-carboxylate (1.57 g, 82%). LC-MS (m / z) 325.87 [M+H] + . Step 2 To a solution of tert-butyl 3-(dibromomethylene)azetidine-1-carboxylate (1.57 g, 4.80 mmol) in anhydrous tetrahydrofuran (20 mL) was added dropwise n-butyllithium (4.43 mL, 1.3 M) under argon protection at -78 °C. After 10 min, iodomethane was added dropwise, and the reaction mixture was stirred at the same temperature for 2 h. The reaction was quenched with saturated aqueous NH4Cl and extracted twice with ether. The combined organic layers were washed successively with water and brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The product was purified by silica gel column chromatography (petroleum ether / AcOEt, 30 / 1) to give tert-butyl 3-(1-bromoethylidene)azetidine-1-carboxylate as a colorless oil (720 mg, 57%). LC-MS (m / z) 263.45 [M+H] + . Step 3 To a solution of tert-butyl 3-(1-bromoethylidene)azetidine-1-carboxylate (100 mg, 0.38 mmol) and phenylboronic acid (56 mg, 0.46 mmol) in anhydrous 1,4-dioxane (10 mL), tetrakis(triphenylphosphine)palladium (88 mg, 0.76 mmol) and potassium carbonate (158 mg, 1.14 mmol) were added under argon protection. The reaction mixture was stirred at 110 °C for 12 h. The volatiles were removed under reduced pressure, and the residue was suspended in dichloromethane (saturated). The organic layer was washed successively with water and brine. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 1 / 1) to give tert-butyl 3-(1-phenylethylidene)azetidine-1-carboxylate as a pale yellow oil (76 mg, 77%). LC-MS (m / z) 260.68 [M+H] + . Step 4 Intermediate 123-4 was synthesized using tert-butyl 3-(1-phenylethylidene)azetidine-1-carboxylate according to the method for Intermediate 100-2. 3-(1-phenylethylidene)azetidine was obtained as a pale yellow oil (95% yield). LC-MS (m / z) 160.46 [M+H] + . Step 5 Compound 123 was synthesized using 5-phenyl-4,5-dihydro-1H-pyrazole and 3-(1-phenylethylidene)azetidine according to the method for Compound 100. (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-(1-phenylethylidene)azetidin-1-yl)methanone was obtained as a pale white powder (22 mg, 17% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.49 - 7.07 (m, 10H), 6.81 (d, J = 8.2 Hz, 1H), 5.50 - 5.27 (m, 1H), 5.03 - 4.66 (m, 4H), 3.36 (dd, J = 17.6, 10.8 Hz, 1H), 2.76 (d, J = 18.8 Hz, 1H), 1.94 (s, 3H). LC-MS (m / z) 332.57 [M+H] + .
[0215] Compound 124: (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-(1-phenylethyl)azetidin-1-yl)methanone [ka] Step 1 To a solution of tert-butyl 3-(1-phenylethylidene)azetidine-1-carboxylate (217 mg, 836.71 mmol) in methanol (10 mL) was added 10% palladium on carbon under argon protection. Hydrogen was bubbled through the mixture using a balloon. The reaction mixture was stirred at room temperature for 12 hours. The mixture was filtered through Celite, and the filtrate was concentrated. The crude product (123 mg, 56%) was used directly in the next step without further purification. LC-MS (m / z) 262.83 [M+H] + . Step 2 Intermediate 124-2 was synthesized using tert-butyl 3-(1-phenylethyl)azetidine-1-carboxylate according to the method of Intermediate 100-2. 3-(1-phenylethyl)azetidine was obtained as a pale yellow oil (72 mg, 94%). The crude product was used directly in the next step without further purification. LC-MS (m / z) 162.67 [M+H] + . Step 3 Compound 124 was synthesized using 5-phenyl-4,5-dihydro-1H-pyrazole and 3-(1-phenylethyl)azetidine according to the method for Compound 100. (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-(1-phenylethyl)azetidin-1-yl)methanone was obtained as a pale white powder (41 mg, 27% yield). 1 H NMR (400 MHz, Chloroform-d) δ 7.39 - 7.09 (m, 10H), 6.74 (s, 1H), 5.31 (s, 1H), 4.29 (d, J = 28.8 Hz, 1H), 3.92 (d, J = 31.2 Hz, 2H), 3.71 LC-MS (m / z) 334.84 [M+H] + .
[0216] Compound 125: (3-((6-ethynylpyrimidin-4-yl)oxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 125 was prepared in 18% yield by removal of the TMS group from (5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(3-((6-((trimethylsilyl)ethynyl)pyrimidin-4-yl)oxy)azetidin-1-yl)methanone, which was prepared from 4-(azetidin-3-yloxy)-6-((trimethylsilyl)ethynyl)pyrimidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone according to the method outlined for compound 60. LC-MS (m / z) 348.4 (M+H + )
[0217] Compound 126: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-(2,4,6-trifluorophenoxy)azetidin-1-yl)methanone [ka] The title compound 126 was prepared in 21% yield from 3-(2,4,6-trifluorophenoxy)azetidine and (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 6.80 - 6.63 (m, 6H), 5.28 (dd, J = 12.2, 6.4 Hz, 1H),4.93- 4.80 (m, 1H), 4.49-4.40 (m, 2H), 4.38-4.24 (m, 2H), 3.22 (dd, J = 14.0, 7.0 Hz, 1H), 2.69 (ddd, 6.5 Hz, 1H). LC-MS (m / z) 412.33 (M+H + )
[0218] Compound 127: (3-((6-bromopyrimidin-4-yl)oxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 127 was prepared in 18% yield from 4-(azetidin-3-yloxy)-6-bromopyrimidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. LC-MS (m / z) 402.35 (M+H + )
[0219] Compound 128: (3-(2,5-difluorophenoxy)azetidin-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 128 was prepared in 37.7% yield from 3-(2,5-difluorophenoxy)azetidine trifluoroacetate and (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.27 (m, 2H), 7.24 - 7.18 (m, 3H), 7.06 - 6.97 (m, 1H), 6.77 (brs, 1H), 6.60 (ddt, J = 9.0, 7.8, 3.1 Hz, 1H), 6.40 (ddd, J = 9.5, 6.6, 3.0 Hz, 1H), 5.30 (dd, J = 12.2, 6.2 Hz, 1H), 4.92-4.86 (m, J = 10.6, 6.4, 4.2 Hz, 1H), 4.58-4.45(m, J = 25.1, 10.1, 6.5 Hz, 2H), 4.28 (dd, J = 10.3, 3.8 Hz, 1H), 4.21 (dd, J = 10.3, 4.1 Hz, 1H), 3.33 (dd, J = 18.7, 12.4 Hz, 1H), 2.73 (ddd, J = 18.6, 6.3, 1.6 Hz, 1H). LC-MS (m / z) 358.4 (M+H + )
[0220] Compound 129: 3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)benzamide [ka] To a solution of tert-butyl 3-(3-cyanophenoxy)azetidine-1-carboxylate (200 mg), prepared in a similar manner to tert-butyl 3-(2-fluorophenoxy)azetidine-1-carboxylate, in MeOH (3 mL) was added DMSO (0.1 mL), 30% HO (0.4 mL), and 1N NaOH (0.9 mL) at 0 °C. The mixture was stirred at 50 °C for 3 h. The mixture was extracted with DCM, washed with brine, dried (NaSO), and concentrated under reduced pressure to give the crude desired product (250 mg). LC-MS (m / z) 293.43 (M+H + ). The Boc group was removed from tert-butyl 3-(3-carbamoylphenoxy)azetidine-1-carboxylate and 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole was coupled using triphosgene to give the title product 129 (46 mg, 32%). 1H NMR (400 MHz, CDCl3) δ 7.45 - 7.31 (m, 2H), 7.29 - 7.25 (m, 1H), 7.24 - 7.20 (m, 1H), 6.95 (ddd, J = 7.9, 6.5, 2.8 Hz, 1H), 6.82 - 6.63 (m, 3H), 6.16 (brs, 2H), 5.26 (dd, J = 12.1, 6.4 Hz, 1H), 4.96 (ddd, J = 10.4, 6.3, 4.0 Hz, 1H), 4.67-4.46 (m, 2H), 4.21 (dd, J = 24.1, 7.2 Hz, 2H), 3.33 (ddd, LC-MS (m / z) 401.4 (M+H) + ).
[0221] Compound 130: 4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)benzamide [ka] The title compound 130 was prepared in 37% yield from 4-(azetidin-3-yloxy)benzamide trifluoroacetate and 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole using triphosgene following the method outlined for compound 129. LC-MS (m / z) 401.40 (M+H + )
[0222] Compound 131: 2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carbonitrile [ka] The title compound 128 was prepared in 37.7% yield from 2-(azetidin-3-yloxy)thiazole-4-carbonitrile trifluoroacetate and (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 6.81 - 6.60 (m, 4H), 5.45-5.35 (m, 1H), 5.25 (dd, J = 11.9, 6.1 Hz, 1H), 4.64 - 4.48 (m, 2H), 4.23 (dd, J = 17.2, 11.1 Hz, 2H), 3.34 (dd, J = 18.3, 11.9 Hz, 1H), 2.68 (dd, J = 18.2, 5.2 Hz, 1H). LC-MS (m / z) 390.4 (M+H + )
[0223] Compound 132: 2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carboxamide [ka] The title compound 132 was prepared in 27.7% yield from 2-(azetidin-3-yloxy)thiazole-4-carboxamide trifluoroacetate and (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 129. 1 H NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 6.86 - 6.59 (m, 5H), 5.61 (s, 1H), 5.44-5.36 (m, 1H), 5.26 (dd, J = 12.2, 6.5 Hz, 1H), 4.65-4.45 LC-MS (m / z) 408.4 (M+H + )
[0224] Compound 133: (3-(2,6-difluorobenzylidene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 133 was prepared in 37% yield from 3-(2,6-difluorobenzylidene)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.23 - 7.13 (m, 1H), 6.87 (t, J = 8.4 Hz, 2H), 6.81 - 6.73 (m, 3H), 6.72 - 6.65 (m, 1H), 6.34 - 6.27 (m, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 4.95-4.75 (m, 4H), 3.36 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.70 (ddd, J = 18.4, 6.0, 1.6 Hz, 1H). LC-MS (m / z):390.31 [M+H] + .
[0225] Compound 134: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((2,4-difluorophenyl)fluoromethyl)azetidin-1-yl)methanone [ka] Step 1 1-Bromo-2,4-difluorobenzene (474 mg, 2.46 mmol) was dissolved in 5 mL of dry THF. The mixture was cooled to -78 °C, and n-BuLi (1.28 mL, 2.4 M, 3.07 mmol) was added dropwise at -78 °C. The mixture was stirred at -78 °C for 1 hour. To this solution, tert-butyl 3-(methoxy(methyl)carbamoyl)azetidine-1-carboxylate (0.5 g, 2.05 mmol) in 2 mL of THF was slowly added at -78 °C. The mixture was stirred at -78 °C for 1 hour. TLC confirmed that the starting material was completely consumed. The reaction was quenched by adding saturated NH4Cl solution and extracted with EtOAc (20 mL x 3). The organic layer was evaporated to dryness and purified by column chromatography (PE / EA=3 / 1) to give 360 mg of tert-butyl 3-(2,4-difluorobenzoyl)azetidine-1-carboxylate as a pale yellow oil. Yield: 74.4%. LC-MS (m / z): 298.40 [M+H]+ . Step 2 tert-Butyl 3-(2,4-difluorobenzoyl)azetidine-1-carboxylate (160 mg, 0.537 mmol) was dissolved in 5 ml of MeOH. NaBH4 (128.3 mg, 3.29 mmol) was added portionwise at 0 °C. The mixture was stirred at room temperature for 16 hours. Water was added to quench the reaction. The solvent was evaporated to dryness and extracted with DCM (15 ml x 3). The mixture was dried over Na2SO4 and filtered. After evaporation to dryness, the mixture was purified by preparative TLC (PE / EA = 2 / 1) to give 160 mg of tert-butyl 3-((2,4-difluorophenyl)(hydroxy)methyl)azetidine-1-carboxylate as a brown oil. Yield: 99.3%. LC-MS (m / z): 300.45 [M+H] + . Step 3 tert-Butyl 3-((2,4-difluorophenyl)(hydroxy)methyl)azetidine-1-carboxylate (160 mg, 0.533 mmol) was dissolved in 7.5 ml of dry DCM. To this solution, diethylaminosulfur trifluoride (174 mg, 1.07 mmol) in 1 mL of DCM was slowly added at 0° C. The mixture was stirred at 0° C. for 0.5 hours and then at room temperature for another 0.5 hours. The mixture was washed with HO, and the organic layer was evaporated to dryness. The mixture was purified by column chromatography (PE / EA=4 / 1) to give 115 mg of tert-butyl 3-((2,4-difluorophenyl)fluoromethyl)azetidine-1-carboxylate as a pale yellow oil. Yield: 71.7%. LC-MS (m / z): 302.40 [M+H] + . Step 4 Tert-butyl 3-((2,4-difluorophenyl)fluoromethyl)azetidine-1-carboxylate (40 mg, 0.133 mmol) was dissolved in 2 mL of dry DCM. To this solution, 5 mL of TFA / DCM (3 / 1) solution was added at 0° C. The mixture was stirred at room temperature for 1.5 hours. The solvent was evaporated to dryness to give 3-((2,4-difluorophenyl)fluoromethyl)azetidine as a brown oil. This was used in the next step without further purification. Yield: quantitative. LC-MS (m / z): 203.30 [M+H] + . Step 5 The above product, 3-((2,4-difluorophenyl)fluoromethyl)azetidine, was dissolved in 2 ml of THF. (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (36.8 mg, 0.133 mmol) was added. 0.2 ml of TEA was added to the solution. The mixture was stirred at 65° C. for 16 hours. The solvent was evaporated to dryness, and the mixture was purified by preparative TLC (PE / EA=2 / 1) to obtain 40 mg of (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((2,4-difluorophenyl)fluoromethyl)azetidin-1-yl)methanone as a pale yellow oil. Yield: 73.7%. 1 H NMR (400 MHz, CDCl3) δ 7.29-7.58 (m 1H), 6.83-6.94 (m, 2H), 6.73-6.77 (m, 3H), 6.65-6.70 (m, 1H), 5.91-6.05 (m, 1H), 5.26 (dd, 1H, J = 12.0, 6.4 Hz), 4.09-4.41 (m, 3H), 3.71-3.82 (m, 1H), 3.38-3.47 (m, 1H), 3.28-3.37 (m 1H), 2.66 (ddd, 1H, J = 18.4, 6.4, 1.6 Hz).LC-MS (m / z): 410.40 [M+H] + .
[0226] Compound 135: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((2,4-difluorophenyl)difluoromethyl)azetidin-1-yl)methanone [ka] Step 1 tert-Butyl 3-(2,4-difluorobenzoyl)azetidine-1-carboxylate (205 mg, 0.688 mmol) was dissolved in 4 ml of dry DCM. To this solution, bis(2-methoxyethyl)aminosulfur trifluoride (1.272 ml, 6.89 mmol) was slowly added at room temperature. The mixture was stirred at room temperature for 5 days. The solution was poured onto ice and extracted with DCM (15 ml x 3). The combined organic layer was washed with saturated NaHCO3. The solvent was evaporated to dryness and purified by preparative TLC (PE / EA = 2 / 1) to give 122 mg of tert-butyl 3-((2,4-difluorophenyl)difluoromethyl)azetidine-1-carboxylate as a pale yellow oil. Yield: 61.6%. LC-MS (m / z): 320.3 [M+H] + . Step 2 3-((2,4-Difluorophenyl)difluoromethyl)azetidine-1-carboxylate (60 mg, 0.188 mmol) was dissolved in 2 mL of dry DCM. To this solution, 5 mL of TFA / DCM (3 / 1) solution was added at 0° C. The mixture was stirred at room temperature for 1.5 hours. The solvent was evaporated to dryness to give 3-((2,4-difluorophenyl)difluoromethyl)azetidine as a brown oil, which was used in the next step without further purification. Yield: quantitative. LC-MS (m / z): 221.30 [M+H] + . Step 3 The product obtained above, 3-((2,4-difluorophenyl)difluoromethyl)azetidine, was dissolved in 3 ml of THF. (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (51.9 mg, 0.187 mmol) was added. 0.4 ml of TEA was added to the solution. The mixture was stirred at 65° C. for 16 hours. The solvent was evaporated to dryness, and the mixture was purified by preparative TLC (PE / EA=2 / 1) to obtain 40 mg of (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((2,4-difluorophenyl)difluoromethyl)azetidin-1-yl)methanone as a pale yellow oil. Yield: 50.1%. 1 H NMR (400 MHz, CDCl3) δ 7.37-7.67 (m, 1H), 6.88-6.99 (m, 2H), 6.62-6.77 (m, 3H), 6.65-6.71 (m, 1H), 5.27 (dd, 1H, J = 12.0, 6.4 Hz), 4.35-4.39 (m, 1H), 4.19-4.32 (m, 3H), 3.47-3.60 (m, 1H), 3.34 (ddd, 1H, J = 18.4, 12.4, 1.6 Hz), 2.68 (ddd, 1H, J = 18.4, 6.4, 1.6 Hz). LC-MS (m / z): 428.35 [M+H] + .
[0227] Compound 136: 4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-3-fluorobenzonitrile [ka] The title compound 136 was prepared in 74.7% yield from 4-(azetidin-3-yloxy)-3-fluorobenzonitrile trifluoroacetate and (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 60. 1H NMR (400 MHz, CDCl3) δ 7.41-7.39 (m, 1H), 7.38-7.36 (m, 1H), 6.81 - 6.62 (m, 5H), 5.25 (dd, J = 12.2, 6.4 Hz, 1H), 5.05 - 4.96 (m, LC-MS (m / z) 301.4 (M+H + )
[0228] Compound 137: 4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2-fluorobenzonitrile [ka] The title compound 137 was prepared in 74.7% yield from 4-(azetidin-3-yloxy)-2-fluorobenzonitrile trifluoroacetate and (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.55-7.50 (m, 1H), 6.78 (t, J = 1.7 Hz, 1H), 6.74 - 6.52 (m, 5H), 5.25 (dd, J = 12.2, 6.4 Hz, 1H), 4.93 (tt, J = 6.4, 4.0 Hz, 1H), 4.63 - 4.45 (m, 2H), 4.28 - 4.12 (m, 2H), 3.34 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.69 (ddd, J = 18.6, 6.4, 1.7 Hz, 1H).LC-MS (m / z) 301.4 (M+H + )
[0229] Compound 138: (3-(4-chloro-2-fluorobenzylidene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 138 was prepared in 36.3% yield from 3-(4-chloro-2-fluorobenzylidene)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.13 - 7.06 (m, 2H), 7.05-6.99 (m, 1H), 6.83 - 6.74 (m, 3H), 6.72-6.66 (m, 1H), 6.40 (t, J = 2.0 Hz, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 4.99 (dd, J = 30.6, 15.4 Hz, 2H), 4.85 (dd, J = 28.0, 14.4 Hz, 2H), 3.37 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.72 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H). LC-MS (m / z):406.29 [M+H] + .
[0230] Compound 139: (3-(2-chloro-4-fluorobenzylidene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 139 was prepared in 36.3% yield from 3-(2-chloro-4-fluorobenzylidene)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1H NMR (400 MHz, CDCl3) δ 7.18-7.04 (m, 2H), 6.97 (td, J = 8.4, 2.8 Hz, 1H), 6.84 - 6.73 (m, 3H), 6.73-6.66 (m, 1H), 6.60 (t, J = 2.4 Hz, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 5.08 - 4.77 (m, 4H), 3.37 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.72 (ddd, J = 184, 6.4, 1.6 Hz, 1H).LC-MS (m / z):406.33 [M+H] + .
[0231] Compound 140: (3-(3,4-difluorobenzylidene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 140 was prepared in 36.3% yield from 3-(3,4-difluorobenzylidene)azetidine hydrochloride, 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole and triphosgene following the method outlined for compound 37. 1 H NMR (400 MHz, CDCl3) δ 7.17-7.07 (m, 1H), 6.94-6.88 (m, 1H), 6.87-6.81 (m, 2H), 6.81 - 6.66 (m, 3H), 6.19 (t, J = 2.0 Hz, 1H), 5.31 (dd, J = 12.0, 6.4 Hz, 1H), 5.03 (dd, J = 30.0,14.8 Hz, 2H), 4.83 (dd, J = 28.0, 14.4 Hz, 2H), 3.38 (ddd, J = 18.4, 12.0, 1.6 Hz, 1H), 2.72 (ddd, J = 18.5, 6.5, 1.7 Hz, 1H). LC-MS (m / z):390.29 [M+H] + .
[0232] Compound 141: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((6-fluoropyridin-3-yl)oxy)azetidin-1-yl)methanone [ka] The title compound 141 was prepared in 34.7% yield from 5-(azetidin-3-yloxy)-2-fluoropyridine trifluoroacetate and (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 60. 1 H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.23 - 7.11 (m, 2H), 6.86 (brs, 1H), 6.78-6.62 (m, 3H), 5.30-5.25 (m, 1H), 4.98-4.86 (m, 1H), 4.64-4.45 (m, 2H), 4.30-4.12 (m, 2H), 3.41-3.26 (m, 1H), 2.75-2.60 (m, 1H). LC-MS (m / z) 377.4 (M+H + )
[0233] Compounds 142~147 142-147 were prepared according to the following route. [ka]
[0234] Compound 148~150 Compounds 148-150 were prepared according to the following route. [ka]
[0235] Compounds 151~154 151-154 were prepared according to the following route. [ka]
[0236] Compounds 155~191 155-191 were prepared according to the following route. [ka]
[0237] Preparation of Intermediate 1: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone [ka] CDI (44.5 g, 274.7 mmol) was dissolved in 450 mL of THF, and TEA (38.00 g, 375.00 mmol) was added. Compound A2 (45.50 g, 249.75 mmol) was dissolved in 460 mL of THF and added to the mixture. The mixture was stirred at room temperature overnight. The mixture was evaporated to dryness and purified by column chromatography (PE / EA = 3 / 1 to 1 / 1) to give the title compound as a pale yellow solid (40.7 g, 59%). LCMS (m / z): 277, [M+H] +. H-NMR
[0238] The following intermediates used in the preparation of the title example compounds were synthesized in a similar manner to that described above. [ka]
[0239] The intermediate was isolated as a racemate. Chiral HPLC separation afforded two single enantiomers. Based on the assignment of XXX as described in the examples, the absolute configuration of the active enantiomer was (S) in each case, and the S-configured enantiomer was used in selected examples, as shown in the structure. [ka]
[0240] Step 1 To 2,4-difluoro-5-nitrophenol (10 g) in 150 ml DMF was added NaH (4.57 g, 60% in oil) under nitrogen protection at 0°C, and after 30 min, CHCl (12.17 g) was added. The mixture was stirred at room temperature for 12 h. The solution was added to H2O and extracted with EA. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification by column chromatography gave 10 g of 1,5-difluoro-2-methoxy-4-nitrobenzene as a yellow solid. LC-MS (m / z) 199.2 (M+H + )
[0241] Step 2 3.44 g of methyl 2-hydroxyacetate was dissolved in 150 ml of THF, and NaH (1.8 g, 60% in oil) was added under nitrogen protection at 0°C. After 30 min, 6.56 g of 1,5-difluoro-2-methoxy-4-nitrobenzene was added. The mixture was stirred at room temperature for 3 h. The reaction mixture was added to EA and H2O. After separation, the combined organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. 8 g of methyl 2-(5-fluoro-4-methoxy-2-nitrophenoxy)acetate was obtained as a crude product. It was used in the next step without further purification. LC-MS (m / z) 260.2 (M+H + )
[0242] Step 3 Fe (11.63 g) and NH4Cl (9.3 g) were added to a suspension of methyl 2-(5-fluoro-4-methoxy-2-nitrophenoxy)acetate (8 g) in CH5OH and HO (v / v = 10:1, 110 ml) at room temperature. The mixture was stirred at 70 °C for 2 h. The resulting precipitate was filtered. The filtrate was concentrated under reduced pressure, and DCM was added. The mixture was filtered again and concentrated under reduced pressure. Purification by column chromatography gave 2.8 g of 7-fluoro-6-methoxy-2H-benzo[b][1,4]oxazin-3(4H)-one as a brown solid (80% purity, UPLC). LC-MS (m / z) 198.2 (M+H + )
[0243] Step 4 2.8 g of 7-fluoro-6-methoxy-2H-benzo[b][1,4]oxazin-3(4H)-one was dissolved in 60 ml of DCM, and BBr3 (20 ml) was slowly added under nitrogen protection at -78 °C. The mixture was allowed to warm to room temperature and stirred for 12 hours. The resulting solution was quenched by adding H2O and extracted with EA. The organic layer was dried over Na2SO4 and concentrated under reduced pressure. Purification by column chromatography gave 0.29 g of 7-fluoro-6-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one as a yellow solid. LC-MS (m / z) 184.2 (M+H + ).
[0244] Compound 192: (S)-7-fluoro-6-((1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one [ka]
[0245] Step 1 tert-Butyl 3-hydroxyazetidine-1-carboxylate (15 g, 86.6 mmol) was dissolved in 150 ml of dry DCM, and TEA (26.2 g, 259.8 mmol) was added. To this solution, MsCl (1.2 g, 103.92 mmol) was added slowly at 0° C. The mixture was stirred overnight. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated. The crude product was crystallized from EtOH / petroleum to give tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (13 g, 59.8%). LCMS (m / z) 252.3 (M+H + ).
[0246] Step 2 To a solution of tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (26.5 g, 144.7 mmol), 7-fluoro-6-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one (40 g, 159.17 mmol) in DMSO (270 mL) was added CsCO (94.3 g, 289.4 mmol) at room temperature, and the temperature was then raised to 100 °C and stirred for an additional 3 h. Upon completion, the reaction was diluted with ethyl acetate (500 mL), washed with HO (700 mL), brine (250 mL), dried over NaSO, and concentrated to give the crude product. The crude product was purified by adding EA / PE=1:3 (300 ml) to give tert-butyl 3-((7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)oxy)azetidine-1-carboxylate (35.1 g, 71.8%). MS (m / z) 338.4 (M+H + ).
[0247] Step 3 tert-Butyl 3-((7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)oxy)azetidine-1-carboxylate (100 mg, 0.3 mmol) was dissolved in DCM (5 mL) and TFA (350 mg, 10 mmol) was added. The mixture was stirred at room temperature for 4 hours. The mixture was concentrated to give 6-(azetidin-3-yloxy)-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one as a TFA salt, which was used in the next step without further purification. LC-MS (m / z) 238.4 (M+H + ).
[0248] Step 4 Half of the crude 6-(azetidin-3-yloxy)-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one trifluoroacetate salt, (S)-(1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (65 mg, enantiomer B), and TEA (0.2 ml) were dissolved in THF (5 ml) and stirred at room temperature for 16 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by preparative HPLC afforded the title compound 192 (36 mg) as a white solid, which has potent activity in cellular activity assays. LC-MS (m / z) 411.2 (M+H) + ). 1 H NMR (400 MHz, Chloroform-d) δ 9.30 (s, 1H), 7.30 - 7.24 (m, 2H), 7.23 - 7.17 (m, 3H), 6.81 (t, J = 1.7 Hz, 1H), 6.73 (d, J = 11.2 Hz, 1H), 6.20 (d, J = 8.0 Hz, 1H), 5.48 (dd, J = 12.1, 5.9 Hz, 1H), 4.77 - 4.69 (m, 1H), 4.54 - 4.46 (m, 3H), 4.46 - 4.39 (m, 1H), 4.38 - 4.31 (m, 1H), 4.14 - 4.06 (m, 1H), 3.38 (ddd, J = 18.5, 12.1, 1.7 Hz, 1H), 2.72 (ddd, J = 18.5, 5.9, 1.8 Hz, 1H). Another portion of 6-(azetidin-3-yloxy)-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one trifluoroacetate was reacted with (R)-(1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone to give (R)-7-fluoro-6-((1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one, which had weak activity in cellular activity assays.
[0249] Compound 193: (S)-6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one [ka] The title compound 193 was synthesized in a manner similar to the preparation of compound 192. LC-MS (m / z): 447.2 [M+H] + . 1 H NMR (400 MHz, Chloroform-d) δ 8.93 (s, 1H), 6.83 - 6.80 (m, 1H), 6.78 (s, 1H), 6.77 - 6.73 (m, 2H), 6.66 (tt, J = 9.0, 2.4 Hz, 1H), 6.22 (d, J = 7.8 Hz, 1H), 5.46 (dd, J = 12.1, 6.1 Hz, 1H), 4.88 - 4.79 (m, 1H), 4.60 - 4.45 (m, 4H), 4.43 - 4.34 (m, 1H), 4.19 - 4.08 (m, 1H), 3.44 - 3.33 (m, 1H), 2.75 - 2.64 (m, 1H).
[0250] Compound 194: (S)-7-fluoro-6-((1-(5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one [ka] The title compound 194 was synthesized in a manner similar to the preparation of compound 1. LC-MS (m / z): 430.2 [M+H] + . 1H NMR (400 MHz, Chloroform-d) δ 8.43 - 8.36 (m, 2H), 7.38 (d, J = 8.8 Hz, 1H), 6.87 - 6.84 (m, 1H), 6.78 (dd, J = 11.2, 2.3 Hz, 1H), 6.27 - 6.21 (m, 1H), 5.58 - 5.45 (m, 1H), 4.91 - 4.81 (m, 1H), 4.57 - 4.54 (m, 2H), 4.53 - 4.44 (m, 2H), 4.39 - 4.28 (m, 1H), 4.23 - 4.10 (m, 1H), 3.50 -3.40 (m, 1H), 2.75 (dd, J = 18.5, 6.4 Hz, 1H).
[0251] Compound 195: (S)-3-(1-(3-((7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)oxy)azetidine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)benzonitrile
change
[0252] Compound 196: 7-(((R)-1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)oxy)-6-fluoro-3,4-dihydroquinolin-2(1H)-one
change
[0253] Compound 197: (S)-5-(1-(3-((7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)oxy)azetidine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)nicotinonitrile [ka] The title compound 197 was synthesized in a manner similar to the preparation of compound 192. LC-MS (m / z): 437.2 [M+H] + . 1 H NMR (400 MHz, Chloroform-d) δ 8.96 - 8.82 (br, 1H), 8.80 - 8.71 (m, 2H), 7.84 (t, J = 2.1 Hz, 1H), 6.91 - 6.84 (m, 1H), 6.77 (d, J = 11.1 Hz, 1H), 6.22 (d, J = 7.8 Hz, 1H), 5.65 - 5.54 (m, 1H), 4.88 - 4.81 (m, 1H), 4.54 (s, 2H), 4.52 - 4.43 (m, 2H), 4.42 - 4.33 (m, 1H), 4.19 - 4.07 (m, 1H), 3.48 (ddd, J = 18.7, 12.2, 1.7 Hz, 1H), 2.73 (ddd, J = 18.6, 6.7, 1.7 Hz, 1H).
[0254] Compound 198: (S)-3-fluoro-5-(1-(3-((3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)oxy)azetidine-1-carbonyl)-4,5-dihydro-1H-pyrazol-5-yl)benzonitrile [ka] The title compound 198 was synthesized in a manner similar to the preparation of compound 192. Yield 92.9%. 1 H NMR (400 MHz, Chloroform-d) δ 8.86 (s, 1H), 7.33 (t, J = 1.6Hz, 1H), 7.24 - 7.17 (m, 2H), 6.87 (d, J = 8.8 Hz, 1H), 6.81 (t, J = 1.6 Hz, 1H), 6.34 (dd, J = 8.8, 2.8 Hz, 1H), 6.25 (d, J = 2.8 Hz, 1H), 5.47 - 5.37 (m, 1H), 4.88-4.80 (m, 1H), 4.64-4.40(m,4 H) 4.32 - 4.04 (m, 2H), 3.46-3.35(m 1H), 2.73-2.63(m,1). LC-MS (m / z) 436.2 (M+H + )
[0255] Compound 199: (S)-6-((1-(5-phenyl-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one [ka] The title compound 199 was synthesized in a manner similar to the preparation of compound 192. Yield 90.9%. 1H NMR (400 MHz, Chloroform-d) δ 8.82 (s, 1H), 7.36 - 7.27 (m, 2H), 7.26-7.17 (m, 3H), 6.85 (d, J = 8.8 Hz, 1H), 6.78 (t, J = 1.6 Hz, 1H), 6.32 (dd, J = 8.8, 2.8 Hz, 1H), 6.23 (d, J = 2.8 Hz, 1H), 5.39 (dd, J = 12.0, 6.2 Hz, 1H), 4.82-4.74 (m, 1H), 4.53 (s, 2H), 4.51 - 4.41 (m, 2H), 4.26-4.04 (m, 2H), 3.42-3.30 (m, 1H), 2.78-2.68 (m, 1H). LC-MS (m / z) 393.2 (M+H + )
[0256] Compound 200: (S)-7-fluoro-6-((1-(5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one [ka] (S)-(5-(3-Fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (64 mg, 0.25 mmol) was added to a solution of EtN (303 mg, 3.0 mmol) in MeOH, and 6-(azetidin-3-yloxy)-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one (71 mg, 0.25 mmol) was added in several portions, and the entire reaction mixture was stirred and refluxed at 25 °C overnight. After concentrating the organic solvent, the residue was further purified by silica gel column chromatography (PE / EA=2 / 1) to give 30 mg of (S)-7-fluoro-6-((1-(5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one as a white solid in a yield of 28% (30 mg). 1H NMR (400 MHz, Chloroform-d) δ 9.04 (s, 1H), 7.26 - 7.21 (m, 1H), 7.03 - 6.98 (m, 1H), 6.94 - 6.87 (m, 2H), 6.81 (t, J = 1.6 Hz, 1H), 6.74 (d, J = 11.2 Hz, 1H), 6.20 (d, J = 7.9 Hz, 1H), 5.49 (dd, J = 12.1, 6.0 Hz, 1H), 4.82 - 4.75 (m, 1H), 4.59 - 4.50 (m, 3H), 4.48 - 4.33 (m, 2H), 4.10 (d, J = 10.1 Hz, 1H), 3.39 (ddd, J = 18.5, 12.2, 1.7 Hz, 1H), 2.70 (ddd, J = 18.5, 6.1, 1.8 Hz, 1H). LC-MS (ESI, m / z): M+H] + =429.2.
[0257] Compound 201: (S)-6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one
change
[0258] Compound 202: (S)-7-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-6-fluoro-3,4-dihydroquinolin-2(1H)-one [ka]
[0259] Step 1 4-Fluoro-3-methoxyaniline (3 g, 21.26 mmol) was dissolved in dry DCM (80 mL) and pyridine (2.02 g, 25.51 mmol) was added. To this mixture, (E)-3-ethoxy-N-(4-fluoro-3-methoxyphenyl)acrylamide (3.43 g, 25.506 mmol) in 5 mL of dry DCM was added at 0 °C. The mixture was stirred at room temperature for 16 hours, then evaporated to dryness, and the residue was purified by flash chromatography (PE / EA = 3 / 2) to give (E)-N-(4-fluoro-3-methoxyphenyl)-3-methoxyacrylamide as an orange solid (5.1 g, 99%). LC-MS (ESI) m / z = 240.2 [M+H + ]
[0260] Step 2 (E)-N-(4-Fluoro-3-methoxyphenyl)-3-methoxyacrylamide (5.1 g, 21.32 mmol) was added to 57 mL of concentrated HSO at 0° C., and the mixture was stirred at room temperature for 1.5 h. The reaction mixture was slowly added to ice with good stirring, and the resulting solid was filtered, washed with water, and evaporated to dryness to give 6-fluoro-7-methoxyquinolin-2(1H)-one as a pale pink solid (3.21 g, 77.6%). 1 H NMR (DMSO ,400 MHz) δ 11.68 (s, 1H), 7.78 (d, 1H, J = 9.6 Hz), 7.54 (d, 1H, J = 11.6 Hz), 6.96 (d, 1H, J = 7.6 Hz), 6.38 (d, 1H, J = 9.6 Hz), 3.88 (s, 3H). LC-MS(ESI) m / z=194.2[M+H + ]
[0261] Step 3 6-Fluoro-7-methoxyquinolin-2(1H)-one (3.41 g, 17.57 mmol) was suspended in DCM (100 mL), and to this mixture was added BBr3 (1 M in DCM, 30 mL) at 0 °C. The mixture was stirred at room temperature for 16 h, and the reaction was quenched by the addition of MeOH and water. The resulting solid was filtered, washed with water, and evaporated to dryness to give 6-fluoro-7-hydroxyquinolin-2(1H)-one as a pale pink solid (3.06 g, 97%). 1 H NMR (DMSO ,400 MHz) δ 11.59 (s, 1H), 10.67 (brs, 1H), 7.72 (d, 1H, J = 9.6 Hz), 7.45 (d, 1H, J = 11.6 Hz), 6.88 (d, 1H, J = 7.6 Hz), 6.30 (d, 1H, J = 9.6 Hz). LC-MS(ESI) m / z=180.2 [M+H + ].
[0262] Step 4 A mixture of 6-fluoro-7-hydroxyquinolin-2(1H)-one (300 mg, 1.676 mmol), tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (420 mg, 1.676 mmol), and K2CO3 (275 mg, 2.01 mmol) in dry DMF (5 mL) was stirred at 120 °C for 60 hours. The mixture was evaporated to dryness and purified by flash chromatography (MeOH / DCM = 1 / 20) to give tert-butyl 3-((6-fluoro-2-oxo-1,2-dihydroquinolin-7-yl)oxy)azetidine-1-carboxylate as a yellow solid (258 mg, 46%). LC-MS (ESI) m / z = 335.4 [M+H + ].
[0263] Step 5 tert-Butyl 3-((6-fluoro-2-oxo-1,2-dihydroquinolin-7-yl)oxy)azetidine-1-carboxylate (200 mg) was dissolved in MeOH (20 mL), and Raney nickel (50% in water, 20 mg) and AcOH (2-3 drops) were added. The mixture was stirred under 1 atm H2 atmosphere for 16 h. The mixture was filtered and evaporated to dryness to give tert-butyl 3-((6-fluoro-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy)azetidine-1-carboxylate (200 mg, crude product), which was used in the next step without purification. LC-MS (ESI) m / z = 337.4 [M+H + ]
[0264] Step 6 Tert-butyl 3-((6-fluoro-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy)azetidine-1-carboxylate (200 mg, crude) was dissolved in DCM (5 mL) and TFA (1 mL) was added. The mixture was stirred at room temperature for 2 hours and then evaporated to dryness to give 7-(azetidin-3-yloxy)-6-fluoro-3,4-dihydroquinolin-2(1H)-one (180 mg, crude), which was used in the next step without purification. LC-MS (ESI) m / z=237.3 [M+H + ]
[0265] Step 7 To a mixture of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (149 mg) and 7-(azetidin-3-yloxy)-6-fluoro-3,4-dihydroquinolin-2(1H)-one (180 mg) in dry THF (5 mL) was added TEA (0.1 mL). The mixture was stirred at room temperature for 2 hours, evaporated to dryness, and the residue was purified by preparative HPLC to give the title compound 202 as a white solid (40 mg, 15% over three steps). LC-MS (ESI) m / z = 445.2 [M+H +] 1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 6.88 (d, J = 11.0 Hz, 1H), 6.77-6.76 (m, 1H), 6.73 (dd, J = 8.0, 2.2 Hz, 2H), 6.64 (tt, J = 8.9, 2.3 Hz, 1H), 6.13 (d, J = 7.2 Hz, 1H), 5.37 (dd, J = 12.2, 6.3 Hz, 1H), 4.92 - 4.84 (m, 1H), 4.51 (d, J = 6.7 Hz, 2H), 4.23 (dd, J = 75.9, 9.8 Hz, 3H), 3.35 (ddd, J = 18.5, 12.2, 1.5 Hz, 1H), 2.85 (t, J = 7.5 Hz, 2H), 2.67 (ddd, J = 18.6, 6.3, 1.7 Hz, 1H), 2.56 (t, J = 7.5 Hz, 2H).
[0266] Compound 203: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-(naphthalen-2-yloxy)azetidin-1-yl)methanone [ka]
[0267] Step 1 tert-Butyl 3-hydroxyazetidine-1-carboxylate (15 g, 86.6 mmol) was dissolved in 150 ml of dry DCM, and TEA (26.2 g, 259.8 mmol) was added. To this solution, MsCl (1.2 g, 103.92 mmol) was added slowly at 0° C. The mixture was stirred overnight. The mixture was extracted with DCM, washed with brine, dried (Na2SO4), and concentrated. The crude product was crystallized from EtOH / petroleum to give tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (13 g, 59.8%). LCMS (m / z) 252.3 (M+H + ).
[0268] Step 2 A mixture of tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (1.0 g, 6.94 mmol), naphthalen-2-ol (1 g, 6.94 mmol), and CsCO (4.52 g, 13.88 mmol) was added to DMF (20 mL). The mixture was stirred at 110 °C overnight, water was added, extracted with EA, washed with brine, dried (NaSO), and concentrated. The crude product was purified by silica gel column chromatography (eluted with EA / PE = 1:5) to give tert-butyl 3-(naphthalen-2-yloxy)azetidine-1-carboxylate as a yellow oil (880 mg, 48%). LC-MS (m / z) 300.4 (M+H + ).
[0269] Step 3 Tert-butyl 3-(naphthalen-2-yloxy)azetidine-1-carboxylate (300 mg, 1 mmol) was dissolved in DCM (5 mL) and TFA (1.14 g, 10 mmol) was added. The mixture was stirred at room temperature for 4 hours. The mixture was concentrated to give the desired product, 3-(naphthalen-2-yloxy)azetidine trifluoroacetate, as the TFA salt, which was used in the next step without further purification. LC-MS (m / z) 200.3 (M+H + ).
[0270] Step 4 3-(Naphthalen-2-yloxy)azetidine trifluoroacetate (43 mg, 0.22 mmol), (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (50 mg, 0.18 mmol), and TEA (55 mg, 0.54 mmol) were dissolved in THF (5 ml) and stirred at room temperature for 16 hours. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by preparative TLC (EA / PE=1:1) afforded the title compound 204 (71 mg, 97%) as a yellow solid. LC-MS (m / z) 408.4 (M+H + ). 1H NMR (400 MHz, Chloroform-d) δ 7.77 (d, J = 9.0 Hz, 2H), 7.71 (d, J = 8.2 Hz, 1H), 7.47-7.43(m, 1H), 7.38 - 7.33 (m, 1H), 7.13 (dd, J = 8.9, 2.5 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.78-6.75 (m, 3H), 6.69 (tt, J = 8.8, 2.3 Hz, 1H), 5.35 - 5.22 (m, 1H), 5.10-5.05 (m, 1H), 4.70 - 4.55 (m, 2H), 4.39 - 4.21 (m, 2H), 3.35 (dd, J = 18.6, 12.0 Hz, 1H), 2.69 (dd, J = 18.5, 6.2 Hz, 1H).
[0271] Compound 204: 7-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)quinolin-2(1H)-one
change
[0272] Compound 205: (S)-7-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)quinolin-2(1H)-one [ka] The title compound 205 was synthesized in a manner similar to the preparation of compound 203. Yield: 56.9%. 1 H NMR (400 MHz, Chloroform-d) δ 11.71 (s, 1H), 7.77 (d, J = 9.4 Hz, 1H), 7.49 (d, J = 8.7 Hz, 1H), 6.81 - 6.71 (m, 4H), 6.70 - 6.58 (m, 3H), 5.36 (dd, J = 12.2, 6.4 Hz, 1H), 5.08-4.98 (m, 1H), 4.69 -4.52(m, 2H), 4.31 (d, J = 5.3 Hz, 1H), 4.19 (d, J = 10.2 Hz, 1H), 3.36 (m, 1H), 2.72 - 2.61 (m, 1H). LC-MS (m / z) 425.3(M+H + ).
[0273] Compound 206: (S)-7-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-3,4-dihydroquinolin-2(1H)-one [ka] The title compound 206 was synthesized in a manner similar to the preparation of compound 203. Yield: 65.2%. 1H NMR (400 MHz, Chloroform-d) δ 8.05 (s, 1H), 7.06 - 7.02 (m, 1H), 6.81 - 6.71 (m, 3H), 6.71 - 6.63 (m, 1H), 6.34 (dd, J = 8.4, 2.4 Hz, 1H), 6.21 (d, J = 2.4 Hz, 1H), 5.36 - 5.22 (m, 1H), 4.94 - 4.81 (m, 1H), 4.60-4.42 (m, 2H), 4.24 (d, J = 10.1 Hz, 1H), 4.14 (d, J = 8.8 Hz, 1H), 3.35 (m, 1H), 2.89 (dd, J = 8.4, 6.4 Hz, 2H), 2.68 (m, 1H), 2.61 (dd, J = 8.4, 6.4 Hz, 2H). LC-MS (m / z) 427.3(M+H + ).
[0274] Compound 207: (S)-(3-((1H-indazol-6-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone
change
[0275] Compound 208: (S)-7-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-8-fluoroquinolin-2(1H)-one
change
[0276] Compound 209: (S)-6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)indolin-2-one [ka] The title compound 209 was prepared in 90% yield from (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-pyrrol-1-yl)methanone and 6-(azetidin-3-yloxy)indolin-2-one following the method outlined for compound 203. LC-MS (m / z) 413.4 (M+H + ). 1H NMR (400 MHz, Chloroform-d) δ 7.47 (brs, 1H), 7.10 - 7.06 (m, 1H), 6.77 - 6.71 (m, 2H), 6.71 - 6.63 (m, 1H), 6.35 - 6.30 (m, 2fH), 5.26 (dd, J = 12.3, 6.4 Hz, 1H), 4.92 - 4.85 (m, 1H), 4.55-4.45 (m, 2H), 4.26 - 4.12 (m, 2H), 3.45 (s, 2H), 3.33 (dd, J = 18.6, 12.3 Hz, 1H), 2.67 (ddd, J = 18.5, 6.5, 1.6 Hz, 1H).
[0277] Compound 210: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((3,5-difluoropyridin-2-yl)oxy)azetidin-1-yl)methanone [ka] The title compound 210 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 7.79 (d, J = 2.6 Hz, 1H), 7.25 - 7.20 (m, 1H), 6.78-6.74 (m, 3H), 6.68 (tt, J = 8.9, 2.3 Hz, 1H), 5.40-5.34 (m, 1H), 5.28 (dd, J = 12.2, 6.5 Hz, 1H), 4.61-4.53 (m, 2H), 4.32 - 4.14 (m, 2H), 3.34 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.69 (ddd, J = 18.5, 6.5, 1.7 Hz, 1H).
[0278] Compound 211: (3-((6-(benzyloxy)pyridin-3-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 211 was synthesized in a manner similar to the preparation of compound 203. 1H NMR (400 MHz, Chloroform-d) δ 7.63 - 7.59 (m, 1H), 7.47 - 7.25 (m, 5H), 7.15 (dd, J = 8.9, 3.0 Hz, 1H), 6.78 - 6.71 (m, 4H), 6.67 (tt, J = 8.9, 2.3 Hz, 1H), 5.30 (s, 2H), 5.25 (dd, J = 12.2, 6.5 Hz, 1H), 4.90-4.85 (m, 1H), 4.57 - 4.38 (m, 2H), 4.28 - 4.11 (m, 2H), 3.33 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.68 (ddd, J = 18.6, 6.5, 1.7 Hz, 1H).
[0279] Compound 212: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((5-fluoropyridin-2-yl)oxy)azetidin-1-yl)methanone SN-038-91
change
[0280] Compound 213: (3-(2,4-difluorophenoxy)azetidin-1-yl)(5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)methanone
change
[0281] Compound 214: (S)-(3-(4-(benzyloxy)phenoxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 214 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 7.43 - 7.27 (m, 5H), 6.92 - 6.86 (m, 2H), 6.78 - 6.63 (m, 6H), 5.26 (dd, J = 12.6, 6.9 Hz, 1H), 4.99 (s, 2H), 4.87-4.82 (m, 1H), 4.56 - 4.40 (m, 2H), 4.26 - 4.10 (m, 2H), 3.32 (dd, J = 18.6, 12.1 Hz, 1H), 2.72 - 2.62 (m, 1H).
[0282] Compound 215: (S)-6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)pyrimidine-4-carbonitrile [ka] The title compound 215 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 8.83 (d, J = 1.2 Hz, 1H), 7.17 (d, J = 1.1 Hz, 1H), 6.79 (s, 1H), 6.77 - 6.73 (m, 2H), 6.70 (tt, J = 8.8, 2.3 Hz, 1H), 5.49-5.44 (m, 1H), 5.27 (dd, J = 12.2, 6.5 Hz, 1H), 4.63-4.55 (m, 2H), 4.29 - 4.13 (m, 2H), 3.36 (dd, J = 18.7, 11.9 Hz, 1H), 2.70 (dd, J = 18.6, 6.1 Hz, 1H).
[0283] Compound 216: (3-(benzofuran-5-yloxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 216 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 7.54 (d, J = 2.2 Hz, 1H), 7.47 (d, J = 8.5 Hz, 1H), 6.85 - 6.73 (m, 5H), 6.71 - 6.65 (m, 2H), 5.28 (dd, J = 12.1, 6.4 Hz, 1H), 4.98 - 4.95 (m, 1H), 4.64 - 4.48 (m, 2H), 4.26 (dd, J = 31.3, 9.6 Hz, 2H), 3.34 (dd, J = 18.6, 12.0 Hz, 1H), 2.69 (dd, J = 18.5, 6.2 Hz, 1H).
[0284] Compound 217: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((6-hydroxypyridin-3-yl)oxy)azetidin-1-yl)methanone [ka] The title compound 217 was prepared from 5-(azetidin-3-yloxy)azetidin-2-ol trifluoroacetate and (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 203. LC-MS (m / z) 375.5 (M+H + ) 1 H NMR (400 MHz, Chloroform-d) δ 7.32 - 7.28 (m, 1H), 6.78 (t, J = 1.7 Hz, 1H), 6.76-6.74 (m, 3H), 6.73 - 6.66 (m, 1H), 6.60 (d, J = 9.8 Hz, 1H), 5.26 (dd, J = 12.2, 6.5 Hz, 1H), 4.72 - 4.65 (m, 1H), 4.51-4.42 (m, 2H), 4.22 - 4.18 (m, 2H), 3.35 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.69 (ddd, J = 18.6, 6.5, 1.8 Hz, 1H).
[0285] Compound 218: (S)-4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-N-methylbenzamide [ka] The title compound 218 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 7.72 - 7.69 (m, 2H), 6.77 - 6.64 (m, 5H), 6.05 (s, 1H), 5.25 (dd, J = 12.0, 8.0 Hz, 1H), 4.97-4.92 (m, 1H), 4.57 - 4.53 (m, 2H), 4.25 - 4.15 (m, 2H), 3.37-3.29 (m, 1H), 2.98 (d, J = 4.0 Hz, 3H), 2.71-2.64 (m, 1H).
[0286] Compound 219: (S)-(3-(4-(1H-imidazol-2-yl)phenoxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 219 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 7.89 (d, J = 8.0 Hz, 2H), 7.08 (s, 2H), 6.80 (s, 1H), 6.71 - 6.61 (m, 5H), 5.23 (s, 1H), 4.86 (s, 1H), 4.49 (s, 2H), 4.11 (s, 2H), 3.34 (dd, J = 20.0, 12.0 Hz, 1H), 2.67 (dd, J = 16.0, 4.0 Hz, 1H).
[0287] Compound 220: (S)-4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2-fluorobenzamide [ka] The title compound 220 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 7.39 - 7.36 (m, 1H), 7.10 - 7.05 (m, 1H), 6.99 - 6.94 (m, 1H), 6.76 - 6.65 (m, 4H), 5.93 (s, 1H), 5.26 (dd, J = 12.0, 8.0, 1H), 4.96-4.91(m, 1H), 4.56 (dd, J = 16.0, 8.0 Hz, 2H), 4.18 (dd, J = 24.0, 8.0 Hz, 2H), 3.33 (dd, J = 20.0,12.0Hz, 1H), 2.70- 2.64(m, 1H), 2.08 (s, 2H). LC-MS (m / z) 419.4(M+H+)
[0288] Compound 221: (S)-4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-3-fluorobenzamide [ka] The title compound 221 was synthesized in a manner similar to the preparation of compound 203. 1H NMR (400 MHz, DMSO-d6) δ 8.00 (s, 1H), 7.53-7.49 (m, 1H), 7.43 (s, 1H), 7.34 - 7.29 (m, 2H), 7.11 - 7.05 (m, 1H), 6.99 (s, 1H), 6.91 - 6.86 (m, 2H), 5.21 (dd, J = 12.0, 4.0 Hz, 1H), 5.09 (s, 1H), 4.48 (s, 2H), 3.98 (s, 2H), 3.40 - 3.34 (m, 1H), 2.64-2.57 (m, 1H). LC-MS (m / z) 419.4(M+H + )
[0289] Compound 222: (S)-4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-3,5-difluorobenzamide [ka] The title compound 222 was synthesized in a manner similar to the preparation of compound 203. 1 H NMR (400 MHz, Chloroform-d) δ 7.38 (d, J = 8.0 Hz, 2H), 6.77 - 6.65 (m, 4H), 5.26 (dd, J = 12.0, 8.0 Hz, 1H), 5.07 (s, 1H), 4.48-4.44 (m, 2H), 4.37-4.26 (m, 2H), 3.34 (dd, J = 16.0, 12.0 Hz, 1H), 2.68 (dd, J = 20.0, 8.0 Hz, 1H), 1.79 (s, 2H).
[0290] Compound 223: (S)-(3-((1H-indol-6-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 223 was synthesized in a manner similar to the preparation of compound 203. 1H NMR (400 MHz, Methanol-d4) δ 7.40 (d, J = 8.0 Hz, 1H), 7.09 (d, J = 4.0 Hz, 1H), 6.91 (s, 1H), 6.83 - 6.78 (m, 3H), 6.72 (d, J = 2.4 Hz, 1H), 6.61 (dd, J = 12.0, 4.0 Hz, 1H), 6.33 (dd, J = 3.2, 1.2 Hz, 1H), 5.26 (dd, J = 12.0, 8.0 Hz, 1H), 5.01-4.96 (m, 1H), 4.56 (s, 2H), 4.14 (dd, J = 28.0, 12.0 Hz, 2H), 3.44-3.36 (m, 1H), 2.71-2.64 (m, 1H).
[0291] Compound 224: 6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)indolin-2-one
change
[0292] Compound 225: (S)—N-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)pyrimidin-4-yl)acetamide
change
[0293] Step 1 2-Chloropyrimidin-4-amine (3.0 g, 23.16 mmol) was dissolved in 30 ml of dry DMF. To this solution, NaH (1.38 g, 34.80 mmol) was added at 0°C under a nitrogen atmosphere. The mixture was stirred at 0°C for 0.5 h. Acetyl chloride (2.16 g, 27.69 mmol) was added, and the mixture was further stirred at room temperature overnight. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave N-(2-chloropyrimidin-4-yl)acetamide as a white solid (2.7 g, 68%). (ES, m / s): 172.1 [M+H] +
[0294] Step 2 (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (1.0 g, 3.39 mmol) was dissolved in 15 ml of dry DMF. To this solution, N-(2-chloropyrimidin-4-yl)acetamide (1.2 g, 6.97 mmol) and DIEA (870 mg, 6.74 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 140° C. for 1.0 h under microwave irradiation. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 225 as a white solid (950 mg, 38%). (ES, m / s): 430.4 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 8.22 (d, J = 5.6 Hz, 1H), 7.25 (d, J = 5.6 Hz, 1H), 7.14 - 7.05 (m, 2H), 7.01 - 6.94 (m, 2H), 5.28 - 5.20 (m, 1H), 3.79 - 3.45 (m, 8H), 3.39 - 3.33 (m, 1H), 2.67 - 2.58 (m, 1H), 2.08 (s, 3H).
[0295] Compound 226: (S)—N-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidin-4-yl)cyclopropanecarboxamide [ka] The title compound 226 was prepared from (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone and N-(2-chloropyrimidin-4-yl)cyclopropanecarboxamide following the method outlined for compound 225 as a white solid (62 mg, 29%). (ES, m / s): 474.4 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 10.59 (brs, 1H), 8.32 (d, J = 2.8 Hz, 1H), 7.13 - 7.05 (m, 2H), 6.99 - 6.96 (m, 2H), 5.24 (dd, J = 11.6, 10.0 Hz, 1H), 3.73 - 3.66 (m, 2H), 3.65-3.57 (m, 4H), 3.54 - 3.46 (m, 2H), 3.38 - 3.32 (m, 1H), 2.65-2.59 (m, 1H), 2.03 - 1.94 (m, 1H), 0.87 - 0.77 (m, 4H).
[0296] Compound 227: 2-chloro-4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)benzamide [ka]
[0297] Step 1: Synthesis of tert-butyl 3-(4-chloro-3-cyanophenoxy)azetidine-1-carboxylate To a solution of tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (200 mg, 0.80 mmol, 1.0 equiv.) and 2-chloro-4-hydroxybenzonitrile (134 mg, 0.88 mmol, 1.1 equiv.) in anhydrous N,N-dimethylformamide (10 mL) was added cesium carbonate (777.9 mg, 3.0 equiv.) at room temperature. The reaction mixture was heated to 110 °C and stirred for 4 h. The volatiles were removed under reduced pressure, and the residue was suspended in dichloromethane (saturated). The organic layer was washed successively with water and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 4 / 1) to give tert-butyl 3-(3-chloro-4-cyanophenoxy)azetidine-1-carboxylate as a pale yellow solid (190 mg, 77.3% yield). LC-MS (m / z) 254.4, 252.5 [M-tBu] + .
[0298] Step 2: Synthesis of tert-butyl 3-(3-carbamoyl-4-chlorophenoxy)azetidine-1-carboxylate A solution of tert-butyl 3-(3-chloro-4-cyanophenoxy)azetidine-1-carboxylate (190 mg, 0.615 mmol, 1.0 equiv) in methanol (6 mL) was treated with 30% aqueous hydrogen peroxide (75 mmL) and 1 M aqueous sodium hydroxide (3 mL). The reaction mixture was stirred at 40 °C overnight and then quenched with saturated aqueous NaHCO3. The volatiles were removed under reduced pressure, and the residue was suspended in dichloromethane. After filtration, the filtrate was concentrated and used directly in the next step without further purification. LC-MS (m / z) 327.5 [M+H] +
[0299] Step 3: Synthesis of 5-(azetidin-3-yloxy)-2-chlorobenzamido-2,2,2-trifluoroacetaldehyde Trifluoroacetic acid was added dropwise to a solution of tert-butyl 3-(3-carbamoyl-4-chlorophenoxy)azetidine-1-carboxylate in dichloromethane at 0° C., and the mixture was refluxed for 2 hours. The volatiles were removed under reduced pressure, and the residue was used directly in the next step without further purification. LC-MS (m / z) 227.6 [M+H] + .
[0300] Step 4: Synthesis of (S)-2-chloro-5-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)benzamide (Intermediate 4) To a solution of 4-(azetidin-3-yloxy)-2-chlorobenzamide-2,2,2-trifluoroacetaldehyde (1 / 1) in tetrahydrofuran (10 mL), triethylamine was slowly added dropwise at 0°C, followed by the addition of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (50 mg, 0.18 mmol, 1.0 equiv.) at room temperature. The reaction mixture was stirred overnight at the same temperature. The reaction was quenched with saturated aqueous NH4Cl and extracted three times with dichloromethane. The combined organic layer was washed successively with water, saturated aqueous NaHCO3, and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (AcOEt / methanol, 20 / 1) to give 28.6 mg of 2-chloro-4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)benzamide 227 as a white powder. Yield: 36.3%. 1H NMR (400 MHz, Chloroform-d) δ 7.48 - 7.06 (m, 2H), 7.04 - 6.43 (m, 5H), 5.31 (s, 1H), 4.97 (s, 1H), 4.62 (s, 2H), 4.18 (s, 2H), 3.31-3.42 (m, 1H), 2.81 - 2.62 (m, 1H). LC-MS (m / z) 435.5, 437.4 [M+H] + . 1 H NMR (400 MHz, Chloroform-d) δ 7.48 - 7.06 (m, 2H), 7.04 - 6.43 (m, 5H), 5.31 (s, 1H), 4.97 (s, 1H), 4.62 (s, 2H), 4.18 (s, 2H), 3.31-3.42 (m, 1H), 2.81 - 2.62 (m, 1H). LC-MS (m / z) 435.3 [M+H] + .
[0301] Compound 228: N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)acetamide [ka]
[0302] Step 1: Synthesis of 2,2,2-trifluoroacetaldehyde-azetidin-3-ol (1 / 1) (Intermediate 1) Trifluoroacetic acid was added dropwise to a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (4.0 g, 23.09 mmol) in dichloromethane at 0° C., and the mixture was refluxed for 2 hours. The volatiles were removed under reduced pressure, and the residue was used directly in the next step without further purification. LC-MS (m / z) 74.2 [M+H] + .
[0303] Step 2: Synthesis of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-hydroxyazetidin-1-yl)methanone To a solution of 2,2,2-trifluoroacetaldehyde-azetidin-3-ol (1 / 1) in tetrahydrofuran (100 mL), triethylamine was slowly added dropwise at 0°C, followed by the addition of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (1.05 g, 0.18 mmol, 1.3 equiv.) at room temperature. The reaction mixture was stirred overnight at the same temperature. The reaction was quenched with saturated aqueous NH4Cl and extracted three times with dichloromethane. The combined organic layer was washed successively with water, saturated aqueous NaHCO3, and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 1 / 1) to give 2.05 g of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-hydroxyazetidin-1-yl)methanone as a pale yellow solid in 71.9% yield. LC-MS (m / z) 283.6 [M+H] + .
[0304] Step 3: Synthesis of (S)-1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl methanesulfonate (Intermediate 3) To a solution of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-hydroxyazetidin-1-yl)methanone (1.55 g, 5.51 mmol, 1.0 equiv.) in tetrahydrofuran (60 mL), triethylamine was slowly added dropwise at room temperature, followed by the addition of methanesulfonyl chloride (469 mmL, 6.06 mmol, 1.1 equiv.) at 0°C. The reaction mixture was stirred overnight at the same temperature. The reaction was quenched with saturated aqueous NaHCO3 and extracted twice with dichloromethane. The combined organic layer was washed successively with water, saturated aqueous NH4Cl, and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 1 / 1) to give 1.9 g of (S)-1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl methanesulfonate as a pale yellow solid in 95.9% yield. LC-MS (m / z) 360.6 [M+H] + .
[0305] Step 4: Synthesis of (S)—N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)acetamide (37) To a solution of (S)-1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl methanesulfonate (200 mg, 0.56 mmol, 1.0 equiv.) and N-(3-hydroxyphenyl)acetamide (92.6 mg, 0.61 mmol, 1.1 equiv.) in anhydrous N,N-dimethylformamide (5 mL) was added cesium carbonate (544 mg, 1.67 mmol, 3.0 equiv.) at room temperature. The reaction mixture was heated to 100 °C and stirred for 4 h. The volatiles were removed under reduced pressure, and the residue was suspended in dichloromethane (saturated). The organic layer was washed successively with water and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 1 / 1) to give 48 mg of N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)acetamide 228 as a pale yellow powder in a yield of 20.8%. 1H NMR (400 MHz, Chloroform-d) δ 7.23 - 7.17 (m, 2H), 6.95 (d, J = 8.1 Hz, 1H), 6.75 (d, J = 9.3 Hz, 3H), 6.68 (t, J = 8.8 Hz, 1H), 6.51 (d, J = 8.1 Hz, 1H), 5.26 (d, J = 9.6 Hz, 1H), 4.93 (s, 1H), 4.54 (s, 2H), 4.21 (dd, J = 27.9, 9.4 Hz, 2H), 3.34 (d, J = 6.6 Hz, 1H), 2.69 (d, J = 18.7 Hz, 1H), 2.18 (s, 3H). LC-MS (m / z) 415.5 [M+H] + .
[0306] Compound 229: (3-(3-aminophenoxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] To a solution of N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)acetamide (16 mg, 0.038 mmol, 1.0 equiv) in methanol (2 mL) was added a solution of hydrogen chloride in ethyl acetate at room temperature. The reaction mixture was heated to 69 °C and stirred for 2 h. The reaction was quenched with saturated aqueous NaHCO3, the volatiles were removed under reduced pressure, and the residue was suspended in dichloromethane. The organic layer was washed successively with water and brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 1 / 5) to give 2.7 mg of (3-(3-aminophenoxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone 229 as a pale white solid, yield 18.8%. 1H NMR (400 MHz, Chloroform-d) δ 7.06 (s, 1H), 6.93 - 6.61 (m, 4H), 6.38 (s, 1H), 6.28 - 6.09 (m, 2H), 5.27 (s, 1H), 4.88 (s, 1H), 4.51 (s, LC-MS (m / z) 373.1 [M+H] + .
[0307] Compound 230: N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)-N-methylacetamide [ka] To a solution of N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)acetamide (20 mg, 0.048 mmol, 1.0 equiv.) in ultra-dehydrated tetrahydrofuran (5 mL), sodium hydride (60% in mineral oil) was added in several portions at 0°C using an ice bath. Then, iodomethane was added dropwise at room temperature. The mixture was stirred at the same temperature overnight. The reaction was quenched with saturated aqueous NH4Cl and extracted three times with dichloromethane. The combined organic layer was washed successively with water, saturated aqueous NaHCO3, and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / AcOEt, 1 / 3) to give 16 mg of N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)-N-methylacetamide as a yellow oil in a yield of 77.4%. 1H NMR (400 MHz, Chloroform-d) δ 7.32 (t, J = 8.0 Hz, 2H), 6.74 (m, 6H), 5.28 (dd, J = 12.2, 6.5 Hz, 1H), 4.92 (dd, J = 7.6, 3.2 Hz, 1H), 4.56 (s, LC-MS (m / z) 429.3 [M+H] + .
[0308] Compound 231: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-(3-(methylamino)phenoxy)azetidin-1-yl)methanone [ka] To a solution of N-(3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)phenyl)-N-methylacetamide (10 mg, 0.023 mmol) in methanol (5 mL) was added 1 M aqueous sodium hydroxide solution (15 mL) at room temperature. The reaction mixture was heated to 100°C and stirred for 4 hours. The mixture was cooled to room temperature and extracted three times with dichloromethane. The combined organic layer was washed successively with water, saturated aqueous NaHCO3, and brine. It was then dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative thin-layer liquid chromatography (developed with ethyl acetate) to obtain 3.5 mg of (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-(3-(methylamino)phenoxy)azetidin-1-yl)methanone as a pale yellow powder in a yield of 38.88%. 1H NMR (400 MHz, Chloroform-d) δ 7.09 (t, J = 8.0 Hz, 1H), 6.75 (dd, J = 8.3, 2.1 Hz, 3H), 6.72 - 6.64 (m, 1H), 6.33 (d, J = 8.0 Hz, 1H), 6.13 (m, 2H), 5.27 (dd, J = 12.2, 6.5 Hz, 1H), 5.00 - 4.86 (m, 1H), 4.52 (s, 2H), 4.22 (d, J = 30.9 Hz, 2H), 3.41 - 3.26 (m, 1H), 2.84 (s, 3H), 2.68 (ddd, J = 18.4, 6.5, 1.7 Hz, 1H). LC-MS (m / z) 387.4 [M+H] + .
[0309] Compound 232: (S)-2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)isonicotinonitrile [ka] (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (213 mg, 0.72 mmol) was dissolved in 5 ml of dry DMF. To this solution, 2-chloroisonicotinonitrile (100 mg, 0.72 mmol) and DIEA (188 mg, 1.45 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 120° C. overnight. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 232 as a yellow solid (26 mg, 9%). (ES, m / s): 397.4 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 8.46-8.40 (m, 1H), 7.47-7.41 (m, 2H), 7.28-7.19 (m, 2H), 7.17-7.08 (m, 2H), 5.43-5.33 (m, 1H), 3.84-3.63 (m, 8H), 3.52 - 3.47(m, 1H), 2.83 - 2.71(m, 1H).
[0310] Compound 233: (S)-6-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)picolinonitrile [ka] (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (213 mg, 0.72 mmol) was dissolved in 5 ml of dry DMF. To this solution, 6-chloropicolinonitrile (100 mg, 0.72 mmol) and DIEA (188 mg, 1.45 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 120° C. overnight. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 233 as a yellow solid (40 mg, 14%). (ES, m / s): 397.4 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 7.73-7.68 (m, 1H), 7.23 - 7.15 (m, 2H), 7.13 - 7.06 (m, 2H), 7.02-6.95 (m, 2H), 5.32 - 5.16 (m, 1H), 3.70 - 3.45 (m, 8H), 3.39 - 3.33 (m, 1H), 2.68 - 2.59 (m, 1H).
[0311] Compound 234: (S)-(3-((1H-indazol-6-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 234 was synthesized in a manner similar to the preparation of compound 203. Yield: 11.4%. 1H NMR (400 MHz, Chloroform-d) δ 7.99 (s, 1H), 7.64 (d, J = 8.8 Hz, 1H), 6.86 - 6.54 (m, 5H), 5.29 (dd, J = 12.0, 6.4 Hz, 1H), 5.06 - 4.91 (m, 1H), 4.70 - 4.52 (m, 2H), 4.35 - 4.14 (m, 2H), 3.78 - 3.68 (m, 1H), 3.40-3.30(m,1H), 2.73-2.64( m, 1H). LC-MS (m / z) 398.2(M+H) + ).
[0312] Compound 235: (S)-3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-4-fluorobenzonitrile [ka] (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-hydroxyazetidin-1-yl)methanone (187 mg, 0.66 mmol) was dissolved in 10 ml of dry THF. To this solution, DEAD (160 mg, 0.92 mmol), 4-fluoro-3-hydroxybenzonitrile (100 mg, 0.72 mmol), and PPh3 (240 mg, 0.92 mmol) were added at room temperature. The mixture was stirred at 60°C under a nitrogen atmosphere for 2.0 hours. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 235 as a white solid (25 mg, 9%). (ES, m / s): 401.2 [M+H] + 1H NMR (400 MHz, DMSO-d6) δ 7.56 - 7.51 (m, 2H), 7.50 - 7.46 (m, 1H), 7.10 (tt, J = 9.4, 2.4 Hz, 1H), 7.01 (t, J = 1.6 Hz, 1H), 6.93 - 6.87 (m, 2H), 5.23 (dd, J = 12.2, 6.6 Hz, 1H), 5.13 (tt, J = 6.6, 3.6 Hz, 1H), 4.52 (brs, 2H), 4.00 (brs, 2H), 3.42 - 3.36 (m, 1H), 2.68-2.55 (m, 1H).
[0313] Compound 236: (S)-5-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2-fluorobenzonitrile [ka] (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-hydroxyazetidin-1-yl)methanone (187 mg, 0.66 mmol) was dissolved in 10 ml of dry THF. To this solution, DEAD (160 mg, 0.92 mmol), 2-fluoro-5-hydroxybenzonitrile (100 mg, 0.72 mmol), and PPh3 (240 mg, 0.92 mmol) were added at room temperature. The mixture was stirred at 60°C under a nitrogen atmosphere for 2 hours. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 236 as a white solid (30 mg, 10%). (ES, m / s): 401.2 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 7.73 - 7.61 (m, 2H), 7.56-7.48 (m, 1H), 7.37-7.28 (m, 1H), 7.23 (d, J = 3.2 Hz, 1H), 7.16-7.08 (m, 2H), 5.49 - 5.39 (m, 1H), 5.26 (brs, 1H), 4.72 (brs, 2H), 4.17 (brs, 2H), 3.66 - 3.57 (m, 1H), 2.91-2.81 (m, 1H).
[0314] Compound 237: (S)-3-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluorobenzonitrile [ka]
[0315] Step 1 3-Fluoro-5-hydroxybenzonitrile (200 mg, 1.46 mmol) was dissolved in 10 ml of dry DMF. To this solution, CsCO (958 mg, 2.92 mmol) and tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (439 mg, 1.75 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 120 °C for 45 min under microwave irradiation. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave tert-butyl 3-(3-cyano-5-fluorophenoxy)azetidine-1-carboxylate as a white solid (280 mg, 655%). (ES, m / s): 293.3 [M+H] +
[0316] Step 2 Tert-butyl 3-(3-cyano-5-fluorophenoxy)azetidine-1-carboxylate (280 mg, 0.96 mmol) was dissolved in 6 mL of dry DCM. To this solution, TFA (2 mL) was added at room temperature. The mixture was stirred at room temperature for 2.0 hours. The mixture was concentrated under reduced pressure to give 3-(azetidin-3-yloxy)-5-fluorobenzonitrile trifluoroacetate as a brown oil (300 mg, crude product). This was used in the next step without further purification. (ES, m / s): 191.3 [MH] -
[0317] Step 3 (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (200 mg, 0.72 mmol) was dissolved in 10 mL of dry THF and TEA (3 mL). To this solution, 3-(azetidin-3-yloxy)-5-fluorobenzonitrile trifluoroacetate (300 mg, crude product) in 5 mL of THF was added at room temperature. The mixture was stirred at 60° C. for 3.0 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 237 (146 mg, 38%) as a white solid. (ES, m / s): 401.0 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 7.46 (ddd, J = 8.4, 2.2, 1.2 Hz, 1H), 7.25 (t, J = 2.0 Hz, 1H), 7.19 (dt, J = 10.8, 2.4 Hz, 1H), 7.10 (tt, J = 9.4, 2.4 Hz, 1H), 7.01 - 6.98 (m, 1H), 6.92 - 6.85 (m, 2H), 5.22 (dd, J = 12.2, 6.6 Hz, 1H), 5.11-5.05 (m, 1H), 4.51 (brs, 2H), 3.94 (brs, 2H), 3.42 - 3.33 (m, 1H), 2.63 (ddd, J = 18.6, 6.6, 1.8 Hz, 1H).
[0318] Compound 238: (S)-5-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2,4-difluorobenzonitrile [ka]
[0319] Step 1 2,4-Difluoro-5-methoxybenzaldehyde (3 g, 17.44 mmol) was dissolved in 100 ml of dry EtOH. To this solution, hydroxylamine hydrochloride (2.4 g, 34.78 mmol) was added at room temperature. The mixture was stirred at 80° C. for 1.0 hour. The mixture was concentrated under reduced pressure to give (E)-2,4-difluoro-5-methoxybenzaldehyde oxime as a yellow solid (4.5 g, crude product). This was used in the next step without further purification. (ES, m / s): 188.1 [M+H] +
[0320] Step 2 (E)-2,4-Difluoro-5-methoxybenzaldehyde oxime (4.5 g, crude product) was dissolved in 60 ml of dry THF. To this solution, acetic anhydride (15 mL) was added at room temperature. The mixture was stirred at 60° C. for 2.0 hours. The mixture was concentrated under reduced pressure to give 2,4-difluoro-5-methoxybenzonitrile as a yellow solid (5.0 g, crude product), which was used in the next step without further purification. (ES, m / s): 170.1 [M+H] +
[0321] Step 3 2,4-Difluoro-5-methoxybenzonitrile (1.3 g, crude product) was dissolved in 20 ml of dry DCM. To this solution, BBr3 (35 mL, 1N in DCM) was added at room temperature. The mixture was stirred at room temperature. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography gave 2,4-difluoro-5-hydroxybenzonitrile as a white solid (950 mg, 79%). (ES, m / s): 156.1 [M+H] +
[0322] Step 4 (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-hydroxyazetidin-1-yl)methanone (1.73 g, 6.13 mmol) was dissolved in 10 ml of dry THF. To this solution, DEAD (1.56 g, 9.17 mmol), 2,4-difluoro-5-hydroxybenzonitrile (950 mg, 6.13 mmol), and PPh3 (2.4 g, 9.16 mmol) were added at room temperature. The mixture was stirred at 70°C under a nitrogen atmosphere for 1.0 hour. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 238 as a white solid (1.3 g, 51%). (ES, m / s): 419.4 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 7.76 (t, J = 10.2 Hz, 1H), 7.62 - 7.55 (m, 1H), 7.10 (t, J = 9.4 Hz, 1H), 7.01 (s, 1H), 6.89 (d, J = 7.6 Hz, 2H), 5.22 (dd, J = 12.2, 6.6 Hz, 1H), 5.08 (brs, 1H), 4.50 (brs, 2H), 3.98 (brs, 2H), 3.37 (dd, J = 18.6, 12.2 Hz, 1H), 2.63 (dd, J = 18.6, 6.6 Hz, 1H).
[0323] Compound 239: (S)-5-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2,4-difluorobenzamide [ka] (S)-5-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2,4-difluorobenzonitrile (150 mg, 0.36 mmol) was dissolved in 6 mL of dry DMSO and HO (1.5 mL). To this solution, KCO (10 mg, 0.07 mmol) was added at room temperature. The mixture was stirred at room temperature for 2.0 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 48 as a white solid (38 mg, 25%). (ES, m / s): 437.4 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 7.67 (brs, 2H), 7.42 (t, J = 10.6 Hz, 1H), 7.14 - 7.02 (m, 2H), 7.00-6.96 (m, 1H), 6.88 (d, J = 7.8 Hz, 2H), 5.20 (dd, J = 12.2, 6.6 Hz, 1H), 5.07 (brs, 1H), 4.43 (brs, 2H), 3.97 (brs, 2H), 3.40 - 3.33 (m, 1H), 2.60 (dd, J = 18.6, 6.6 Hz, 1H).
[0324] Compound 240: 6-(((R)-1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)oxy)imidazo[1,2-b]pyridazine-3-carbonitrile [ka] ((S)-5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((R)-3-hydroxypyrrolidin-1-yl)methanone (180 mg, 1.2 mmol) was dissolved in 6 ml of dry DMF. To this solution, CsCO (652 mg, 2.0 mmol) and 6-chloroimidazo[1,2-b]pyridazine-3-carbonitrile (300 mg, 1 mmol) were added at room temperature. The mixture was stirred at 100° C. for 12 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 240 as a white solid (320 mg, 73%). (ES, m / s): 438.4 [M+H] + 1 H NMR (400 MHz, Chloroform-d)δ 8.10 (s, 1H), 7.94 (d, J = 9.7 Hz, 1H), 6.91 (d, J = 9.6 Hz, 1H), 6.84 - 6.76 (m, 3H), 6.68 (m, 1H), 5.67 (t, J = 4.2 Hz, 1H), 5.32 (dd, J = 12.0, 9.1 Hz, 1H), 4.08 (dd, J = 13.6, 4.3 Hz, 1H), 3.91 - 3.80 (m, 2H), 3.73 (t, J = 9.9 Hz, 1H), 3.33 (m, 1H), 2.68 (m, 1H), 2.39 - 2.17 (m, 2H).
[0325] Compound 241: 6-(((R)-1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)oxy)imidazo[1,2-b]pyridazine-3-carboxamide [ka] 6-(((R)-1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)oxy)imidazo[1,2-b]pyridazine-3-carbonitrile (40 mg, 0.092 mmol) was dissolved in 6 ml of dry MeOH. To this solution, aqueous ammonia (25 μl) and hydrogen peroxide (25 μl) were added at room temperature. The mixture was stirred at 25° C. for 5 hours. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 241 as a white solid (10 mg, 24%). (ES, m / s): 438.4 [M+H] + 1 H NMR (400 MHz, Chloroform-d) δ 8.37 (s, 1H), 8.01 (d, J = 9.7 Hz, 1H), 6.86 (d, J = 9.7 Hz, 1H), 6.82 - 6.78 (m, 3H), 6.69 (tt, J = 8.8, 2.3 Hz, 1H), 5.97 (s, 1H), 5.46 (t, J = 4.4 Hz, 1H), 5.31 (dd, J = 12.0, 9.2 Hz, 1H), 4.08 (dd, J = 13.4, 4.3 Hz, 1H), 3.96 - 3.85 (m, 2H), 3.78 (t, J = 10.0 Hz, 1H), 3.34 (ddd, J = 18.5, 12.0, 1.8 Hz, 1H), 2.69 (ddd, J = 18.4, 9.2, 1.6 Hz, 1H), 2.45 - 2.35 (m, 1H), 2.30 - 2.16 (m, 1H).
[0326] Compound 242: ((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((R)-3-(pyrazolo[1,5-a]pyrimidin-7-yloxy)pyrrolidin-1-yl)methanone [ka] ((S)-5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((R)-3-hydroxypyrrolidin-1-yl)methanone (100 mg, 0.339 mmol) was dissolved in 6 ml of dry DMF. To this solution, CsCO (260 mg, 0.68 mmol) and 7-chloropyrazolo[1,5-a]pyrimidine (62.24 mg, 0.4068 mmol) were added at room temperature. The mixture was stirred at 100° C. for 12 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 242 as a white solid (8.6 mg, 6.1%). (ES, m / s): 413.4 [M+H] + 1 H NMR (400 MHz, Chloroform-d) δ 8.46 (s, 1H), 8.17 (d, J = 2.3 Hz, 1H), 6.83 - 6.65 (m, 5H), 6.22 (d, J = 4.7 Hz, 1H), 5.39 - 5.22 (m, 2H), 4.22 - 3.83 (m, 4H), 3.33 (dd, J = 18.5, 11.9 Hz, 1H), 2.68 (dd, J = 18.4, 8.6 Hz, 1H), 2.58 - 2.44 (m, 2H), 2.33 (m, 1H).
[0327] Compound 243: 5-(((R)-1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one [ka]
[0328] Step 1 ((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)((R)-3-hydroxypyrrolidin-1-yl)methanone (200 mg, 0.68 mmol) was dissolved in 4 ml of dry DCM. To this solution, TEA (150 mg, 1.10 mmol) and MsCl (386 mg, 1.36 mmol) were added at room temperature. The mixture was stirred at room temperature for 1.0 h. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure to give (R)-1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl methanesulfonate as a yellow solid (260 mg, crude product). (ES, m / s): 374.4 [M+H] +
[0329] Step 2 (R)-1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)pyrrolidin-3-yl methanesulfonate (100 mg, 0.27 mmol) was dissolved in 4 ml of dry DMF. To this solution, CsCO (260 mg, 0.68 mmol) and 5-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one (36.9 mg, 0.23 mmol) were added at room temperature. The mixture was stirred at 100°C for 12 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 243 as a white solid (8.6 mg, 6.1%). (ES, m / s): 443.1 [M+H] + 1H NMR (400 MHz, Chloroform-d) δ 8.03 (s, 1H), 6.98 - 6.44 (m, 7H), 5.30 (ddd, J = 11.3, 7.6, 3.0 Hz, 1H), 4.94 (s, 1H), 4.58 (d, J = 3.1 Hz, 2H), 4.09 - 3.80 (m, 3H), 3.67 (q, J = 8.3 Hz, 1H), 3.31 (m, 1H), 2.66 (dd, J = 18.3, 7.8 Hz, 1H), 2.19 (s, 2H).
[0330] Compound 244: (S)-(6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-ylidene)methyl)-5-fluoropyridin-2-yl)carbamate tert-butyl [ka]
[0331] Step 1 tert-Butyl 3-(bromomethylene)azetidine-1-carboxylate (3 g, 12.1 mmol) was dissolved in 40 ml of dry DCM, and TFA (12 ml) was added to the solution at room temperature. The mixture was stirred at room temperature for 30 minutes. The mixture was concentrated under reduced pressure to give 3-(bromomethylene)azetidine as a yellow oil (2.8 g, crude product). (ES, m / s): 148.0 [M+H] +
[0332] Step 2 3-(Bromomethylene)azetidine (2.8 g, crude product, 12.1 mmol) was dissolved in 30 mL of dry THF. To this solution, TEA (5 mL) and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (3.7 g, 13.3 mmol) were added at room temperature. The mixture was stirred at 60 °C for 12 h. The mixture was extracted with EA, washed with brine, dried (Na SO ), and concentrated under reduced pressure. Purification by silica gel chromatography gave (S)-(3-(bromomethylene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone as a white solid (2.1 mg, 49%). (ES, m / s): 356.4 [M+H] +
[0333] Step 3 (S)-(3-(Bromomethylene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone (200 mg, 0.56 mmol) was dissolved in 3 mL of dry dioxane. To this solution, Pd(dppf)Cl2 (40 mg, 0.17 mmol), KOAc (166 mg, 1.68 mmol), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (215 mg, 1.12 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 80 °C for 12.0 h. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography gave (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)azetidin-1-yl)methanone as a white solid (2.1 mg, 49%). (ES, m / s): 404.2 [M+H] +
[0334] Step 4 (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methylene)azetidin-1-yl)methanone (200 mg, 0.50 mmol) was dissolved in 3 mL of dry dioxane. To this solution, (Pd(PPh3)4 (72 mg, 0.07 mmol), K2CO3 (170 mg, 1.5 mmol), and (S)-(3-(bromomethylene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone (120 mg, 0.41 mmol) were added under a nitrogen atmosphere at room temperature. The mixture was stirred at 80 °C for 12 h. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography gave (S)-(3-((6-amino-3-fluoropyridin-2-yl)methylene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone as a white solid (80 mg, 40%). (ES, m / s): 488.2 [M+H] +
[0335] Step 5 (S)-(3-((6-amino-3-fluoropyridin-2-yl)methylene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone (80 mg, 0.16 mmol) was dissolved in 2 ml of dry DCM. To this solution, TFA (0.6 ml) was added at room temperature. The mixture was stirred at room temperature for 30 minutes. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 244 as a white solid (17 mg, 20.7%). (ES, m / s): 391.1 [M+H] + 1H NMR (400 MHz, Chloroform-d) δ 8.31 (s, 1H), 7.61 (t, J = 8.7 Hz, 1H), 6.96 (d, J = 9.5 Hz, 1H), 6.86 (d, J = 1.7 Hz, 1H), 6.79 (s, 1H), 6.77 - 6.62 (m, 2H), 5.25 (dd, J = 12.1, 6.0 Hz, 1H), 5.08 (s, 2H), 4.49 (dd, J = 17.6, 5.5 Hz, 1H), 4.32 (d, J = 17.3 Hz, 1H), 3.48 (dd, J = 18.7, 12.1 Hz, 1H), 2.83 - 2.73 (m, 1H).
[0336] Compound 245: 3-((S)-6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide [ka]
[0337] Step 1 (R)-5-Oxotetrahydrofuran-2-carboxylic acid (5 g, 3.84 mmol) was dissolved in 40 ml of dry MeOH. To this solution, acetyl chloride (1 ml) was added at room temperature. The mixture was stirred at 60° C. for 12.0 hours. The mixture was concentrated under reduced pressure to give (R)-dimethyl 2-hydroxypentanedioate as a colorless oil (2.8 g, crude product). (ES, m / s): 177.2 [M+H] + Step 2 (R)-Dimethyl 2-hydroxypentanedioate (1.38 g, 7.83 mmol) was dissolved in 10 mL of dry THF. To this solution, DEAD (1.82 mL, 9.4 mmol), 4-bromo-5-fluoro-2-nitrophenol (2.22 g, 9.4 mmol), and PPh3 (3.15 g, 12.03 mmol) were added at room temperature. The mixture was stirred at 25 °C for 12.0 h. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography gave (R)-3-(7-fluoro-6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide as a white solid (2.1 g, 57%). (ES, m / s): 395.2 [M+H] +
[0338] Step 3 (R)-3-(7-Fluoro-6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide (500 mg, 1.27 mmol) was dissolved in 10 mL of dried acetate. To this solution, Fe (71 mg, 12.6 mmol) was added at room temperature. The mixture was stirred at 25°C for 12.0 h. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave methyl (R)-3-(6-bromo-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanoate as a white solid (360 mg, 86%). (ES, m / s): 333.2 [M+H] +
[0339] Step 4 Methyl (R)-3-(6-bromo-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanoate (300 mg, 0.9 mmol) was dissolved in 2 mL of MeOH, and ammonia (2 mL, 15%) was added to the solution at room temperature. The mixture was stirred at 60° C. for 12.0 hours. The mixture was concentrated under reduced pressure to give (R)-3-(6-bromo-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide as a white solid (100 mg, 35%). (ES, m / s): 318.1 [M+H]+
[0340] Step 5 (R)-3-(6-bromo-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide (50 mg, 0.157 mmol) was dissolved in 1 mL of dry dioxane. To this solution, Pd(dppf)Cl2 (11 mg, 0.015 mmol), KOAc (46 mg, 0.48 mmol), and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (80 mg, 0.31 mmol) were added under a nitrogen atmosphere at room temperature. The mixture was stirred at 100 °C for 12.0 h. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure to give (R)-3-(7-fluoro-3-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide as a white solid (52 mg, crude). (ES, m / s): 365.2 [M+H] +
[0341] Step 6 (R)-3-(7-Fluoro-3-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide (52 mg, crude product) was dissolved in 1 mL of THF and NaOH (aq) (0.2 mL, 1 N). To this solution was added HO (0.1 mL, 30% in HO) at room temperature. The mixture was stirred at 0 °C for 1.0 h and slowly warmed to room temperature. The pH of the resulting mixture was adjusted to 3-4 with HCl (aq, 1 N). The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure to give (R)-3-(7-fluoro-6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide as a white solid (30 mg, crude). (ES, m / s): 255.2 [M+H] +
[0342] Step 7 (R)-3-(7-Fluoro-6-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide (30 mg, crude product) was dissolved in 1 mL of dry DMF. To this solution, CsCO (60 mg, 0.24 mmol) and tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (65 mg, 0.2 mmol) were added at room temperature. The mixture was stirred at 100 °C for 12 h. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure to give tert-butyl (R)-3-((2-(3-amino-3-oxopropyl)-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)oxy)azetidine-1-carboxylate as an oil (39 mg, crude). Step 8 (R)-tert-Butyl 3-((2-(3-amino-3-oxopropyl)-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)oxy)azetidine-1-carboxylate (39 mg, crude product) was dissolved in 1 ml of dry DCM. To this solution was added TFA (0.3 ml) at room temperature. The mixture was stirred at room temperature for 1.0 h. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure to give (R)-3-(6-(azetidin-3-yloxy)-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide as a brown solid (45 mg, crude product). (ES, m / s): 410.2 [M+H] +
[0343] Step 9 (R)-3-(6-(azetidin-3-yloxy)-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanamide (39 mg, crude product) was dissolved in 1 ml of dry THF and 0.1 ml of TEA. To this solution, (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (32.2 mg, 0.12) in 5 ml of THF was added at room temperature. The mixture was stirred at 60° C. overnight. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 245 as a white solid (2.4 mg). (ES, m / s): 518.2 [M+H] +
[0344] Compound 246: 6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-2-(2-hydroxyethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one [ka]
[0345] Step 1 2-Amino-4-bromo-5-fluorophenol (4.4 g, 21.4 mmol), 3-bromodihydrofuran-2(3H)-one (3.9 g, 23.5 mmol), and Cs2CO3 (10.5 g, 32.1 mmol) were dissolved in DMF (70 mL). The mixture was stirred at 80 °C for 15 h. The solvent was evaporated to dryness and purified by flash chromatography (PE / EA = 2 / 1) to give the product as a yellow solid (4.5 g). Yield 72.6%. LC-MS (m / z) 291.2 (M+H + )
[0346] Step 2 THP (2.67 g, 31 mmol) was added to a solution of 6-bromo-7-fluoro-2-(2-hydroxyethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (4.5 g, 15.5 mmol) and TsOH (1.33 g, 7.75 mmol) in DCM (80 mL). The mixture was stirred at room temperature overnight. The solvent was evaporated to dryness and purified by flash chromatography (PE / EA=8 / 1) to give the product as a yellow oil (8.0 g). Yield 100%. LC-MS (m / z) 374.2 (M+H + )
[0347] Step 3 6-Bromo-7-fluoro-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (8.0 g, 21.4 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (10.9 g, 42.9 mmol), Pd(PPh3)2Cl2 (1.5 g, 2.14 mmol), and KOAc (6.3 g, 64.3 mmol) were added to dioxane (100 mL) under N2 atmosphere. The mixture was stirred at 100 °C for 3 h. The solvent was evaporated to dryness and used directly in the next step. LC-MS (m / z) 422.2 (M+H + ).
[0348] Step 4 HO (4 mL) was added to a solution of 7-fluoro-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one (4.5 g, 10.7 mmol) and 1N NaOH (4 mL) in THF (60 mL) at 0 °C. The mixture was stirred at room temperature for 2 h. Then, 1N HCl was added to adjust the pH to 6, and EA was added and extracted. The solvent was evaporated to dryness, and the product was purified by flash chromatography (PE / EA = 5 / 1) to give the product (1.7 g) as a yellow solid. Yield 51.5%. LC-MS (m / z) 334.2 (M+Na + ).
[0349] Step 5 7-Fluoro-6-hydroxy-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (710 mg, 2.28 mmol), (S)-1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl methanesulfonate (820 mg, 2.28 mmol), and CsCO (829 mg, 2.74 mmol) were dissolved in DMF (10 mL). The mixture was stirred at 100 °C for 15 h. The solvent was evaporated to dryness and purified by HPLC to give the product as a yellow solid (190 mg). Yield 17.3%. LC-MS (m / z) 575.3 (M+H) + ).
[0350] Step 6 TsOH (2 mg, 0.009 mmol) was added to a solution of 6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-2-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (50 mg, 0.087 mmol) in MeOH (2 mL). The mixture was stirred at room temperature for 1 hour. The solvent was evaporated to dryness and purified by flash chromatography (PE / EA=1 / 1) to give the title compound 246 (40 mg) as a white solid. Yield 93.7%. 1 H NMR (400 MHz, Chloroform-d) δ 8.91 (d, J = 10.8 Hz, 1H), 6.81 (t, J = 7.6 Hz, 1H), 6.79-6.72 (m, 2H), 6.69-6.62 (m, 1H), 6.23 (d, J = 7.8 Hz, 1H), 5.49-5.39 (m, 1H), 4.86-4.79 (m, 1H), 4.71-4.61(m, 1H), 4.61 - 4.43 (m, 2H), 4.41-4.33(m, 1H), 4.20-4.08 (m, 1H), 3.91 - 3.80 (m, 2H), 3.38 (dd, J = 18.4, 12.0 Hz, 1H), 2.74-2.64 (m, 1H), 2.30 - 2.05 (m, 2H). LC-MS (m / z) 491.4(M+H + )
[0351] Compound 247: 6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-2-(2-methoxyethyl)-4-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one [ka] CHCl (28 mg, 0.2 mmol) and AgO (24 mg, 0.1 mmol) were added to a solution of 6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-2-(2-hydroxyethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (10 mg, 0.02 mmol) in CAN (2 mL). The mixture was stirred at room temperature for 24 hours. The solvent was evaporated to dryness, and the mixture was purified by TLC (DCM / MeOH=25 / 1) to give the title compound 247 (2.5 mg) as a white solid. Yield: 25.0%. 1 H NMR (400 MHz, Chloroform-d) δ 6.91 - 6.61 (m, 5H), 6.44 (dd, J = 7.6, 1.2 Hz, 1H), 5.31 - 5.23 (m, 1H), 4.94 (t, J = 5.2 Hz, 1H), 4.66 (dd, J = 9.0, 4.2 Hz, 1H), 4.49 (d, J = 6.8 Hz, 2H), 4.33 - 4.28 (m, 1H), 4.24 (d, J = 10.4 Hz, 1H), 3.68 - 3.47 (m, 2H), 3.41-3.33 (m,4H), 3.30 (s, 3H), 2.75-2.65 (m, 1H), 2.06-1.94 (m, 2H). LC-MS (m / z) 519.5(M+H + )
[0352] Compound 248: 6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-2-(2-hydroxyethyl)-4-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one [ka] The title compound 248 was synthesized in a manner similar to the preparation of compound 246. Yield 25.0%. 1H NMR (400 MHz, Chloroform-d) δ 6.86 - 6.77 (m, 2H), 6.78 - 6.58 (m, 3H), 6.46 (d, J = 7.6 Hz, 1H), 5.30 - 5.24 (m, 1H), 4.98 - 4.91 (m, 1H), 4.68 (dd, J = 7.6, 5.6 Hz, 1H), 4.49 (dd, J = 18.0, 10.4 Hz, 2H), 4.30 (t, J = 6.8 Hz, 1H), 4.23 (d, J = 9.2 Hz, 1H), 3.86 (dd, J = 6.8, 4.8Hz, 2H), 3.42 - 3.24 (m, 4H), 2.74-2.66 (m 1H), 2.26 - 2.13 (m, 2H). LC-MS (m / z) 505.5(M+H) + )
[0353] Compound 249: 6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2-(2-(dimethylamino)ethyl)-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one [ka] 2-(6-((1-((S)-5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-7-fluoro-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)ethyl methanesulfonate (10 mg, 0.018 mmol) and dimethylamine (4 mg, 0.09 mmol) were dissolved in dioxane (2 mL). The mixture was stirred at 90° C. for 2 hours. The solvent was evaporated to dryness and purified by HPLC to give the title compound 249 as a white solid (2.5 mg). Yield 27.8%. 1H NMR (400 MHz, Chloroform-d) δ 12.17 (s, 1H), 9.24 (s, 1H), 6.95 - 6.57 (m, 3H), 6.40-6.28 (m, 1H), 5.68 - 5.50 (m, 1H), 5.40-5.21 (m, 1H), 4.92-4.80 (m, 1H), 4.63-4.42 (m, 2H), 4.35-4.12 m, 2H), 3.89 - 3.66 (m, 1H), 3.43-3.27 (m, 2H), 3.04-2.63(m, 7H), 2.25 (t, J = 7.6 Hz,1H), 2.05-1.98 (m, 1H), 1.69-1.60 (m, 1H). LC-MS (m / z) 518.5(M+H + )
[0354] Compound 250: 6-((1-((S)-5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-2-ethyl-7-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one
change
[0355] Compound 251: (S)-(3-((6-amino-3-fluoropyridin-2-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone
change
[0356] Step 1 6-Chloro-3-fluoropyridin-2-ol (200 mg, 1.36 mmol) was dissolved in 3 mL of dry THF. To this solution, DEAD (328 mg mL, 1.63 mmol), (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-hydroxyazetidin-1-yl)methanone (400 mg, 1.423 mmol), and PPh3 (540 mg, 2.04 mmol) were added at room temperature. The mixture was stirred at 25°C for 12.0 hours. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure. Purification by silica gel chromatography gave (S)-(3-((6-chloro-3-fluoropyridin-2-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone as a white solid (300 mg, 51%). (ES, m / s): 411.2 [M+H] + .
[0357] Step 2 (S)-(3-((6-amino-3-fluoropyridin-2-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone (300 mg, 0.72 mmol) was dissolved in 2 mL of dry dioxane. To this solution, Pd(dba) (33.6 mg mL, 0.036 mmol), 2-(dicyclohexylphosphino)-2',4',6'-tri-i-propyl-1,1'-biphenyl (51.4 mg, 0.108 mmol), and CsCO (240 mg, 0.74 mmol) were added at room temperature. The mixture was stirred at 100 °C for 3 h. The mixture was extracted with EA, washed with brine, dried over NaSO, and concentrated under reduced pressure. Purification by silica gel chromatography gave tert-butyl (S)-(6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyridin-2-yl)carbamate as a white solid (300 mg, 84%). (ES, m / s): 411.2 [M+H] +
[0358] Step 3 (S)-tert-Butyl (6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyridin-2-yl)carbamate (100 mg, 0.2 mml) was dissolved in 1 ml of dry DCM. To this solution, TFA (0.3 ml) was added at room temperature. The mixture was stirred at room temperature for 1.0 h. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure to give title compound 251 as a white solid (30 mg). (ES, m / s): 388.2 [M+H] + . 1H NMR (400 MHz, Chloroform-d) δ 8.69 (d, J = 8.6 Hz, 2H), 7.51 (t, J = 9.2 Hz, 1H), 6.82 (m, 1H), 6.66 (m, 4H), 5.37 (m, 1H), 5.22 (m, 1H), 4.86 - 4.65 (m, 2H), 3.81 (m, 4.9 Hz, 1H), 3.66 (m, 1H), 3.45 (dd, J = 18.7, 12.2 Hz, 1H), 2.74 (m, 1H).
[0359] Compound 252: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((3-fluoro-6-((2-hydroxyethyl)amino)pyridin-2-yl)oxy)azetidin-1-yl)methanone [ka]
[0360] Step 1 (S)-(6-((1-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyridin-2-yl)tert-butylcarbamate (200 mg, 0.4 mml), (2-bromoethoxy)(tert-butyl)dimethylsilane (140 mg, 0.6 mmol), and Pd(dba) (33.6 mg ml, 0.036 mmol) were dissolved in 2 ml of dry DMF. To this solution was added CsCO (240 mg, 0.74 mmol) at room temperature. The mixture was stirred at 100 °C for 12 h. The mixture was extracted with EA, washed with brine, dried over NaSO, and concentrated under reduced pressure. Purification by silica gel chromatography gave (S)-(3-((6-amino-3-fluoropyridin-2-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone as a white solid (300 mg, 84%). LC-MS (ES, m / s): 650.8 [M+H].
[0361] Step 2 (S)-(3-((6-amino-3-fluoropyridin-2-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone (300 mg) was dissolved in 1 ml of dry DCM. To this solution, TFA (0.3 ml) was added at room temperature. The mixture was stirred at room temperature for 1.0 hour. The mixture was extracted with EA, washed with brine, dried (Na2SO4), and concentrated under reduced pressure to give the title compound 252 as a white solid (30 mg). (ES, m / s): 436.4 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 8.09 (td, J = 9.7, 7.7 Hz, 1H), 7.15 - 7.00 (m, 2H), 6.81 (tdd, J = 6.4, 4.4, 2.1 Hz, 2H), 6.60 (dt, J = 9.7, 2.9 Hz, 1H), 5.46 (m, 1H), 5.19 (ddd, J = 12.2, 8.9, 6.1 Hz, 1H), 4.52 (dd, J = 11.5, 9.1 Hz, 1H), 4.28 (ddd, J = 20.5, 11.5, 7.3 Hz, 1H), 3.66 - 3.50 (m, 4H), 3.40 - 3.30 (m, 2H), 2.69 (ddd, J = 18.8, 6.1, 1.8 Hz, 1H).
[0362] Compound 253: (S)-7-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-6-fluoroquinolin-2(1H)-one [ka]
[0363] Step 1 6-Fluoro-7-hydroxyquinolin-2(1H)-one (1.2 g, 6.7 mmol) and tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (1.85 g, 17.37 mmol) were dissolved in 15 mL of DMF. Cs2CO3 (3.28 g, 10.067 mmol) was added. The mixture was stirred at 105 °C for 3 days. The solvent was evaporated to dryness and purified by column chromatography (100% EA) to give 1.7 g of tert-butyl 3-((6-fluoro-2-oxo-1,2-dihydroquinolin-7-yl)oxy)azetidine-1-carboxylate as a yellow solid. Yield: 76%. LC-MS (m / z) 335.3 [M+H] + .
[0364] Step 2 3-((6-Fluoro-2-oxo-1,2-dihydroquinolin-7-yl)oxy)azetidine-1-carboxylate (24 mg, 0.072 mmol) was dissolved in 2 mL of DCM. To this solution, 2 mL of DCM / TFA (1 / 1) was slowly added at 0° C. The mixture was stirred at room temperature for 1 hour. The solvent was evaporated to dryness to give 7-(azetidin-3-yloxy)-6-fluoroquinolin-2(1H)-one as a TFA salt, which was used in the next step without further purification. LC-MS (m / z) 235.4 [M+H] + .
[0365] Step 3 The residue from above was dissolved in 2 mL of THF. 0.2 mL of TEA and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (20 mg, 0.072 mmol) were added. The mixture was stirred at 70° C. for 36 hours. The solvent was evaporated to dryness and purified by preparative TLC (DCM / MeOH=15 / 1) to give the title compound 253 as a light brown solid (9 mg, 28.3% yield for two steps). 1H NMR (400 M Hz, CDCl3) δ (ppm): δ 12.25 (brs, 1H) , 7.67 (d, J = 9.6 Hz ,1H), 7.23-7.25 (m, 1H), 6.71-6.79 (m, 4H), 6.59-6.67 (m,2H), 5.40-5.44 (m,1H), 5.01-5.12 (m,1H), 4.58-4.74 (m, 2H), 4.32-4.45 (m, 1H), 4.15-4.26 (m 1H), 3.37 (dd, J = 12.0, 18.8 Hz, 1H), 2.68 (dd, J = 6.0, 18.4 Hz, 1H). LC-MS (ESI): m / z calcd for C 22 H 17 F3N4O3442.4, found 443.5 [M+H] + .
[0366] Compound 254: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((3,5-difluoropyridin-2-yl)amino)azetidin-1-yl)methanone [ka]
[0367] Step 1 2-Bromo-3,5-difluoropyridine (150 mg, 0.77 mmol), tert-butyl 3-aminoazetidine-1-carboxylate (146.5 mg, 0.85 mmol), and t-BuOK (111 mg, 1 mmol) were mixed in 2 mL of toluene. BINAP (70.8 mg, 0.114 mmol) and Pd2(dba)3 (96.3 mg, 0.105 mmol) were added. The mixture was stirred at 110 °C for 16 hours under a nitrogen atmosphere. The solvent was evaporated to dryness, and the mixture was purified by column chromatography (PE / EA = 2 / 1) to give 90 mg of tert-butyl 3-((3,5-difluoropyridin-2-yl)amino)azetidine-1-carboxylate as a brown oil. Yield: 41%. LC-MS (m / z) 286.3 [M+H] + .
[0368] Step 2 tert-Butyl 3-((3,5-difluoropyridin-2-yl)amino)azetidine-1-carboxylate (35 mg, 0.123 mmol) was dissolved in 2 mL of DCM. To this solution, 2 mL of DCM / TFA (1 / 1) was added slowly at 0° C. The mixture was stirred at room temperature for 1 hour. The solvent was evaporated to dryness and used in the next step without further purification. LC-MS (m / z) 186.2 [M+H] + .
[0369] Step 3 The above residue was dissolved in 2 mL of THF. 0.2 mL of TEA was added. (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (25 mg, 0.09 mmol) was added. The mixture was stirred at 70° C. for 16 hours. The solvent was evaporated to dryness and purified by preparative TLC (PE / EA=1 / 1) to give 12 mg of the title compound 254 as a brown oil. Yield: 33.8%. 1 H NMR (400 MHz, CDCl3) δ (ppm): 7.81 (dd, J = 0.8, 2.4 Hz , 1H), 7.06-7.11 (m, 1H), 6.73-6.78 (m, 3H), 6.66-6.71 (m, 1H), 5.27 (dd, J = 6.4, 12.0 Hz, 1H), 4.79-4.88 (m, 1H), 4.66-4.75 (m, 1H), 4.58 (t, J = 7.6 Hz, 1H), 4.51 (t, J = 8.0 Hz,1H), 3.95-3.98 (m, 1H), 3.34 (dd, J = 12.4, 18.8 Hz, 1H), 2.68 (dd, J = 6.8, 18.8 Hz, 1H). LC-MS (ESI): m / z calcd for C 18 H 15 F4N5O 393.4, found 394.3 [M+H] + .
[0370] Compound 255: (5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((2,4-difluorophenyl)amino)azetidin-1-yl)methanone [ka] The title compound 255 was synthesized in a manner similar to the preparation of compound 254. 1 H NMR (400 MHz, Chloroform-d) δ 7.63 - 7.55 (m, 1H), 6.85 - 6.81 (m, 2H), 6.80 - 6.73 (m, 2H), 6.70 (tt, J = 8.9, 2.3 Hz, 1H), 6.37 - 6.33 (m, 1H), 5.31 (dd, J = 12.2, 6.5 Hz, 1H), 5.05-4.81 (m, 4H), 3.38 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.72 (ddd, J = 18.6, 6.5, 1.7 Hz, 1H).LC-MS (m / z) 393.4 [M+H] + .
[0371] Compound 256: (S)-6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)pyrido[2,3-b]pyrazin-3(4H)-one [ka]
[0372] Step 1 6-Chloropyrido[2,3-b]pyrazin-3(4H)-one (80 mg, 0.44 mmol) and tert-butyl 3-hydroxyazetidine-1-carboxylate (76.3 mg, 0.44 mmol) were dissolved in 2 mL of DMF. t-BuOK (74 mg, 0.66 mmol) was added. The mixture was stirred at 110°C for 16 hours. The solvent was evaporated to dryness and purified by preparative TLC (EA) to give 100 mg of a pale yellow solid. Yield: 71.5%. LC-MS (m / z): 319.2 [M+H] + .
[0373] Steps 2 and 3 The title compound 256 was prepared in 12.9% yield from 6-(azetidin-3-yloxy)pyrido[2,3-b]pyrazin-3(4H)-one and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 62. 1 H NMR (400 MHz, CDCl3) δ (ppm): δ 9.63 (brs, 1H) , 8.17 (s, 1H), 8.07 (d, J = 8.8 Hz ,1H), 6.75-6.80 (m, 4 H), 6.66 (t, J = 8.8 Hz, 1H), 5.38-5.44 (m,1H), 5.32 (dd, J = 6.4, 12.8 Hz, 1H), 4.59-4.68 (m, 2H), 4.26-4.29 (m, 1H), 4.17-4.20 (m,1H), 3.36 (dd, J = 12.0, 18.4 Hz, 1H), 2.69 (dd, J = 6.4, 18.8 Hz, 1H). LC-MS (ESI): m / z calcd for C 20 H 16 F2N6O3426.4, found 427.5 [M+H] + .
[0374] Compound 257: (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carboxylate methyl [ka]
[0375] Step 1 A solution of MeONa in MeOH (11.57 ml, 5.4 M, 62.5 mmol) was slowly added to a mixture of 2-bromothiazole-5-carbaldehyde (3 g, 15.625 mmol) and methyl 2-azidoacetate (7.2 g, 62.61 mmol) in 80 mL of THF at -15 °C. The mixture was stirred at -15 °C for 2 h. The reaction was quenched by adding saturated NH4Cl solution and extracted with EtOAc (100 mL x 3). The mixture was dried over Na2SO4 and filtered. The solvent was evaporated to dryness and purified by column chromatography (PE / EA = 3 / 1) to give 680 mg of (Z)-2-azido-3-(2-bromothiazol-5-yl)methyl acrylate as a pale yellow solid. Yield: 15%. LC-MS (m / z) 289.2 [M+H] + .
[0376] Step 2 Methyl (Z)-2-azido-3-(2-bromothiazol-5-yl)acrylate (680 mg, 2.28 mmol) in 3 ml toluene was slowly added to the refluxing toluene solution. The mixture was stirred at reflux for another 2 hours. The solvent was evaporated to dryness and purified by column chromatography (PE / EA=4 / 1) to give 585 mg of methyl 2-bromo-4H-pyrrolo[2,3-d]thiazole-5-carboxylate as a pale yellow solid. Yield: 98.2%. LC-MS (m / z) 261.1 [M+H] + .
[0377] Step 3 Tert-Butyl 3-hydroxyazetidine-1-carboxylate (199.6 mg, 1.156 mmol) was dissolved in 5 mL of DMF. NaH (97.1 mg, 2.43 mmol) was added in portions at room temperature. The mixture was stirred at room temperature for 1 hour. To this solution, methyl 2-bromo-4H-pyrrolo[2,3-d]thiazole-5-carboxylate (150 mg, 0.577 mmol) in 3 mL of DMF was added. The mixture was stirred at 80 °C for 3 hours. The reaction was quenched by the addition of water and extracted with EtOAc (20 mL × 3). The solvent was evaporated to dryness, and the residue was purified by column chromatography (PE / EA = 3 / 1) to give 140 mg of methyl 2-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carboxylate) as a pale yellow solid. Yield: 68.7%. LC-MS (m / z) 298.2 [M+H-56] + .
[0378] Step 4 Methyl 2-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carboxylate (80 mg, 0.227 mmol) was dissolved in 2 mL of DCM. To this solution, 2 mL of DCM / TFA (1 / 1) was added slowly at 0° C. The mixture was stirred at room temperature for 1 hour. The solvent was evaporated to dryness and used in the next step without further purification. LC-MS (m / z) 254.1 [M+H] + The residue was dissolved in 3 mL of THF. (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (65 mg, 0.235 mmol) and 0.2 mL of TEA were added. The mixture was stirred at 70 °C for 32 h. The solvent was evaporated to dryness and purified by preparative HPLC to give 47 mg of the title compound 257 as a white solid. Yield: 44.9%. 1H NMR (400 MHz, CDCl3) δ (ppm): δ 9.19 (s, 1H), 6.98 (d, J = 2.0 Hz , 1H), 6.66-6.79 (m, 4H), 5.43-5.48 (m, 1H), 5.27 (dd, J = 6.4, 12.4 Hz ,1H), 4.55-4.62 (m, 2H), 4.33(dd, J = 2.0,10.4 Hz, 1H), 4.26 (dd, J = 2.4,10.8 Hz, 1H), 3.88 (s, 3H), 3.35 (ddd, J = 1.6, 12.0, 13.6 Hz ,1H), 2.69 (ddd, J = 1.6, 6.4, 8.4 Hz, 1H). LC-MS (ESI): m / z calcd for C 20 H 17 F2N5O4S 461.4, found 462.5 [M+H] + .
[0379] Compound 258: (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-N-methyl-4H-pyrrolo[2,3-d]thiazole-5-carboxamide [ka]
[0380] Step 1 Methyl 2-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carboxylate (300 mg, 0.85 mmol) was suspended in 8 mL of EtOH. 6 mL of 1N NaOH was added. Stirred at 60° C. under nitrogen atmosphere for 7 hours. The solvent was evaporated to dryness and adjusted to pH 5 with 1N HCl. The red-purple solid was filtered and used in the next step without further purification. Yield: 100 mg. Yield: 34.7%. LC-MS (m / z) 339.9 [M+H] + .
[0381] Step 2 The product was prepared in 60% yield from 2-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carboxylic acid and methylamine hydrochloride by coupling reaction using HATU.
[0382] Step 3 The title compound 67 was prepared in 25.6% yield from 2-(azetidin-3-yloxy)-N-methyl-4H-pyrrolo[2,3-d]thiazole-5-carboxamide and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 258. 1 H NMR (400 MHz, CDCl3) δ (ppm): δ 9.49 (brs, 1H), 6.67-6.78 (m, 4H), 6.58 (s, 1H), 5,41-5.52 (m, 1H), 5.27 (dd, J = 5.6, 12.0 Hz ,1H), 4.51-4.64 (m, 2H), 4.22-4.36 (m, 2H) , 3.34 (dd, J = 12.0, 17.6 Hz ,1H), 2.99 (s, 3H), 2.69 (dd, J = 6.8, 18.4 Hz, 1H). LC-MS (ESI): m / z calcd for C 20 H 18 F2N6O3S 460.5, found 461.4 [M+H] + .
[0383] Compound 259: (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carboxylic acid [ka] (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carboxylate (28 mg, 0.06 mmol) was dissolved in 2 mL of MeOH. 1 mL of 1N NaOH was added. Stirred at 60° C. for 10 hours. The solvent was evaporated to dryness and dissolved in HO. The pH was adjusted to 5 with 1N HCl. The brown solid was filtered to give the title compound 259 without further purification. Yield: 10 mg, 37%. 1 H NMR (400 MHz, CDCl3) δ (ppm): δ 6.97 (s, 1H), 6.74-6.77 (m, 1H), 6.63-6.72 (m, 3H), 5.39-5.44 (m, 1H), 5.19-5.25 (m, 1H), 4.45-4.65 (m, 2H), 4.20-4.33 (m, 2H), 3.25-3.35 (m, 1H), 2.62-2.70 (m, 1H). LC-MS (ESI): m / z calcd for C 19 H 15 F2N5O4S 447.2, found 448.3 [M+H] + .
[0384] Compound 260: (S)-(4-(1H-pyrazolo[3,4-d]pyrimidin-6-yl)piperazin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (100 mg, 0.34 mmol) and 6-chloro-1H-pyrazolo[3,4-d]pyrimidine (57.8 mg, 0.37 mmol) were dissolved in 2 mL of DMF. 0.5 mL of DIEA was added. The mixture was stirred at 150° C. for 40 minutes under microwave irradiation. The solvent was evaporated to dryness and purified by preparative TLC (PE / EA=1 / 2) to give 56 mg of the title compound 260 as a white solid. Yield: 39.9%. 1H NMR (400 MHz, CDCl3) δ (ppm): 11.41(brs, 1H), 8.82 (s, 1H), 7.92 (s, 1H), 6.75-6.96 (m, 3H), 6.60-6.72 (m, 1H), 5.36 (t, J = 9.6 Hz, 1H), 3.99-4.10 (m, 2H), 3.87-3.97 (m, 2H), 3.76-3.86 (m, 2H), 3.60-3.75 (m, 2H), 3.32 (dd, J = 8.4, 17.2 Hz, 1H), 2.68 (dd, J = 8.8, 17.2 Hz, 1H). Mass (ESI): m / z calcd for C 19 H 18 F2N8O 412.4, found 413.3 [M+H] + .
[0385] Compound 261: (S)-Azetidin-1-yl(2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazol-5-yl)methanone [ka] The title compound 261 was prepared in 46% yield from azetidine and (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-4H-pyrrolo[2,3-d]thiazole-5-carbonyl chloride following the method outlined for compound 67. 1H NMR (400 MHz, CDCl3) δ (ppm): δ 9.47 (brs, 1H), 6.74-6.78 (m, 3H), 6.67-6.72 (m, 1H), 6.48 (d, J = 2.0 Hz, 1H), 5.43-5.48 (m, 1H), 5.27 (dd, J = 6.4, 12.0 Hz ,1H), 4.52-4.65 (m, 2H), 4.35-4.46 (m, 2H), 4.17-4.34 (m, 4H), 3.34 (ddd, J = 1.6, 12.4, 14.0 Hz ,1H), 2.69 (ddd, J = 1.6, 6.4,8.4 Hz, 1H), 2.38-2.47 (m, 2H). LC-MS (ESI): m / z calcd for C 22 H 20 F2N6O3S 486.5, found 487.3 [M+H] + .
[0386] Compound 262: (S)-(3-((3,5-difluoro-6-(methylamino)pyridin-2-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka]
[0387] Step 1 2,3,5,6-Tetrafluoropyridine (350 mg, 2.32 mmol), tert-butyl 3-hydroxyazetidine-1-carboxylate (441 mg, 2.55 mmol), and t-BuOK (415.6 mg, 3.70 mmol) were mixed in 10 mL of 1,4-dioxane. The mixture was stirred at room temperature for 16 hours. Water was added, and the mixture was extracted with EtOAc (30 mL x 3). The solvent was evaporated to dryness, and the mixture was purified by column chromatography (PE / EA = 85 / 15) to give 460 mg of tert-butyl 3-((3,5,6-trifluoropyridin-2-yl)oxy)azetidine-1-carboxylate as a pale yellow solid. Yield: 63.9%. LC-MS (m / z) 305.2 [M+H] + .
[0388] Step 2 tert-Butyl 3-((3,5,6-trifluoropyridin-2-yl)oxy)azetidine-1-carboxylate (200 mg, 0.66 mmol), methylamine hydrochloride (48.8 mg, 0.73 mmol), and CsCO (427.6 mg, 1.316 mmol) were mixed in 5 mL of DMF. The mixture was stirred at 100° C. for 16 hours. Water was added and the mixture was extracted with EtOAc (30 mL×3). The solvent was evaporated to dryness and purified by preparative TLC (PE / EA=4 / 1) to give 170 mg of tert-butyl 3-((3,5-difluoro-6-(methylamino)pyridin-2-yl)oxy)azetidine-1-carboxylate as a pale yellow solid. Yield: 81.8%. LC-MS (m / z) 317.1 [M+H] + .
[0389] Step 3 tert-Butyl 3-((3,5-difluoro-6-(methylamino)pyridin-2-yl)oxy)azetidine-1-carboxylate (100 mg, 0.316 mmol) was dissolved in 2 mL of DCM. To this solution, 2 mL of DCM / TFA (1 / 1) was added slowly at 0° C. The mixture was stirred at room temperature for 1 hour. The solvent was evaporated to dryness and used in the next step without further purification. LC-MS (m / z) 217.2 [M+H] + .
[0390] Step 4 The above residue was dissolved in 2 mL of THF. 0.2 mL of TEA was added. (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (87 mg, 0.315 mmol) was added. The mixture was stirred at 70° C. for 16 hours. The solvent was evaporated to dryness and purified by preparative TLC (PE / EA=1 / 1) to give 80 mg of the title compound 262 as a pale yellow solid. Yield: 59.8%. 1H NMR (400 MHz, CDCl3) δ (ppm): δ 7.11 (t, J = 8.8 Hz ,1H), 6.74-6.79 (m, 3H), 6.66-6.71 (m, 1H), 5.32-5.37 (m, 1H), 5.28 (dd, J = 6.4, 12.0 Hz ,1H), 4.51-4.59 (m, 2H), 4.31(dd, J = 4.8, 10.4 Hz ,1H), 4.22 (dd, J = 4.0, 10.4 Hz ,1H), 3.34 (ddd, J = 2.0, 12.4, 14.0 Hz ,1H), 2.94 (s, 3H), 2.69 (ddd, J = 2.0, 6.8, 8.4 Hz, 1H). LC-MS (ESI): m / z calcd for C 19 H 17 F4N5O2423.4, found 424.3 [M+H] + .
[0391] Compound 263: (S)-(3-((6-amino-3,5-difluoropyridin-2-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka]
[0392] Step 1: tert-Butyl 3-((3,5,6-trifluoropyridin-2-yl)oxy)azetidine-1-carboxylate To a solution of 2,3,5-trifluoropyridine (795 mg, 5.2 mmol) and tert-butyl 3-hydroxyazetidine-1-carboxylate (1.0 g, 5.8 mmol) in 1,4-dioxane (200 mL) was added t-BuOK (882 mg, 7.8 mmol). The mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was purified by silica gel chromatography (petroleum ether / EtOAc = 5 / 1) to give the title compound as a white solid (1.1 g, 45% yield). LCMS (ES, m / z): 305.3 [M+H]+.
[0393] Step 2: tert-Butyl 3-((6-amino-3,5-difluoropyridin-2-yl)oxy)azetidine-1-carboxylate To a solution of tert-butyl 3-((3,5,6-trifluoropyridin-2-yl)oxy)azetidine-1-carboxylate (3.4 g, 11.2 mmol) in DMSO (30 mL) was added a solution of NH in MeOH (20 mL, 7 M). The mixture was stirred at 150 °C overnight. The mixture was extracted with DCM, washed with brine, dried (Na SO ), and concentrated under reduced pressure to give the title compound as a yellow solid (2.0 g, 62%). (ES, m / s): 302.1 [M+H].
[0394] Steps 3 and 4 The title compound 72 was prepared in 5% yield (two steps) from 6-(azetidin-3-yloxy)-3,5-difluoropyridin-2-amine TFA salt and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 62. 1 H NMR (400 MHz, Chloroform-d) δ 7.15 (t, J = 8.8 Hz, 1H), 6.80 - 6.62 (m, 4H), 5.31 - 5.23 (m, 2H), 4.56-4.49 (m, 2H), 4.27-4.17 (m, 2H), 3.76 (brs, 2H), 3.34 (ddd, J = 18.6, 12.2, 1.5 Hz, 1H), 2.68 (ddd, J = 18.5, 6.5, 1.6 Hz, 1H). Yield:5% (5 mg), LCMS (ES, m / z):410.1[M+H]+
[0395] Compound 264: (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)pyrimidine-4-carbonitrile [ka] The title compound 264 was synthesized in a manner similar to the preparation of compound 256. 1H NMR (400 MHz, Chloroform-d) δ 8.77 (d, J = 4.7 Hz, 1H), 7.33 (d, J = 4.8 Hz, 1H), 6.79 (t, J = 1.7 Hz, 1H), 6.77 - 6.73 (m, 2H), 6.69 (tt, J = 8.9, 2.3 Hz, 1H), 5.39 (tt, J = 6.6, 4.2 Hz, 1H), 5.28 (dd, J = 12.2, 6.5 Hz, 1H), 4.66 - 4.52 (m, 2H), 4.34 - 4.19 (m, 2H), 3.35 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.69 (ddd, J = 18.6, 6.5, 1.7 Hz, 1H). LC-MS (m / z): 385.2[M+H] + .
[0396] Compound 265: (S)-4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)pyrimidine-2-carbonitrile
change
[0397] Compound 266: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((5-fluoro-2-((2-hydroxyethyl)amino)pyrimidin-4-yl)oxy)azetidin-1-yl)methanone [ka]
[0398] Step 1: Preparation of tert-butyl 3-((2-chloro-5-fluoropyrimidin-4-yl)oxy)azetidine-1-carboxylate 2,4-Dichloro-5-fluoropyrimidine (5 g, 29.9 mmol) was added to a solution of CsCO (19.5 g, 59.9 mmol) in DMF (100 mL), followed by tert-butyl 3-hydroxyazetidine-1-carboxylate (5.7 g, 32.9 mmol). The mixture was stirred at 100 °C for 2 h. The reaction mixture was then extracted three times with EtOAc / HO (50 mL / 50 mL). The combined organic layers were washed with brine, dried over NaSO, concentrated, and further purified by silica gel column chromatography (PE / EA = 5 / 1) to give tert-butyl 3-((2-chloro-5-fluoropyrimidin-4-yl)oxy)azetidine-1-carboxylate (3.9 g) as a colorless oil (43%). LC-MS (ESI) m / z [M+H] + : 304.1.
[0399] Step 2: Preparation of 4-(azetidin-3-yloxy)-2-chloro-5-fluoropyrimidine TFA (5 mL) was added to a solution of tert-butyl 3-((2-chloro-5-fluoropyrimidin-4-yl)oxy)azetidine-1-carboxylate (3.9 g, 12.9 mmol) in DCM (10 mL). The reaction mixture was stirred at room temperature for 0.5 h. The solvent was then evaporated under reduced pressure to give 5.2 g of 4-(azetidin-3-yloxy)-2-chloro-5-fluoropyrimidine as a colorless oil (crude product). LC-MS (ESI) m / z [M+H] + :204.1.
[0400] Step 3: Preparation of (S)-(3-((2-chloro-5-fluoropyrimidin-4-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (3.23 g, 11.7 mmol) was added to a solution of 4-(azetidin-3-yloxy)-2-chloro-5-fluoropyrimidine and TEA (3.55 g, 35.1 mmol) in 1,4-dioxane (30 mL). The reaction mixture was stirred overnight at room temperature. The solvent was then evaporated under reduced pressure. The oily residue was purified by silica gel column chromatography (PE / EA=1 / 1) to give 4.35 g of (S)-(3-((2-chloro-5-fluoropyrimidin-4-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone as a yellow oil (90%). LC-MS (ESI) m / z [M+H] + :412.1.
[0401] Step 4: Preparation of (S)-(2-((tert-butyldimethylsilyl)oxy)ethyl)(4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyrimidin-2-yl)carbamate tert-butyl (2-Bromoethoxy)(tert-butyl)dimethylsilane (29.1 mg, 0.122 mmol) was added to a solution of CsCO (66.5 mg, 0.204 mmol) in DMF (1 mL), followed by the addition of 3-01 (50 mg, 0.102 mmol). The mixture was stirred at 100 °C for 1 h. The reaction mixture was then extracted three times with EtOAc / HO (50 mL / 50 mL). The combined organic layers were washed with brine, dried over Na2SO4, and concentrated to give tert-butyl (S)-(2-((tert-butyldimethylsilyl)oxy)ethyl)(4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyrimidin-2-yl)carbamate (60 mg) as a yellow oil.
[0402] Step 5: Preparation of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((5-fluoro-2-((2-hydroxyethyl)amino)pyrimidin-4-yl)oxy)azetidin-1-yl)methanone TFA (5 mL) was added to a solution of tert-butyl (S)-(2-((tert-butyldimethylsilyl)oxy)ethyl)(4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyrimidin-2-yl)carbamate (60 mg, 0.092 mmol) in DCM (10 mL). The reaction mixture was stirred at room temperature for 0.5 hours. The reaction mixture was concentrated and purified by preparative HPLC to afford 16 mg of the title compound 266: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((5-fluoro-2-((2-hydroxyethyl)amino)pyrimidin-4-yl)oxy)azetidin-1-yl)methanone (40%). LC-MS (ESI) m / z [M+H] + :437.2 1 H NMR (400 MHz, CDCl3): δ 7.82 (d, J = 3.4 Hz, 1H), 6.85 - 6.64 (m, 4H), 5.50 (s, 1H), 5.27 (dd, J = 12.1, 6.4 Hz, 1H), 4.60 (br, 2H), 4.38-4.26 ((m, 2H), 3.85 (s, 2H), 3.55 (s, 2H), 3.41-3.33 (m, 1H), 2.77 - 2.66 (m, 1H).
[0403] Compound 267: (S)-(3-((2-chloropyrimidin-4-yl)oxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 267 was synthesized by the method for the preparation of compound 75. 1H NMR (400 MHz, Chloroform-d) δ 8.25 (d, J = 2.1 Hz, 1H), 6.79 (t, J = 1.7 Hz, 1H), 6.78 - 6.73 (m, 2H), 6.69 (tt, J = 8.9, 2.3 Hz, 1H), 5.50 (tt, J = 6.7, 4.1 Hz, 1H), 5.27 (dd, J = 12.2, 6.5 Hz, 1H), 4.69 - 4.54 (m, 2H), 4.34 - 4.22 (m, 2H), 3.36 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.70 (ddd, J = 18.6, 6.5, 1.7 Hz, 1H). LC-MS (m / z): 412.1[M+H] + .
[0404] Compound 268: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((5-fluoro-2-(methylamino)pyrimidin-4-yl)oxy)azetidin-1-yl)methanone The title compound 268 was synthesized in 68% yield from compound 267 and methylamine following a method similar to the preparation of compound 266. [ka] 1 H NMR (400 MHz, Chloroform-d) δ 10.25 - 10.01 (br, 1H), 7.80 (d, J = 3.7 Hz, 1H), 6.82 (t, J = 1.7 Hz, 1H), 6.78 - 6.73 (m, 2H), 6.70 (tt, J = 8.8, 2.3 Hz, 1H), 5.54 (tt, J = 6.7, 4.1 Hz, 1H), 5.28 (dd, J = 12.2, 6.4 Hz, 1H), 4.68 - 4.55 (m, 2H), 4.42 - 4.33 (m, 1H), 4.33 - 4.25 (m, 1H), 3.37 (ddd, J = LC-MS (m / z): 407.2[M+H] + .
[0405] Compound 269: (S)-3-((4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyrimidin-2-yl)amino)propanenitrile [ka] The title compound 269 was prepared in a manner similar to that of 266. 1 H NMR (400 MHz, Chloroform-d) δ 10.29 (s, 1H), 8.00 (s, 1H), 6.88 (s, 1H), 6.80 - 6.61 (m, 3H), 5.68 - 5.57 (m, 1H), 5.30 (dd, J = 12.4,6.0 Hz,1H), 4.76-4.62 (m, 2H), 4.51 - 4.30 (m, 2H), 3.84-3.77 (m, 2H), 3.45-3.30 (m, 1H), 2.81 - 2.64 (m, 3H). LC-MS (m / z) 446.3(M+H + ), yield 12.4%.
[0406] Compound 270: (S)-3-((4-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-5-fluoropyrimidin-2-yl)amino)propanamide [ka] The title compound 270 was prepared from compound 269 by hydrolysis using 1N NaOH solution. Yield 48.2%. 1 H NMR (400 MHz, Chloroform-d) δ 7.95 (s, 1H), 6.78 (t, J = 1.6 Hz, 1H), 6.77-6.71 (m, 2H), 6.71 - 6.65 (m, 1H), 5.74 (s, 1H), 5.60 (s, 2H), 5.39-5.32 (m, 1H), 5.27 (dd, J = 12.4, 6.4 Hz, 1H), 4.61-4.47 (m, 2H), 4.36 - 4.09 (m, 2H), 3.64 (q, J = 6.0 Hz, 2H), 3.40-3.29(m, 1H), 2.73-2.64(m, 1H), 2.50 (t, J = 6.0 Hz, 2H). LC-MS (m / z) 464.3 (M+H + ).
[0407] Compound 271: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-methoxypyrimidin-2-yl)piperazin-1-yl)methanone [ka] (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (100 mg, 0.34 mmol) and 2-chloro-5-fluoro-4-methoxypyrimidine (60.8 mg, 0.37 mmol) were dissolved in 2 mL of 1,4-dioxane. p-Toluenesulfonic acid (11.7 mg, 0.068 mmol) was added. The mixture was stirred in a sealed tube at 100° C. for 16 hours. The solvent was evaporated to dryness and purified by preparative TLC (PE / EA=1 / 2) to give 35 mg of the title compound as a white solid. Yield: 24.5%. 1 H NMR (400 MHz, CDCl3) δ (ppm): δ 7.96 (s, 1H) , 6.81-6.85 (m,3H), 6.69 (t, J = 8.8 Hz , 1H), 5.33 (t, J = 10.8 Hz , 1H), 3.98 (s, 3H), 3.70-3.87 (m, 6H), 3.58-3.64 (m, 2 H), 3.32 (dd, J = 12.0, 18.4 Hz, 1H), 2.68 (dd, J = 10.4, 18.4 Hz, 1H). Mass (ESI): m / z calcd for C 19 H 19 F3N6O2420.4, found 421.5 [M+H] + .
[0408] Compound 272: (S)-5-chloro-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carboxylate ethyl [ka]
[0409] Step 1 To a solution of ethyl 2-((1-(tert-butoxycarbonyl)azetidin-3-yl)oxy)-5-chlorothiazole-4-carboxylate (240 mg, 0.7 mmol) in DCM (5 mL) was added TFA (1 mL). The resulting mixture was stirred at room temperature for 2 hours and concentrated under reduced pressure to give ethyl 2-(azetidin-3-yloxy)-5-chlorothiazole-4-carboxylate (174 mg, crude) as the TFA salt, which was used directly in the next step.
[0410] Step 2 To a solution of (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (183 mg, 0.7 mmol) and ethyl 2-(azetidin-3-yloxy)-5-chlorothiazole-4-carboxylate (174 g, crude, 0.7 mmol) in THF (5 mL) was added EtN (0.5 mL, 2.0 mmol). The mixture was stirred at 70 °C for 3 h. Upon completion of the reaction, the reaction mixture was concentrated under reduced pressure to give a residue. The crude product was purified by preparative TLC (petroleum ether / EtOAc = 1 / 1) to give the title compound (220 mg, 74% yield) as a white solid. LCMS (ES, m / z): 471.1 [M+H] + . 1 H NMR (400 MHz, Chloroform-d) δ 6.84 - 6.55 (m, 4H), 5.53-5.51 (m, 1H), 5.33 (dd, J = 5.2, 16.4 Hz, 1H), 4.63-4.47 (m, 2H), 4.37 (q, J = 7.2 Hz, 2H), 4.33 - 4.06 (m, 2H), 3.34 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.69 (ddd, J = 18.6, 6.5, 1.7 Hz, 1H), 1.39 (t, J = 7.2 Hz, 3H).
[0411] Compound 273: (S)-5-chloro-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)-N-methylthiazole-4-carboxamide [ka]
[0412] Step 1 To a solution of ethyl (S)-5-chloro-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carboxylate (180 mg, 0.4 mmol) in THF (3 mL) was added a solution of LiOH (17 g, 0.4 mmol) in water (3 mL). The resulting mixture was stirred at room temperature for 2 hours. TLC analysis confirmed the reaction was complete. THF was evaporated under reduced pressure and 1N HCl was added to adjust the pH to <5. The mixture was poured into water (20 ml) and extracted with DCM (3 x 10 ml). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give (S)-5-chloro-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carboxylic acid as a white solid (170 mg, crude).
[0413] Step 2 To a solution of (S)-5-chloro-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carboxylic acid (50 mg, 0.11 mmol) in 10 mL of dry THF was added DMF (catalytic amount). To this solution was added SO2Cl2 (0.738 g, 6.42 mmol) slowly at 0 °C. The mixture was stirred for 1 hour and then concentrated under reduced pressure to give the crude product as a residue. The residue was dissolved in DCM (100 mL), and methylamine hydrochloride (13.5 mg, 0.2 mmol) was added. The mixture was stirred at room temperature for 1 hour and then concentrated under reduced pressure to give the crude product. The crude product was purified by preparative TLC (petroleum ether / EtOAc = 1 / 1) to give the title compound 273 (12 mg, 24%). 1H NMR (400 MHz, Chloroform-d) δ 6.90 (brs, 1H), 6.80 (t, J = 1.6 Hz, 1H), 6.78 - 6.66 (m, 3H), 5.42-5.36 (m, 1H), 5.28 (dd, J = 6.4, 12.4 Hz, 1H), 4.57-4.52 (m, 2H), 4.32-4.20 (m, 2H), 3.36 (ddd, J = 18.4, 12.2, 1.6 Hz, 1H), 2.94 (d, J = 3.6 Hz, 3H), 2.71 (ddd, J = 18.4, 6.4, 1.6 Hz, 1H).LCMS (ES, m / z): 456.9 [M+H] + .
[0414] Compound 274: (S)-5-chloro-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carboxamide SN-115-14 [ka] The title compound 274 was prepared in a manner similar to the preparation of compound 273. Yield: 30%. 1H NMR (400 MHz, Chloroform-d) δ 6.83 - 6.63 (m, 4H), 5.68 (brs, 1H), 5.42-5.36 (m, 1H), 5.33 (dd, J = 6.4, 12.4 Hz, 1H), 4.68 - 4.45 (m, LCMS (ES, m / z): 442.8 [M+H]+.
[0415] Compound 275: [ka] The title compound 275 was prepared in a manner similar to the preparation of compound 273. 1H NMR (400 MHz, cdcl3) δ 6.87 - 6.65 (m, 4H), 5.38-5.33 (m, 1H), 5.27 (dd, J =6.4, 12.0 Hz, 1H), 4.61 - 4.47 (m, 2H), 4.47 - 4.36 (m, 2H), 4.31-4.27 (m, 1H), 4.25 - 4.10 (m, 3H), 3.36 (dd, J = 17.3, 12.3 Hz, 1H), 2.71 (ddd, J = 18.6, 6.5, 1.7 Hz, 1H)., 2.35-2.27 (m, 2H). Yield:45% (12.1 mg). LCMS (ES, m / z):482.1[M+H]+.
[0416] Compound 276: (3-(benzo[d]thiazol-2-yloxy)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone
change
[0417] Compound 277: 7-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-ylidene)methyl)-3,4-dihydroquinolin-2(1H)-one
change
[0418] Step 1 7-Bromo-3,4-dihydroquinolin-2(1H)-one (100 mg, 0.44 mmol) was dissolved in 5 mL of dry 1,4-dioxane, and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (223 mg, 0.88 mmol), KOAc (130 mg, 1.32 mmol), and Pd(PPh)Cl (32 mg, 0.04 mmol) were added. The mixture was stirred at 80 °C overnight. The mixture was filtered, and the filtrate was concentrated to give 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one, which was used in the next step without further purification. LC-MS (m / z) 274.15(M+H + ).
[0419] Step 2 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one (120 mg) was dissolved in 5 mL of 1,4-dioxane / HO, and tert-butyl 3-(bromomethylene)azetidine-1-carboxylate (90 mg, 0.36 mmol), KCO (150 mg, 1.08 mmol), and Pd(PPh) (83 mg, 0.072 mmol) were added. The mixture was stirred at 80 °C for 2 hours. The mixture was filtered, and the filtrate was concentrated under reduced pressure. Purification by silica gel chromatography (EA / PE = 1:1) afforded tert-butyl 3-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methylene)azetidine-1-carboxylate (58 mg) as a yellow solid. LC-MS (m / z) 315.16(M+H + )
[0420] Step 3 tert-Butyl 3-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methylene)azetidine-1-carboxylate (58 mg, 0.18 mmol) was dissolved in 3 ml of DCM, and trifluoroacetic acid (210 mg, 1.8 mmol) was added. The mixture was stirred at room temperature for 4 hours. The mixture was concentrated to give 7-(azetidin-3-ylidenemethyl)-3,4-dihydroquinolin-2(1H)-one trifluoroacetate, which was used in the next step without further purification. LC-MS (m / z) 215.15 (M+H + ).
[0421] Step 4 7-(Azetidin-3-ylidenemethyl)-3,4-dihydroquinolin-2(1H)-one, (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (45 mg, 0.16 mmol) and TEA (0.4 ml) were dissolved in THF (5 mL) and stirred at 65° C. for 6 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by preparative HPLC gave the title compound 277 (0.6 mg, 0.8% yield over two steps). LC-MS (m / z) 423.16 (M+H) + ). 1 H NMR (400 MHz, Chloroform-d) δ 8.05 (s, 1H), 7.14 (d, J = 7.4 Hz, 1H), 6.84 (s, 1H), 6.80 - 6.64 (m, 3H), 6.50 (s, 1H), 6.21 (s, 1H), 5.37 - 5.30 (m, 1H), 5.11-5.10 (m, 2H), 4.90-4.80 (m, 2H), 3.38 (dd, J = 18.6, 11.7 Hz, 1H), 2.96 (t, J = 7.5 Hz, 2H), 2.72 (dd, J = 18.6, 5.8 Hz, 1H), 2.65 (m, J = 7.5 Hz, 2H).
[0422] Compound 278: 6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-ylidene)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one [ka]
[0423] Step 1 6-Bromo-2H-benzo[b][1,4]oxazin-3(4H)-one (100 mg, 0.44 mmol) was dissolved in 5 mL of ACN, and tert-butyl 3-methyleneazetidine-1-carboxylate (149 mg, 0.88 mmol), Pd(OAc) (10 mg, 0.044 mmol), tris(2-methylphenyl)phosphine (27 mg, 0.08 mmol), and triethanolamine (133 mg, 1.32 mmol) were added. The mixture was stirred at 100 °C for 3 h. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography (EA / PE=1:1) gave tert-butyl 3-((3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methylene)azetidine-1-carboxylate (100 mg). LC-MS (m / z) 316.14 (M+H +)
[0424] Step 2 tert-Butyl 3-((3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)methylene)azetidine-1-carboxylate (100 mg, 0.32 mmol) was dissolved in 6 ml of DCM, and trifluoroacetic acid (1.5 ml) was added. The mixture was stirred at room temperature for 4 hours. The mixture was concentrated to give 6-(azetidin-3-ylidenemethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one trifluoroacetate, which was used in the next step without further purification. LC-MS (m / z) 216.15 (M+H) + )
[0425] Step 3 6-(Azetidin-3-ylidenemethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one, (1H-imidazol-1-yl)(5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)methanone (73 mg), and TEA (0.4 mL) were dissolved in THF (10 ml) and stirred at 65°C for 6 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography gave the title compound 278 (15 mg, 8% yield over three steps). LC-MS (m / z) 425.13 (M+H) + ). 1 H NMR (400 MHz, DMSO-d6) δ 10.68 (s, 1H), 7.11 (tt, J = 9.4, 2.4 Hz, 1H), 7.05 (brs, 1H), 6.97 - 6.90 (m, 3H), 6.76-6.74 (m, 2H), 6.25 (brs, 1H), 5.28 (dd, J = 12.2, 6.6 Hz, 1H), 4.90 (bs, 2H), 4.73 (brs, 2H), 4.56 (s, 2H), 3.46 - 3.36 (m, 1H), 2.66 - 2.60 (m, 1H).
[0426] Compound 279: (S)-(4-(7H-pyrrolo[2,3-d]pyrimidin-2-yl)piperazin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 279 was prepared in 3.9% yield from 2-chloro-7H-pyrrolo[2,3-d]pyrimidine and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone following the method outlined for compound 271. 1H NMR (400 MHz, CDCl3) δ (ppm): 8.93(brs, 1H), 8.62 (s, 1H), 6.91 (dd, J = 2.0, 3.6 Hz, 1H), 6.80-6.86 (m, 3H), 6.66-6.72 (m, 1H), 6.37 (dd, J = 1.6,4.0 Hz , 1H), 5.35 (dd, J = 10.0, 11.6 Hz , 1H), 3.90-3.96 (m, 2H), 3.78-3.86 (m, 4H), 3.65-3.71 (m, 2H), 3.31 (ddd, J = 2, 11.6, 13.6 Hz, 1H), 2.68 (ddd, J = 1.6, 10.0, 11.6 Hz, 1H). Mass (ESI): m / z calcd for C 20 H 19 F2N7O 411.4, found 412.3 [M+H] + .
[0427] Compound 280: (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-5-carboxamide [ka] The title compound 280 was prepared from 2-(azetidin-3-yloxy)thiazole-5-carboxamide trifluoroacetate and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone following the method outlined for compound 203. LC-MS (m / z) 408.4 (M+H + ) 1H NMR (400 MHz, Chloroform-d) δ 7.54 (s, 1H), 6.78 (t, J = 1.7 Hz, 1H), 6.77 - 6.73 (m, 2H), 6.72-6.66 (m, 1H), 5.45-5.40 (m, 1H), 5.27 (dd, J = 12.1, 6.4 Hz, 1H), 4.62 - 4.49 (m, 2H), 4.31-4.22 (m, 2H), 3.35 (ddd, J = 18.6, 12.2, 1.7 Hz, 1H), 2.70 (ddd, J = 18.6, 6.5, 1.8 Hz, 1H).
[0428] Compound 281: 2-((1-(5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carbonitrile [ka] The title compound 90 was prepared from 2-(azetidin-3-yloxy)thiazole-4-carbonitrile trifluoroacetate and (5-(5-fluoropyridin-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone according to the method outlined for compound 203. LC-MS (m / z) 373.4 (M+H+) LC-MS (m / z) 395.5 (M+H + ) 1 H NMR (400 MHz, Chloroform-d) δ 8.43 (d, J = 8.0 Hz, 2H), 7.50 - 7.45 (m, 1H), 7.43 (brs, 1H), 6.86 - 6.84 (m, 1H), 5.45 - 5.40 (m, 1H), 5.40 - 5.35 (m, 1H), 4.57 (brs, 2H), 4.27-4.22 (m, 2H), 3.44 (ddd, J = 18.7, 12.3, 1.7 Hz, 1H), 2.76 (ddd, J = 18.7, 6.8, 1.7 Hz, 1H).
[0429] Compound 282: (S)-2-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-yl)oxy)thiazole-4-carboxamide [ka] The title compound 282 was prepared from compound 281 by hydrolysis using 1N NaOH. LC-MS (m / z) 391.4 (M+H + ). 1 H NMR (400 MHz, Chloroform-d) δ 7.65 (s, 1H), 6.81 (t, J = 1.7 Hz, 1H), 6.77 - 6.73 (m, 2H), 6.70 (tt, J = 8.8, 2.3 Hz, 1H), 5.46 - 5.39 (m, 1H), 5.29 (dd, J = 12.2, 6.3 Hz, 1H), 4.62-4.54 (m, 2H), 4.37 - 4.23 (m, 2H), 3.37 (ddd, J = 18.7, 12.2, 1.7 Hz, 1H), 2.71 (ddd, J = 18.6, 6.4, 1.7 Hz, 1H).
[0430] Compound 283: (S)-6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-ylidene)methyl)-3,3-difluoroindolin-2-one [ka]
[0431] Step 1 6-Bromoindoline-2,3-dione (1 g, 4.44 mmol) was dissolved in 2 mL of DCM. To this suspension, DAST (1.78 g, 11.04 mmol) was slowly added at 0°C. The mixture was stirred at room temperature under a nitrogen atmosphere for 16 hours. Water was added to quench the reaction, and the mixture was extracted with DCM (50 mL x 3). The combined organic layer was evaporated to dryness and purified by column chromatography (PE / EA = 4 / 1) to give 0.5 g of 6-bromo-3,3-difluoroindolin-2-one as a red solid. Yield: 45.6%. LC-MS (m / z) 249.1 [M+H] + .
[0432] Step 2 6-Bromo-3,3-difluoroindolin-2-one (140 mg, 0.57 mmol), tert-butyl 3-methyleneazetidine-1-carboxylate (115 mg, 0.68 mmol), and DIEA (0.19 mL) were dissolved in 5 mL of CH3CN. Pd(AcO)2 (12.8 mg, 0.057 mmol) and tri-o-tolylphosphane (35 mg, 0.115 mmol) were added. The mixture was stirred at 100 °C under a nitrogen atmosphere for 16 hours. The solvent was evaporated to dryness, and the mixture was purified by column chromatography (PE / EA = 7 / 1) to afford 100 mg of tert-butyl 3-((3,3-difluoro-2-oxoindolin-6-yl)methylene)azetidine-1-carboxylate as a pale yellow solid. Yield: 43.8%. LC-MS (m / z) 337.2 [M+H] + .
[0433] Step 3 tert-Butyl 3-((3,3-difluoro-2-oxoindolin-6-yl)methylene)azetidine-1-carboxylate (35 mg, 0.104 mmol) was dissolved in 2 mL of DCM. To this solution, 2 mL of DCM / TFA (1 / 1) was added slowly at 0° C. The mixture was stirred at room temperature for 1 hour. The solvent was evaporated to dryness and used in the next step without further purification. LC-MS (m / z) 237.1 [M+H] + .
[0434] Step 4 The residue from above was dissolved in 2 mL of THF, and 0.2 mL of TEA was added. (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(1H-imidazol-1-yl)methanone (28.7 mg, 0.104 mmol) was added. The mixture was stirred at 70° C. for 16 hours. The solvent was evaporated to dryness, and the mixture was purified by preparative TLC (PE / EA=1 / 1) to give 25 mg of the title compound 283 as a white solid. Yield: 53%. 1H NMR (400 MHz, CDCl3) δ (ppm): δ 8.86 (brs, 1H), 7.46 (d, J = 7.6 Hz ,1H), 6.83-6.88 (m, 2 H), 6.73-6.79 (m, 2H), 6.61-6.67 (m, 2H), 6.25(s, 1H), 5.43 (dd, J = 6.0, 12.0 Hz, 1H), 4.94-5.09 (m, 4H), 3.41 (ddd, J = 1.6, 12.4, 13.6 Hz, 1H), 2.70 (ddd, J = 1.6, 6.4, 7.6 Hz, 1H). LC-MS (ESI): m / z calcd for C 22 H 16 F4N4O2444.4, found 445.3 [M+H] + .
[0435] Compound 284: (S)-(3-((1H-benzo[d]imidazol-5-yl)methylene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] To 6-bromo-1H-benzo[d]imidazole (8.5 mg, 0.043 mmol) and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-methyleneazetidin-1-yl)methanone (10 mg, 0.036 mmol) were added Pd(AcO) (5 mg) and tri-o-tolylphosphane (1.8 mg, 0.006 mmol). 0.2 mL of DIEA was added. The mixture was stirred at 160 °C for 1 hour under microwave irradiation. The solvent was evaporated to dryness and purified by column chromatography (DCM / MeOH = 92 / 8) to give the title compound 284 as an orange solid (6 mg, 42.4%). 1H NMR (400 MHz, CDCl3) δ (ppm): δ 8.64 (s, 1H), 7.61 (d, J = 7.6 Hz ,1H), 7.45 (s,1H), 7.10 (d, J = 7.6 Hz ,1H), 6.84 (s,1H), 6.78 (d, J = 5.6 Hz ,2H), 6.64-6.70 (m, 1 H), 6.34 (s, 1H), 5.35 (dd, J = 6.4, 8.4 Hz, 1H), 5.09 (s, 2H), 4.90 (s, 2H),3.39 (dd, J = 12.8, 18.0 Hz, 1H), 2.71 (dd, J = 6.8, 18.0 Hz, 1H). LC-MS (ESI): m / z calcd for C 21 H 17 F2N5O 393.4, found 394.3 [M+H] + .
[0436] Compound 285: (S)-(3-((3-chloro-5-fluoro-1H-indazol-6-yl)methylene)azetidin-1-yl)(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)methanone [ka] The title compound 285 was synthesized in a manner similar to the preparation of compound 284. 1 H NMR (400 MHz, Methanol-d4) δ 7.71-7.68 (m, 1H), 7.61-7.58 (m, 1H), 7.33 - 7.26 (m, 1H), 6.96 (s, 1H), 6.85 - 6.79 (m, 2H), 6.59 (s, 1H), 5.30 (dd, J = 12.0, 8.0 Hz, 1H), 5.07 (s, 2H), 4.89 (s, 2H), 3.48 - 3.40 (m, 1H), 2.74-2.68 (m, 1H).
[0437] Compound 286: (S)-6-((1-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)azetidin-3-ylidene)methyl)-5-fluoro-1H-315-indazol-3-one [ka] The title compound 286 was synthesized in a manner similar to the preparation of compound 284. 1H NMR (400 MHz, Methanol-d4) δ 7.37 (d, J = 12.0 Hz, 1H), 7.06 (d, J = 4.0 Hz, 1H), 6.96 (d, J = 4.0 Hz, 1H), 6.85 - 6.79 (m, 3H), 6.58 (s, 1H), 5.30 (dd, J = 12.0, 4.0 Hz, 1H), 5.06 (s, 2H), 4.89 (s, 2H), 3.48 - 3.40 (m, 1H), 2.74-2.67 (m, 1H).
[0438] Compound 287: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(2-morpholinoethoxy)pyrimidin-2-yl)piperazin-1-yl)methanone [ka]
[0439] Step 1: 4-(2-((2-chloro-5-fluoropyrimidin-4-yl)oxy)ethyl)morpholine 2-Morpholinoethan-1-ol (863 mg, 7.13 mmol) was dissolved in 20 ml of dry DMF. To this solution, NaH (263 mg, 6.57 mmol) was added at 0°C under a nitrogen atmosphere. The mixture was stirred at 0°C for 0.5 hours. To this was added 2,4-dichloro-5-fluoropyrimidine (1.0 g, 5.98 mmol), and the mixture was further stirred at room temperature overnight. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound as a yellow oil (500 mg, 32%). (ES, m / s): 262.1 [M+H] +
[0440] Step 2: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(4-(5-fluoro-4-(2-morpholinoethoxy)pyrimidin-2-yl)piperazin-1-yl)methanone (S)-(5-(3,5-Difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone (295 mg, 1.00 mmol) was dissolved in 5 mL of dry DMF. To this solution, 4-(2-((2-chloro-5-fluoropyrimidin-4-yl)oxy)ethyl)morpholine (261 mg, 1.00 mmol) and DIEA (260 mg, 2.00 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 120° C. for 2.0 hours. The mixture was extracted with EA, washed with brine, dried (NaSO), and concentrated under reduced pressure. Purification by silica gel chromatography afforded the title compound 287 (200 mg, 39%) as a white solid. (ES, m / s): 520.2 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 8.17 (d, J = 3.2 Hz, 1H), 7.13 - 7.05 (m, 2H), 7.01 - 6.94 (m, 2H), 5.28 - 5.18 (m, 1H), 4.47 (t, J = 5.8 Hz, 2H), 3.73 - 3.65 (m, 2H), 3.64 - 3.56 (m, 4H), 3.55 - 3.46 (m, 6H), 3.39 - 3.32 (m, 1H), 2.68 (t, J = 5.8 Hz, 2H), 2.65 - 2.56 (m, 1H), 2.45-2.41 (m, 4H).
[0441] Compound 288: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-(pyrazolo[1,5-a]pyridin-5-ylmethylene)azetidin-1-yl)methanone [ka] The title compound 288 was prepared in 50% yield from 5-bromopyrazolo[1,5-a]pyridine and (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-methyleneazetidin-1-yl)methanone following the method outlined for compound 284. 1H NMR (400 MHz, CDCl3) δ (ppm): δ 8.39 (d, J = 7.2 Hz ,1H), 7.92 (d, J = 2.4 Hz ,1H), 7.25 (s, 1H), 6.83 (t, J = 1.6 Hz ,1H), 6.75-6.80 (m, 2H), 6.66-6.72 (m, 1 H), 6.53 (dd, J = 1.6, 7.2 Hz ,1H), 6.49 (d, J = 2.0 Hz ,1H), 6.25 (t, J = 2.0 Hz ,1H), 5.31 (dd, J = 6.4, 12.0 Hz, 1H), 5.12 (q, J = 14.0 Hz, LC-MS (ESI): m / z calcd for C21H17F2N5O 393.4, found 394.3 [M+H] + .
[0442] Compound 289: (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(3-((3-methyl-1H-indazol-6-yl)methylene)azetidin-1-yl)methanone [ka]
[0443] Step 1 6-Bromo-3-methyl-1H-indazole (100 mg, 0.47 mmol) was dissolved in 10 mL of dry dioxane. To this solution, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (241 mg, 0.95 mmol), Pd(dppf)Cl2 (52 mg, 0.07 mmol), and AcOK (140 mg, 1.01 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 90 °C for 5.0 h. The mixture was filtered and concentrated under reduced pressure to give 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole as a brown oil (400 mg, crude product), which was used in the next step without further purification. LC-MS (m / z): 259.2[M+H] + .
[0444] Step 2 3-Methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (400 mg, crude product) was dissolved in 15 mL of dioxane and 4 mL of HO. To this solution, Pd(PPh) (82 mg, 0.07 mmol) and KCO (197 mg, 1.43 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 90 °C for 3.0 h. The resulting solution was added to HO and extracted with EA. The organic layer was washed with brine, dried over NaSO, and concentrated under reduced pressure. The crude product was purified by silica gel chromatography to give 20 mg of tert-butyl 3-((3-methyl-1H-indazol-6-yl)methylene)azetidine-1-carboxylate as a yellow solid (two-step yield: 14%). LC-MS (m / z): 300.2[M+H] + .
[0445] Step 3 Tert-butyl 3-((3-methyl-1H-indazol-6-yl)methylene)azetidine-1-carboxylate (20 mg, 0.07 mmol) was dissolved in 10 ml of dry DCM. To this solution, TFA (1 mL) was added at room temperature. The mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to give the TFA salt of 6-(azetidin-3-ylidenemethyl)-3-methyl-1H-indazole as a brown oil (30 mg, crude product), which was used in the next step without further purification. LC-MS (m / z): 200.2 [M+H] + .
[0446] Step 4 6-(Azetidin-3-ylidenemethyl)-3-methyl-1H-indazole (20 mg, crude product) was dissolved in 10 ml of dry THF. To this solution, TEA (0.5 mL) and 3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole (22 mg, 0.08 mmol) were added at room temperature. The mixture was stirred at room temperature for 12 hours. The resulting solution was concentrated under reduced pressure. Purification by preparative HPLC afforded 1 mg of the title compound 289 as a white solid (yield: 4%). LC-MS (m / z): 408.2 [M+H] + . 1 H NMR (400 MHz, Chloroform-d) δ 8.13 (s, 1H), 7.18 (d, J = 7.7 Hz, 1H), 6.85 - 6.72 (m, 4H), 6.61 (s, 1H), 6.26 - 6.18 (m, 1H), 5.34 (dd, J = 12.2, 6.5 Hz, 1H), 5.13 - 4.95 (m, 2H), 4.94 - 4.76 (m, 2H), 3.52 (s, 3H), 3.44 - 3.30 (m, 1H), 2.78 - 2.64 (m, 1H).
[0447] Compound 290: (S)-2-Cyclopentyl-N-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidin-4-yl)acetamide [ka] The title compound 290 was obtained from (S)-2-cyclopentyl-N-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidin-4-yl)acetamide and N-(2-chloro-5-fluoropyrimidin-4-yl)-2-cyclopentylacetamide as a grey solid (21.8 mg, 25%) following the method outlined for compound 225. (ES, m / s): 416.2 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 10.27 (brs, 1H), 8.30 (d, J = 3.0 Hz, 1H), 7.12-7.04 (m, 2H), 7.00-6.93 (m, 2H), 5.23 (m, 1H), 3.72-3.64 (m, 2H), 3.62-3.58 (m, 4H), 3.54-3.44 (m, 2H), 3.38-3.34 (m, 1H), 2.66-2.57 (m, 1H), 2.41 (d, J = 7.6 Hz, 2H), 2.21-2.12 (m, 1H), 1.76-1.67 (m, 2H), 1.60-1.52 (m, 1H), 1.51-1.43 (m, 1H), 1.23-1.19 (m, 2H), 1.17-1.10 (m, 2H).
[0448] Compound 291: (S)—N-(2-(4-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbonyl)piperazin-1-yl)-5-fluoropyrimidin-4-yl)-3-methylbutanamide [ka] The title compound 291 was obtained as a grey solid (5.4 mg, 6%) from (S)-(5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)(piperazin-1-yl)methanone and N-(2-chloro-5-fluoropyrimidin-4-yl)-3-methylbutanamide following the method outlined for compound 225. (ES, m / s): 490.2 [M+H] + 1H NMR (400 MHz, DMSO-d6) δ 10.46 (b...
Claims
1. A compound having the following structure, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof: 【Chemistry 1】 During the ceremony, R 1 is a substituted or unsubstituted phenyl, or a substituted or unsubstituted 2-pyridine, 3-pyridine, or 4-pyridine; R 2 is a dihydropyrazole or isoxazolidine; R 3 and R 4 form together with the nitrogen atom to which they are attached a 4- to 6-membered ring containing 1 to 3 heteroatoms, i.e., N, or N and either N, S or O; the 4- to 6-membered ring is fused to a second ring or is attached to R 5 via a linker, L; L is a bond, -CH2-, -O-, or =CH-; R 5 is a substituted or unsubstituted C 3 -C 9 cycloalkyl, cycloalkenyl, or cycloalkynyl having 0 to 3 heteroatoms, or a substituted or unsubstituted C 5 -C 14 aryl having 0 to 3 heteroatoms; The substituents include halogen, -R', -OR', =O, =NR', =N-OR', -NR'R'', -SR', -SiR'R''R''', -OC(O)R', -C(O)R', -CO 2 R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR'-SO 2 NR''', -NR''CO 2 R', -NH-C(NH 2 )=NH, -NR'C(NH 2 )=NH, -NH-C(NH 2 )=NR', -S(O)R', -SO 2 R', -SO 2 NR'R'', -NR''SO 2 R, -CN, -NO 2 , -N 3 , -CH(Ph) 2 , perfluoro(C 1 -C 4 )alkoxy and perfluoro(C 1 -C 4 )alkyl; R', R'', and R''' are each independently hydrogen, unsubstituted (C1-C8) alkyl or heteroalkyl, (C1-C8) alkyl or heteroalkyl substituted with 1 to 3 halogens, unsubstituted aryl, aryl substituted with 1 to 3 halogens, unsubstituted alkyl, unsubstituted alkoxy, unsubstituted thioalkoxy, or aryl-(C1-C4)alkyl, and when R' and R'' are attached to the same nitrogen atom, R' and R'' may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
2. R 1 2. The compound of claim 1, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein: is substituted or unsubstituted phenyl.
3. R 1 The compound of claim 1 , or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein: is fluorine-substituted phenyl or unsubstituted phenyl.
4. R 1 2. The compound of claim 1, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein:
5. R 3 and R 4 are joined together with the nitrogen atom to which they are attached to form a 4-6 membered N-containing heterocycloalkyl ring, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof.
6. R 3 and R 4 are joined together with the nitrogen atom to which they are attached to form a 4-6 membered N-containing heterocycloalkyl ring and are fused with phenyl to form isoindoline, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof.
7. L is -CH 2 2. The compound of claim 1, wherein: - or a pharma- ceutically acceptable salt, hydrate or stereoisomer thereof.
8. 2. The compound of claim 1, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein L is -O-.
9. 2. The compound of claim 1, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein L is =CH-.
10. R 5 but, (a) substituted or unsubstituted phenyl; (b) substituted or unsubstituted 2-pyridine, 3-pyridine, or 4-pyridine; (c) Substituted or unsubstituted naphthyl or 3-azanaphthyl; (d) substituted or unsubstituted cyclohexyl or cyclopentyl having 0 to 3 heteroatoms; or (e) The compound according to any one of claims 1 to 9, which is a substituted or unsubstituted cyclopentene or cyclopentadiene having 0 to 3 heteroatoms, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof.
11. R 5 The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt, hydrate or stereoisomer thereof, wherein is substituted or unsubstituted phenyl, cyclohexyl, furan, thiophene, or azole.
12. R 5 The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt, hydrate or stereoisomer thereof, wherein is substituted or unsubstituted phenyl or cyclohexyl.
13. R 5 The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein is substituted or unsubstituted phenyl.
14. R 5 The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt, hydrate or stereoisomer thereof, wherein is fluorine-substituted phenyl or unsubstituted phenyl.
15. R 5 The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein is 3,5-difluorophenyl.
16. The substituents of R 1 are selected from the group consisting of halogen and CN, and / or R 5 substituents are halogen, -R', -OR', ═O, -NR'R'', -CO 2 R', -CONR'R'', -NR''C(O)R', and CN; The compound of any one of claims 1 to 3 and 5 to 14, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, wherein R' and R'' are each independently selected from hydrogen, unsubstituted (C1-C4) alkyl, and unsubstituted (C1-C8) heteroalkyl, wherein the heteroalkyl has a heteroatom selected from N, S, and O.
17. A compound, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof, having the structure: 【Chemistry 2】 During the ceremony, R 1 is a substituted or unsubstituted phenyl, or a substituted or unsubstituted 2-pyridine, 3-pyridine, or 4-pyridine; The substituents of R 1 are selected from the group consisting of halogen and CN; R2 is dihydropyrazole or isoxazolidine; R 3 and R 4 together with the nitrogen atom to which they are attached form a 4- to 6-membered N-containing heteroalkyl ring; the 4-6 membered heteroalkyl ring is fused to a phenyl or attached to R 5 via a linker L; L is a bond, -CH2-, -O-, or =CH-; R5 is (a) substituted or unsubstituted phenyl; (b) substituted or unsubstituted 2-pyridine, 3-pyridine, or 4-pyridine; (c) Substituted or unsubstituted naphthyl or 3-azanaphthyl; (d) substituted or unsubstituted cyclohexyl or cyclopentyl having 0 to 3 heteroatoms selected from N, S, and O; or (e) a substituted or unsubstituted cyclopentene or cyclopentadiene having 0 to 3 heteroatoms selected from N, S, and O; R 5 substituents are halogen, -R', -OR', ═O, -NR'R'', -CO 2 R', -CONR'R'', -NR''C(O)R', and CN; R' and R'' are each independently selected from hydrogen, unsubstituted (C1-C8) alkyl, and unsubstituted (C1-C8) heteroalkyl having at least one heteroatom selected from N, S, and O.
18. A compound having any of the following structures, or a pharma- ceutically acceptable salt, hydrate, or stereoisomer thereof: 【Chemistry 3】 【Chemistry 4】 【Chemistry 5】 【Chemistry 6】 【Chemistry 7】 【Chemistry 8】 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 【Chemistry 14】 【Chemistry 15】 【Chemistry 16】 【Chemistry 17】 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemistry 21】 【Chemical 22】 【Chemistry 23】
19. 20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 18 or a pharma- ceutically acceptable salt, hydrate or stereoisomer thereof, and one or more pharma- ceutically acceptable excipients, wherein a therapeutically effective amount of the compound is contained in a unit dosage form.
20. 20. Use of a compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt, hydrate or stereoisomer thereof, or a composition according to claim 19, in the manufacture of a medicament for inhibiting necrosis, ferroptosis, human receptor interacting protein 1 kinase (RIP1), or a disease associated therewith, in a human in need thereof.
21. 20. The compound of any one of claims 1 to 18, or a pharma- ceutically acceptable salt, hydrate or stereoisomer thereof, or the composition of claim 19, for use in the manufacture of a medicament for inhibiting necrosis, ferroptosis, human receptor interacting protein 1 kinase (RIP1), or a disease associated therewith, in a human in need thereof.
Citation Information
Patent Citations
Novel 2-pyrazolines and remedy for cerebrovascular disorder containing said compound as active component
JP1989079157A
Pyrazolidinone type CCK and gastrin antagonist and medicinal preparations thereof
JP1992230367A
mitotic kinesin inhibitor
JP2005526091A
cis-2,4,5-triaryl-imidazoline
JP2006527712A
nk1 antagonist
JP2006527756A
Cited By
Azetidine cyclic ureas
JP2023526839A
Receptor-interacting protein 1 inhibitors containing piperazine heterocyclic amide ureas
JP2023526840A
Piperazine Cyclic Ureas
JP2023526841A
Azetidine cyclic ureas
JP2026009205A
Piperazine cyclic ureas
US12454529B2
